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Retinoic acid (RA) is the main endogenous bioactive form of vitamin A that plays im-
portant role in many biological events by regulating gene expression. One of the major
mechanisms via which endogenous RA regulate gene expression is through the canoni-
cal signalling, which involves binding and activation of RA receptors (RARs) by RA. It
is well-acknowledged that the canonical signalling of endogenous RA is indispensable
for embryonic kidney development but its role in the kidney after birth is not as well-
established. It is hypothesised that the canonical signalling of endogenous RA continues
to regulate gene expression in the kidney after birth. In the kidney of young and adult
RARE-hsp68-lacZ mice, a constitutive signal of RA response element (RARE) activa-
tion was observed. The signal was largely localised to collecting duct principal cells,
inner medullary collecting duct cells, and intercalated cells. In concordance with the
in vivo observation, basal RARE activity was detected in mIMCD-3 cells, a cell line
derived from mouse inner medullary collecting ducts. The RARE activity was likely a
result of constitutive activation of RARs given rise by cell-autonomous synthesis of en-
dogenous RA as the activity was suppressed by antagonists of RARs and by an inhibitor
of RA synthesising enzymes. Using mIMCD-3 cells as an in vitro model, target genes
of endogenous RA/RARs were identified using microarray at the whole genome level,
and the results were validated with reverse transcription quantitative polymerase chain
reaction. Gene ontology analysis on the validated genes suggests their involvement in
vitamin A metabolism, as well as in some classical and novel functions of collecting
ducts including kidney development.
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This chapter comprises three main sections. The first section is composed of a brief
overview of the retinoid system, which includes the transport and metabolism of retinoids
and gene expression regulation by retinoids. Data on gene knockout mice, where avai-
lable, is presented to illustrate functions of genes involved in regulation of the retinoid
system. Other molecules reported to be involved in crosstalk with the retinoid system
signalling cascade will also be introduced. The second section covers current knowledge
on the retinoid system with relevance to the kidney. Finally, the aims of this project are
set out in the third section.
1.1 An overview of the retinoid system
Back in 1920s-1940s, knowledge on the importance of retinoids was largely derived
from the symptoms observed in vitamin A deficient (VAD) patients and animals, such as
xerophthalmia and night blindness [25, 26, 86], keratinisation of tissue epithelium, with
and without accompanying inflammation [106,325], infections in multiple organs [113],
as well as developmental defects [323]. Therefore, vitamin A was often referred as “anti-
xerophthalmic”, “growth-promoting”, and “anti-infective” back then [25,113]. Notably,
the regularity of developmental defects involving multiple organs had led to the introduc-
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tion of the term “VAD syndromes”, which can be largely prevented by maternal vitamin
A supplementation [322]. Nevertheless, excessive administration of vitamin A to preg-
nant rats caused teratogenic effects to developing embryos, resulting in a plethora of
developmental anomalies [48]. It is now clear that vitamin A is one of the many compo-
nents within the retinoid system. Symptoms of vitamin A deficiency and teratogenicity
are in fact due to suboptimal and over-active retinoid signalling activities, respectively.
The retinoid system comprises multiple components that govern retinoid metabolism,
transport, and their activities, all of which are highly evolutionarily conserved, and act
collaboratively as a coherent system to support many basic biological events [302]. In
this section, the retinoid system will be introduced from five major aspects: (i) endo-
genous retinoids, (ii) transport of retinoids, (iii) metabolism of retinoids, (iv) regulation
of gene expression by retinoids through the canonical signalling and the non-canonical
signalling pathways, and (v) target genes of retinoids.
1.1.1 Endogenous retinoids
Early work dedicated to investigation of nutritional theories in the late 19th and early
20th century had led to discovery of vitamin A, the first retinoid compound described,
known then as fat-soluble vital amines essential for growth [281]. Since the discovery of
vitamin A, more analogs of vitamin A were discovered and subsequently synthesised.
According to the International Union of Pure and Applied Chemistry - International
Union of Biochemistry (IUPAC-IUB), the term “retinoids” is defined as “compounds
consisting of four isoprenoid units joined in a head-to-tail manner; all retinoids may
be formally derived from a monocyclic parent compound containing five carbon-carbon
double bonds and a functional terminal group at the terminus of the acyclic portion”.
The skeletal formula of retinoids is shown in Figure 1.1 [127].
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Figure 1.1: Skeletal formula of retinoids. Four isoprenoid units made up a single retinoid
molecule of 20 carbons, as numbered. Figure shown here is in an all-trans configuration.
R represents the functional group of retinoids, which largely determines the activity of
an individual retinoid compound. Examples of common retinoid compounds are: retinol
(R=OH), retinaldehyde (R=CHO) and retinoic acid (R=COOH) (Figure adapted from
IUPAC-IUB [127]).
This thesis is focusing on naturally occurring retinoids with biological activity, i.e., vi-
tamin A, also known as retinol (Rol), which is the parental retinoid compound, and
its oxidative derivatives, retinaldehyde (Ral) and retinoic acid (RA). As one could ap-
preciate from the skeletal formula depicting a non-polar aromatic ring and an aliphatic
chain, containing only 20 carbons in total (Figure 1.1), retinoids are small lipophilic
compounds, with their water solubility decreasing in the order of RA>Ral>Rol [27].
Without a natural mechanism in place for de novo retinoid biosynthesis, mammalian
cells obtain endogenous retinoids from food primarily in the form of carotenoids, which
is the retinoid precursor found in plants and egg yolks, and retinyl ester (such as retinyl
stearate and retinyl palmitate), which is the storage form of retinoids in animals [302].
The processes by which dietary retinoids are absorbed then subsequently released into
circulation and other tissues are highly complex events involving multiple catabolising
enzymes and binding proteins of retinoids [52]. These processes are briefly summarised
below:
1. Dietary carotenoids are absorbed from the intestine into enterocytes then be con-
verted into Ral and subsequently into Rol; dietary retinyl ester is hydrolised to Rol
in the intestine for absorption.
2. Newly absorbed Rol in enterocytes is esterified, predominantly by lecithin:retinol
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acyltransferase (Lrat) and to a lesser extent by intestinal acyl-coA acyltransferase
(Arat), into retinyl ester.
3. The newly synthesised retinyl ester is packaged into nascent chylomicron along
with other dietary lipid, which is then secreted into the lymphatic system and then
into the bloodstream.
4. In the circulation, chylomicron are reduced into chylomicron remnant; retinyl ester
in chylomicron and chylomicron remnant are taken up by hepatocytes in liver
(around 75%) and other tissues (around 25%) for storage.
5. In hepatocytes, retinyl ester is rapidly hydrolysed into Rol, which is then trans-
ferred to hepatic stellate cells where it is re-esterified, predominantly by Lrat, for
storage in lipid droplets.
6. When required, retinyl ester in hepatic stellate cells will be hydrolysed into Rol
and be transferred back to hepatocytes, where it will be bound by the retinol bind-
ing protein (Rbp) before being released into the bloodstream.
7. In the bloodstream, Rol-Rbp is bound by transthyretin to facilitate its transport to
extra-hepatic tissues.
8. Rol taken up by the extra-hepatic tissues is then converted to Ral and RA for
execution of biological function, or back to retinyl ester for storage.
The role of retinoids in maintaining a healthy visual system was one of the most actively
researched areas back in 1950s. It was found that vision impairment associated with vita-
min A deficiency is not a direct consequence of Rol per se but rather due to insufficiency
of its oxidative derivative, Ral, which is required for the synthesis of rhodopsin, the
retina pigment responsible for phototransduction [314]. It is now well-established that
an intact retinoid cycle, constituting enzymatic inter-conversation of 11-cis retinalde-
hyde (11cRal), all-trans retinaldehyde (tRal), all-trans retinol (tRol), and 11-cis retinol
(11cRol), is crucial for normal operation of the visual system [241].
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RA: the primary bioactive endogenous retinoids
In 1960, researchers found that almost all symptoms of vitamin A deficiency were re-
versed by replenishing VAD rats with RA, except for vision impairment [64]. Since
then, the role of RA has been extensively studied and it is now recognised as the primary
bioactive endogenous retinoid that mediates many important biological events, such as
embryonic development [67,231], regulation of immune system [249], and cancer deve-
lopment [298].
All-trans RA (tRA) is the most widely studied isomer of RA, which is derived from
tRol, the most abundant Rol isomer in vivo [302]. Other isomers of endogenous RA also
exist and among them, 13-cis RA (13cRA) and 9-cis RA (9cRA) are the most commonly
studied. The presence of various RA isomers might be a result of active isomerisation
process among the RA isomers [173,202,343] or might be a direct oxidative conversion
from the parental Rol in 13-cis and 9-cis configurations. By using a liquid chromatogra-
phy tandem mass spectrometric assay with improved sensitivity, Kane et al. found tRA
to be the most abundant RA isomer (in the range of 1.5 ± 0.2 to 38.1 ± 3.4 pmol/g tis-
sue) in a wide range of mouse tissues, including adipose, brain, kidneys, liver, muscle,
spleen, and testis, as well as in serum, while 9cRA was not detected [139]. Interestingly,
the same group had recently reported that 9cRA was present specifically in mouse pan-
creas, at a level higher than tRA [138].
A few early studies had attempted to examine the potency and activities of different
RA isomers, whereby the RA isomers were added to in vitro cell culture or administered
to animals. For example, in VAD rats, 13cRA was reported to be as effective and as po-
tent as tRA in supporting growth [343]; 13cRA and 9cRA were reported to be almost as
effective as tRA in promoting HL-60 human promyelocytic leukemia cell differentiation
in vitro [197]; topical 9cRA was found to be more potent than tRA in inducing pattern
duplications in chick wing bud [301]. However, interpretation of these results are not
as straight forward, because isomerisation or inactivation of the RA isomers could have
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taken place during the course of preparing the reagents and upon entering the cells.
Other derivatives of RA, some of which more polar than RA, had also been isolated
and examined. For example, 4-hydroxy-RA and 4-oxo-RA were reported to be bioactive
albeit far less potent than RA [88]; 5,6-monoepoxy-RA was found to promote growth
in VAD rats [133]. In terms of their roles in development, Thaller et al. reported the
isolation of 3,4-didehydro-RA, which was found to be as potent as tRA in promoting
digit duplication in chick wing bud [300], while Niederreither et al. provided genetic
evidence that the oxidative metabolites of RA are not involved in mediating embryonic
development in mice [230].
While the importance of other bioactive retinoid compounds cannot be ignored, RA,
particularly tRA, is the most abundant isomer of endogenous RA in vivo and is by far
the most studied retinoid compound in a multitude of experimental models. Thus, it is
generally believed that tRA is the predominant and the most physiologically relevant
retinoid compound in mediating most of the biological processes, except in vision.
1.1.2 Transport of retinoids
Given their high lipophilicity, retinoids are bound to specific binding proteins to facili-
tate their transport in the circulation and within the cells. In the circulation, tRol is the
predominant form of retinoid compound and it is bound by Rbp; inside the cells, cellu-
lar retinol binding proteins 1, 2, and 3 (Crbp1, Crbp2, and Crbp3) bind both tRol and
tRal with varied affinity, while cellular retinoic acid binding proteins 1 and 2 (Crabp1
and Crabp2) as well as fatty acid binding protein 5 (Fabp5) bind tRA, again with varied
affinity [52, 280]. The focus of this section is to introduce the aforementioned binding
proteins and their functions in mediating activity of RA. The cellular retinaldehyde bind-
ing protein (Cralbp) and the interphotoreceptor retinoid binding protein (Irbp), which are
expressed exclusively in retina and in neural tissues [52], will not be covered here.
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Rbp and stimulated by retinoic acid (Stra6)
Rbp is a member of the lipocalin superfamily that binds to circulating Rol [228]. Al-
though Rbp is the only known protein that binds to and facilitate transport of circulating
Rol, classical symptoms of vitamin A deficiency were not observed when Rbp gene was
defected or absent. Patients with mutation of Rbp gene had very low level of circulating
Rol, but were physiologically normal other than suffering from vision impairment [23].
Similarly, mice with genetic ablation of Rbp had low serum Rol level, but remained vi-
able, fertile, and otherwise healthy; impaired retinal function was found, consistent with
a lower Rol level in the eye, which were rescued with vitamin A supplementation [253].
The retinal function impairment was later found to be associated with a defect in Rol
uptake into the eye rather than to low maternal retinoid supply from lactation [313].
Despite a lower basal level of circulating Rol, Rol level in the liver, kidney, spleen, and
reproductive organs of 13-week-old Rbp null mutants was similar to that of the wild-type
mice; hepatic retinyl ester store in Rbp null mutants was higher compared to that of wild-
type mice [253]. When fed a VAD diet for one week, the Rbp null mutants suffered a
rapid decline of serum Rol but hepatic Rol level remained the same, whereas hepatic Rol
level in wild-type mice was reduced in compensation for reduced serum Rol [253]. Se-
vere embryonic malformation resembling the VAD syndromes was observed only when
pregnant Rbp null mutants mothers were fed a VAD diet over a prolonged period [254].
Based on these observation, the authors suggested that post-prandial and maternal sup-
ply of retinoids, i.e., retinyl ester-containing chylomicrons and cyhlomicron remnants,
play a dominant role in contributing towards endogenous retinoid pool in the absence of
Rbp, and that Rbp has specific function(s) in mobilisation of hepatic Rol into the circu-
lation [253, 254].
Interestingly, circulating RA level was found to be comparable between Rbp null mutants
and wild-type mice [253], and between individuals with mutated Rbp and their normal
family member [23]. In another report, it was found that both hepatic and extra-hepatic
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tissues can directly absorb the low circulating level of tRA, in the form of albumin-
bound tRA derived from diet [157]. Thus, when Rbp was defected or absent, the intra-
and extra-cellular RA equilibrium could still be somehow achieved, which might explain
the lack of overt VAD syndromes.
In 2007, Kawaguchi et al. showed that Stra6 serves as a receptor of Rbp that mediates
uptake of Rbp-bound Rol, which was further enhanced in the presence of intra-cellular
Lrat, and proposed that the Rbp-Stra6 system constitutes an important physiological
mechanism of Rol uptake in many tissues [146]. In the same year, Pasutto et al. reported
that mutations of Stra6 gene in human resulted in a broad spectrum of malformations,
some of which overlapped with the developmental defects observed in congenital VAD
animals [244]. The severe outcomes observed in human with Stra6 gene mutation and
the relatively mild defects involving only the vision system in human with Rbp mutation
leads to speculation that Stra6 may have additional yet identified functions [24].
Recent reports had provided evidence of Stra6 facilitating not only Rol uptake into the
cells but also export of cellular Rol [129]. In addition, Stra6 was also reported to acti-
vate transcription factors to regulate gene expression thereby inhibiting insulin responses
upon associating with Rbp-bound Rol [22]. A zebrafish genetic model of Stra6 knock-
down had shed light on the role of Stra6 in clearing circulating Rbp-bound Rol to prevent
off-target delivery of Rol [129]. Establishment of mouse null models of Stra6 gene in
the future should better define the roles of Stra6 in homeostasis of endogenous retinoids
and its relationship with Rbp-bound Rol.
Crbps
The role of Rbp as a carrier for Rol ends when Rol enters the cell. In 1973, Bashor et
al. reported the presence of a cellular protein component derived from rat lungs, liver,
kidneys, testis, and intestinal mucosa, which binds Rol with high affinity, but has distinct
property compared to Rbp [15], known as Crbp1. A second type of Crbp, Crbp2, was
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found to be expressed predominantly in neonatal rat intestine and liver, and almost exclu-
sively in adult rat intestine [50,237]. Both Crbp1 and Crbp2 bind Rol (tRol, 13cRol, and
9cRol) and Ral (tRal and 9cRal) but not RA [136]. An additional type of murine Crbp,
Crbp3, which binds only tRol was recently reported, with high expression restricted to
heart, muscle, adipose tissue, and mammary gland [312]. It is worth noting that the
murine Crbp3 is not homologous to the human Crbp3 discovered in the same year [84].
Intra-cellular Rol binds with high affinity to Crbps. For instance, the dissociation con-
stant (Kd) between Crbp1 and Rol is around 0.1 to 10 nM, hence it is believed that there
will be little, if any, unbound Rol in the cells [223, 236]. It was proposed that holo-Crbp
(Crbp bound to retinoids) have many roles other than to circumvent the low aqueous
solubility of retinoids in the cells, such as sequestering retinoids from cell membrane to
protect cell from membranolytic activity of retinoids, protecting retinoids from destruc-
tive enzymatic and non-enzymatic reactions, and limiting access of specific enzymes to
bound-retinoids [223, 224, 236].
Crbp1 null mutants developed normally despite a lower embryonic and foetal Rol and
retinyl ester store [97, 199]. A slight decrease in embryonic RA level was also noted.
However, when mated with RARβ2-lacZ and RARE-hsp68-lacZ mice, which are re-
porter of endogenous RA activity, there was no decrease in reporter activity compared
to the wild-type mice [199]. This suggests minimum impact of Crbp1 deletion on endo-
genous RA activity, which might explain the lack of developmental impairment. After
birth, Crbp1 null mutants were healthy and had a normal intestinal retinoid uptake and
esterification, but hepatic retinyl palmitate had a higher turnover rate leading to a de-
crease in retinoid storage in liver [97]. A lower level of Ral was also found in kidneys
and lungs of adult mutant mice but no abnormalities were reported [97]. When fed a
VAD diet, Crbp1 null mutants exhausted their hepatic retinyl palmitate storage six times
faster than the wild-type mice and accordingly, exhibited many classical symptoms of
vitamin A deficiency earlier than the wild-type mice [97].
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Crbp2 null mutants also developed normally despite lower intestinal Rol uptake and
lower hepatic Rol storage; when pregnant Crbp2 null mutants were fed a diet con-
taining only marginal vitamin A, a higher neonatal lethality associated with lung and
heart defects was found, which was attributed to lower maternal Rol delivery to embryos
as a consequence of lower maternal hepatic Rol storage following lower intestinal up-
take [71].
Crbp3 null mutants had lower retinyl ester store in the milk of lactating mother com-
pared to that in wild-type mice [248]. When fed a high-fat diet for 20 weeks, Crbp3
null mutants had similar level of Rol and retinyl ester in the white adipose tissues and
liver as that of wild-type mice, but were more resistant towards the fat accumulation in
the liver [344]. The phenomenon was attributed to lower food intake and decrease in
glycerol and free fatty acid efflux from adipose tissue [344].
The expression sites of Crbps and their respective knockout phenotypes suggested that
Crbp1 mainly participates in regulating retinoid storage mechanism in a wide variety of
tissues; Crbp2 acts as binding protein of Rol in the intestine to facilitate its intestinal
absorption. On the other hand, the physiological ligand of Crbp3 remained question-
able although it binds to tRol in vitro [52], and hence its role in retinoid transport and
metabolism requires further investigations. It is noteworthy that none of the Crbp knock-
out mice displayed symptoms of vitamin A deficiency when fed a normal diet. Although
in all the aforementioned Crbp knockout models, an up- or down-regulation of the other
Crbp isoforms were observed at certain stages [71, 97, 199, 248, 344], functional redun-
dancy among them is difficult to be justified in view of their non-direct overlapping of
expression sites.
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Crabps and Fabp5
An intra-cellular binding protein that binds specifically to RA with high affinity but not
to Rol was described in the mid 1970s, first in chick embryos [275] then in rats [238],
which was later named as Crabp1. The discovery of a second Crabp isoform, called
Crabp2, were subsequently reported in rats [10] and in mice [99]. More recently, it
was proposed that Fabp5 also serves as an intra-cellular binding protein for RA [280].
While the expression pattern of Fabp5 had not been systematically studied, expression of
Crabp2 transcript was observed in a wide range of tissues, whereas expression of Crabp1
transcript was more restricted in developing mouse embryos [270].
In vitro, Crabp1 binds to RA with higher affinity (Kd of 0.06 nM) compared to Crabp2
(Kd of 0.13 nM) [63], while Fabp5 binds to RA with a Kd of approximately 35 nM [280].
It was proposed that Crabps not only facilitate RA transport in the cells but shuttle RA
specifically into cell nucleus [296]. The proposal was supported by the observations of
Crabp1 and Crabp2 protein in nuclei of embryos and various cell types [93, 116], sug-
gesting an active involvement of these proteins in mediating RA signalling.
Judging from the expression sites of Crabp1 transcript, which correlates well with struc-
tures susceptible towards excessive retinoid induced-teratogenicity, it was speculated
that Crabp1 acts predominantly to sequester RA in order to protect these sensitive struc-
tures from being exposed to excessive RA [270]. Contrary to the speculation, Crabp1
knockout mice were indistinguishable from their wild-type counterparts during develop-
ment and after birth, and when pregnant mothers were fed a low teratogenic dose of RA,
both mutant and wild-type mice suffered axial skeletal malformation to a similar ex-
tent [109]. Crabp2 and Crabp1/Crabp2 double knockout mice also appeared normal, but
exhibited limb outgrowth, which was not fully penetrant [77,160]. Just as null mutants of
Crabps, no apparent abnormalities were noted following genetic ablation of Fabp5 [188].
While genetic null mutants did not suggest crucial involvements of Crabps and Fabp5 in
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mediating RA activity, in vitro experiments had provided invaluable molecular insights
into the roles of Crabps and Fabp5 in this regard. Boylan and Gudas showed that sense
Crabp1 F9 teratocarcinoma stem cell transfectants, characterised by a higher level of
functional Crabp1 protein, had a shorter intra-cellular half-life of RA and a higher rate
of 4-oxo-RA production compared to wild-type cells; anti-sense Crabp1 F9 transfec-
tants, which had reduced level of functional Crabp1, exhibited an opposite result [32].
As opposed to Crabp1, which was shown to not actively participate in mediating RA
signalling [59,308], an increase in tRA-induced reporter activity and target gene expres-
sion was found in cells expressing endogenous and transfected Crabp2, in the presence of
retinoid nuclear receptors [59,63]. Consistent with this result, a direct protein-protein in-
teraction was observed between retinoid nuclear receptors and Crabp2 in cell nuclei [59].
Acting rather similarly as Crabp2, Fabp5 binds to RA and directs RA into cell nuclei to
bind and activate peroxisome proliferator-activated receptor (PPAR) [280]. The roles of
retinoid nuclear receptors and PPAR in transducing RA signalling will be presented in
Sections 1.1.4 and 1.1.5.
All in all, the absence of overt defects during development and adult life in null mu-
tants of Crabps and Fabp5, as well as the lack of evidence suggesting them to be more
susceptible towards RA-induced teratogenicity, argue against their postulated functions
in mediating RA signalling especially at the physiological level, except in the limbs.
However, in vitro evidence strongly suggests their involvement in shuttling RA towards
distinct molecular pathways. Until additional carrier proteins are identified or further
evidence defying these postulations, it is generally accepted that Crabp1 shuttles intra-
cellular RA to the metabolism pathways, whereas Crabp2 and Fabp5 transfer RA into
cell nuclei towards the signalling pathways.
1.1.3 Metabolism of retinoids
Catalysed by specific enzymes, retinoids go through a series of oxidation and reduction
within the cells, including a reversible inter-conversion between Rol and Ral, and an ir-
reversible conversion of Ral into RA. Multiple isoforms of the aforementioned enzymes
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had been discovered in human, rats, and mice, each of which has species-specific on-
tologies. In order to avoid confusion, this section is mainly focusing on enzymes derived
from mice and their respective knockout phenotypes, if available.
Inter-conversion between Rol and Ral
The reversible conversion between Rol and Ral is mainly catalysed by enzymes of two
families: (i) cytosolic alcohol dehydrogenase (Adh), a member of the medium-chain de-
hydrogenase/reductase superfamily, and (ii) microsomal retinol dehydrogenase (Rdh),
a member of the short-chain dehydrogenase/reductase superfamily [156, 242]. Involve-
ment of AKR1B10, a human enzyme of the aldo-keto reductase family, had also been
described to catalyse the conversion of Ral back to Rol [92] but its mouse ortholog was
not identified as yet [271].
Retinoids had long been identified as substrates for Adh [261]. It is now known that there
are six classes of Adh (class I-VI) in mouse, of which Adh class I, III, and IV, herein
referred as Adh1, Adh3, and Adh4, respectively, were reported to possess specific but
somewhat overlapping functions in retinoid metabolism [119, 242]. Similarly, multiple
Rdhs are known to be involved in retinoid metabolism, some of which have higher ac-
tivities towards androgen than towards retinoids such as mouse Rdh7, Rdh9, and Rdh16
[242]. In mice, Rdh1 [335, 336] and Rdh10 [274] were reported to play a significant
role in biosynthesis of tRA. Some of these enzymes have additional catalytic functions,
e.g., Adh1 and Adh3 act as scavengers for ethanol and S-hydroxymethylglutathione, re-
spectively [119,242], while Rdh1 has strong 3α-hydroxy and weak 17β -hydroxy steroid
dehydrogenase activities [335].
Adh1, Adh3, and Adh4 act mainly as oxidases (also called dehydrogenases) that con-
vert tRol into tRal [242]; in vitro, mouse Adh1 and Adh4 are about 1,000x and 4,000x
more active than Adh3, respectively, in generating tRal from tRol [215]. Mouse Rdh1
was found to have a preferential activity towards tRol over cis form of Rol [335] while
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human RDH10 was found to function more efficiently as Rol dehydrogenase to produce
Ral rather than acting as Ral reductase [20].
A great number of kinetic studies had been performed to determine whether Adhs or
Rdhs are the predominant Rol dehydrogenases involved in biosynthesis of RA, but a
general consensus has not been achieved until today due to the use of different param-
eters and methodologies. Specifically, while both Adhs and Rdhs follow Michaelis-
Menten kinetics, enzymatic assays of Rdhs took into account the involvement of Crbp1
as binding protein of intra-cellular Rol, i.e., Crbp1-bound Rol rather than crude Rol as
substrate [224, 242]. In addition, different indexes were used to describe the enzyme
kinetics, i.e., kcat, Km, and Vmax. Depending on the assays performed, certain indexes
were deemed more apt than others in describing the enzyme activity hence precluding a
direct comparison between the cytosolic Adhs and the microsomal Rdhs. It is also im-
portant to note that some of these enzymes are not fully orthologous among rat, mouse,
and human [335] and hence kinetic data derived from enzymes from one species may
not be applicable to another.
Genetic deletions of these enzymes were performed to further elucidate their physio-
logical functions. Null mutants for Adh1, Adh3, Adh4, and Adh1/Adh4 were generated
and were subjected to different amount of dietary vitamin A or challenged with high
dose of Rol to assess rate of RA biosynthesis [57, 58, 214]. The major findings of these
studies, including the phenotypes of these null mutants are summarised in Table 1.1.
Based on the genetic studies, it was concluded that Adh1 likely functions to eliminate
excessive Rol to prevent vitamin A toxicity, whereas Adh4 is essential for survival during
vitamin A deficiency perhaps by maintaining RA supply; the functions of Adh3 overlap
those of Adh1 and Adh4 [156]. It is important to note that the basal retinoid profile,
especially level of RA, had not been described in the null mutants of Adhs. Therefore,
the roles of Adhs in retinoid metabolism under basal condition remains to be established.
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Rdh1-/- mutants were found to develop normally and were fertile under basal condition
but had a different basal retinoid profile compared to their wild-type counterparts [336].
When fed a diet with recommended amount of vitamin A (4 IU/g), a higher level of tRol
was detected in mutant liver; when dietary vitamin A was reduced to 0.6 IU/g, higher
level of tRol and retinyl ester were detected in liver and higher tRol was also detected
in kidney (Table 1.2). In addition, expression of hepatic Cyp26a1, a gene involved in
metabolism of tRA into polar metabolites, was lower in Rdh1-/- mutants compared to
wild-type mice except when fed a diet with copious amount of vitamin A (> 30 IU/g).
The authors postulated the presence of an auto-compensation mechanism to spare tRA
by down-regulation of Cyp26a1 in the absence of Rdh1 gene, and concluded that Rdh1
is involved in retinoid homeostasis under physiological condition [336]. Unexpectedly,
when fed a VAD diet or diet containing minimum vitamin A (0.1 IU/g) for 33 weeks,
Rdh1-/- displayed an increase in length, weight, and adiposity compared to wild-type
mice, for which the mechanisms remain unresolved [224, 336].
Table 1.2: Endogenous retinoid profile in Rdh1-/- mice compared to paired-fed wild-
type mice [336]. Endogenous tRA, tRol, and retinyl ester were assessed in serum, liver,
kidneys, brain, and testis. “Normal” indicates no difference from wild-type animals; *:
in serum and tissues; †: magnitude not stated clearly; ˆ: in tissues.
Dietary
vitamin A
tRA* tRolˆ Retinyl esterˆ Hepatic
Cyp26a1




Liver: 40% increase 2.5-fold
decrease
4 IU/g Normal Liver: 2-fold
increase
Normal Decrease†
> 30 IU/g Normal Normal Normal Normal
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In an attempt to identify genes regulating embryonic development, Sandell et al. discov-
ered a mutant mouse called trex that harboured a mutation in the Rdh10 gene leading
to lower Rdh10 protein expression, lower tRal production, and loss of RA reporter ac-
tivity with minimum residual activity in neural tube when mated to RARE-hsp68-lacZ
reporter mice [274]. These mutants suffered developmental defects including cranio-
facial, limb, and organ abnormalities, beginning at embryonic day (E) 10.5, and died
by approximately E13, which could be rescued by maternal RA supplementation [274].
More recently, a cross between trex mutant and Adh-del-mutant (with null mutations of
Adh1-5) was reported, but the cross mutants exhibited a similar phenotype as trex mu-
tants [156]. While the endogenous retinoid profile had not been described following a
mutation in Rdh10, the embryonic lethality that was reversible with maternal RA sup-
plementation strongly suggest it to be the predominant enzyme in biosynthesis of RA
during development.
Other than the aforementioned enzymes, emerging evidence suggests the involvement
of novel enzymes from the short-chain dehydrogenase/reductase family in the inter-
conversion between Rol and Ral. For example, knockdown of Rdh1l (also known as
Dhrs9) in zebrafish led to developmental defects, which were rescued by tRA treat-
ment [220]. On the other hand, a few potential candidate enzymes has been reported to
serve as reductases that convert tRal back to tRol, such as retinal reductase, RRD [166],
and retSDR1 (also known as Dhrs3) [78, 117]. Mouse null mutants for these genes are
either not established yet or are not being investigated in detail. Thus, their importance
in maintaining a balance of Rol-Ral inter-conversion remains to be further explored. Un-
til then, this thesis would adopt proposals that both Adhs (especially Adh3 and Adh4) as
well as Rdhs (especially Rdh1 and Rdh10) are involved in the biosynthesis of RA, using
Crbp1-bound and unbound Rol as substrates.
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Conversion of Ral into RA
Conversion of Ral into RA is an irreversible oxidative process, catalysed by the class
I cytosolic aldehyde dehydrogenases (Aldh1), also known as retinaldehyde dehydroge-
nases (Raldhs) [4,302]. At least three Raldhs were identified to be involved in catalysing
the formation of RA from Ral, namely, Aldh1a1, Aldh1a2, and Aldh1a3, also known as
Raldh1, Raldh2, and Raldh3, respectively [302]. More recently, a fourth enzyme called
Aldh8a1 or Raldh4, was found to also participate in this enzymatic conversion [177].
Raldh1 was the first Raldh found to oxidise Ral into RA in mouse tissues [163,200], af-
ter which Raldh2 [339], Raldh3 [210], and Raldh4 [177] were reported. In vitro, Raldh1
is about 10-fold less efficient than Raldh2 and Raldh3 in converting tRal into tRA, while
Raldh4 recognises predominantly 9cRal as substrate [66, 112, 177]. In addition to Ral,
Raldhs recognise additional substrates, e.g., Raldh1 recognises 4-hydroxynenonal and
malondialdehyde, which are break-down products of lipid hydroperoxides [4].
In 1999, Aldh1a2-/- mutants were established. The null mutants suffered embryonic
lethality at E10.5 without undergoing body turning and presented with many develop-
mental defects such as shortening of anterior-posterior axis, absence of limb bud, and
truncated frontonasal region, which was largely but not fully rescued with maternal RA
supplementation [234]. A similar phenotype was reproduced in another line of Raldh2
null mutants involving another strain [208]. Of note, a near complete loss of RA re-
porter activity was observed at E7.5-10.5, except for a week signal in the developing
eye, when Aldh1a2-/- were mated to RARE-hsp68-lacZ and RARβ2-lacZ reporter mice,
respectively [208, 234].
In 2003, Aldh1a3-/- mice were established, which were born according to Mendelian
frequency but died shortly after birth due to respiratory distress; when mated to RARE-
hsp68-lacZ reporter mice, there was a partial loss of RA reporter activity in developing
eyes associated with eye development impairment, and a complete loss of RA reporter
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activity in developing nose associated with severe nasal defects [69, 216]. Similar to the
Aldh1a2-/- mice, developmental defects and post-natal lethality observed in Aldh1a3-/-
mice were largely prevented by maternal RA supplementation [69].
Also in 2003, mouse model of Raldh1 genetic ablation was generated. Aldh1a1-/- mice
were viable and appeared normal phenotypically [76, 198], but showed a different hep-
atic retinoid profile compared to wild-type mice [76]. Specifically, tRol and retinyl ester
in the liver of Aldh1a1-/- mice were about 2-fold and 2.5-fold higher, respectively, com-
pared to that in the liver of wild-type mice. No difference in the level of hepatic tRA
was found; a lower level of hepatic tRA in Aldh1a1-/- mice compared to that in wild-
type mice was only apparent when challenged with a single high dose of Rol [76]. An
increase in incidence of cataracts was also reported in Aldh1a1-/- mice of 6-9 months
old compared to age-matched wild-type mice, which was attributed to accumulation of
toxic lipid peroxide aldehydes and free oxygen radicals leading to protein cross-linking
and aggregation [161].
Following the observation of residual RA reporter activity in the developing eye of
Raldh2 null mutants [235], compound null mutants of Raldhs, i.e., Aldh1a1-/- / Aldh1a2-/-
mice [211], Aldh1a1-/- / Aldh1a3-/- mice [198,216], Aldh1a2-/- / Aldh1a3-/- mice [216],
and Aldh1a1-/- / Aldh1a2-/- / Aldh1a3-/- mice [216], were established in an attempt to
further elucidate the contribution of Raldhs other than Raldh2 during eye development.
Many of these compound null mutant mice were subjected to low dose RA supplemen-
tation in order to prevent mid-gestation lethality of their offsprings, and the main con-
clusions drawn from these reports were that both Raldh1 and Raldh3 are indeed required
for eye development, and that genetic deletion of Raldh1 can be compensated by Raldh3
and vice versa.
The aforementioned genetic studies had highlighted the roles of Raldhs in biosynthe-
sis of RA during embryonic development. Raldh2 is required for generating endoge-
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nous RA during embryonic development, Raldh3 is required for nasal development, and
Raldh1 and Raldh3 were needed to generate RA for eye development. The functions of
these enzymes in RA biosynthesis during development were in good concordance with
a diminution of reporter gene expression when the null mutants were mated to reporter
mice of endogenous RA activity. After birth, Raldh1 might have additional roles in the
eyes besides acting as retinaldehyde dehydrogenase, and its role in tRA biosynthesis
might only be applicable when Rol is in excess. The mid-gestation lethality of Raldh2
null mutants and the early post-natal lethality of Raldh3 null mutants had precluded in-
vestigation into their contributions towards RA biosynthesis at later stages but it is well
possible that there are functional redundancies among Raldh1-3, and each may play a
more dominant role at certain stages and under certain conditions. The role of Raldh4
remains unknown given their low affinity towards tRal and the lack of genetic evidence
suggesting its contribution towards RA biosynthesis.
Given the reversible nature of conversion between Rol and Ral, it was deemed an equili-
brium will be achieved between Rol and Ral, and the irreversible conversion of Ral into
RA should be the crucial step in determining the rate of RA biosynthesis [67]. However,
when the involvement of Crbp1 as binding protein of intra-cellular Rol was taken into
consideration, evidence from in vitro studies showed that conversion from Rol to Ral
should be the rate limiting step [224]. Taken together, biosynthesis of RA is a complex
biological process that involves multiple enzymes with potential functional redundan-
cies. Moreover, activities of the enzymes are depending on their sites of expression,
which might be dynamically regulated. To date, the roles of Raldh2, Raldh3, and Rdh10
in generating RA for embryonic and post-natal development are better acknowledged,
whereas the actual physiological roles of other RA synthesising enzymes require further
investigations to achieve more solid conclusions.
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Conversion of RA into polar metabolites
The involvement of microsomal enzymes, cytochrome P450 (Cyp450), in the conver-
sion of RA into polar metabolites was first described in 1984 [170]. Subsequent work
on Cyp450 enzymes had been carried out, leading to identification and characterisation
of Cyp26a1 [89,258,319,320], Cyp26b1 [186,226,321], and Cyp26c1 [294,295], in hu-
man and in mice. Although many other members of the Cyp450, e.g., Cyp2c8, Cyp3a4,
Cyp3a5, and Cyp3a7, have been suggested to be involved in this reaction, it is now
recognised that Cyp26a1-c1 are largely responsible in the phase I oxidation of RA into
more polar metabolites, which are then glucuronidated and excreted [265].
In vitro experiments examining substrate specificity performed using human and mouse
Cyp26a1-c1 revealed that these enzymes recognise specifically RA as substrate, but not
Rol nor Ral [295, 321]. While Cyp26a1-c1 exhibited high specificity towards tRA and
catalysed its metabolism into polar metabolites including 4-hydroxy-RA, 4-oxo-RA, 18-
hydroxy-RA, and 5,8-epoxy-RA, Cyp26c1 also exhibited an equally high specificity to-
wards 9cRA, yielding 4-hydroxy-9cRA and 4-oxo-9cRA [295, 321].
The generation of Cyp26a1 null mutant mice were reported by two independent groups
in 2001 [1, 273]. While Cyp26a1+/- mice were indistinguishable from the wild-type
mice, Cyp26a1-/- mice died before birth or within one day after birth, and exhibited
symptoms recapitulating teratogenic effect of excess RA, e.g., exencephaly, spina bifida,
and abnormal patterning of hindbrain and tailbud [240]. Notably, when Cyp26a1-/- mice
were mated to RARE-hsp68-lacZ mice, an increase in RA reporter activity was noted not
only in the sites where RA reporter activity was normally observed, but also in domains
where RA reporter activity was normally absent [273]. Just as Cyp26a1+/- mice, hete-
rozygous null mutants for Cyp26b1 were no different from their wild-type counterparts
but Cyp26b1-/- died within a few hours after birth due to respiratory distress, and they
exhibited truncated limbs, severe craniofacial abnormalities, and absence of germ cells
(in male mice), which was again attributed to an accumulation of bioactive RA following
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Cyp26b1 inactivation [187,331]. Cyp26c1-/- mice developed normally but when crossed
with Cyp26a1-/- mice, the double null mutants exhibited embryonic lethality at E11-12.5
and severe malformation in the central nervous system [306].
Although there have been reports that metabolism products of RA catalysed by the
Cyp26 enzymes, such as 4-oxo-RA and 4-hydroxy-RA, were bioactive, null mutants
of Cyp26s exhibited phenotypes that recapitulated the classical teratogenic effects in-
duced by RA rather than the VAD syndromes. By partially disrupting RA biosynthesis
via heterozygous ablation of Raldh2 (Aldh1a2+/-) in Cyp26a1-/- mice, Niederreither et
al. had provided genetic evidence that argues against oxidative products of RA playing a
functional role during murine development [230]. Specifically, Cyp26a1-/- / Aldh1a2+/-
mice had higher post-natal survival rate compared to the early lethality of Cyp26a1 null
mutants, and many developmental defects found in Cyp26a1-/-, such as spina bifida were
rescued following heterozygous disruption of Raldh2 [230]. This study supports that the
phenotypes of Cyp26a1-/- mice were a result of RA excess, which were ameliorated by
reducing RA biosynthesis, rather than due to an insufficiency of RA metabolites.
Taken together, genetic studies suggest that Cyp26a1 and Cyp26b1 are essential for
embryonic development and for post-natal survival, respectively, while Cyp26c1 acts
in cooperation with Cyp26a1 to reduce the sensitivity of embryo to excessive RA. In
addition, Cyp26b1 may play a unique role in germ cell development. However, specific
functions of these enzymes, especially in adults, are not well defined until today [265].
1.1.4 The canonical signalling
The canonical signalling of retinoids is the focus of this project. It involves activation
of retinoid nuclear receptors by RA and subsequent mobilisation of the transcription co-
regulators, leading to gene transcription modulation [264]. Target genes of RA canoni-
cal signalling are often characterised by the presence of retinoic acid response element
(RARE) in their regulatory region [41]. All the key players involved in the canonical
signalling are briefly introduced here.
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Retinoid nuclear receptors
There are two families of retinoid nuclear receptors, namely, retinoic acid receptors
(RARs) and retinoic acid X receptors (RXRs), which are members of the steroid nu-
clear receptor superfamily and act as transcription factors [41]. There are three isotypes
of RARs, i.e., RARα , RARβ , and RARγ , encoded by Rara, Rarb, and Rarg, respec-
tively, and three isotypes of RXRs, i.e., RXRα , RXRβ , RXRγ , encoded by Rxra, Rxrb,
and Rxrg, respectively. Each RAR and RXR isotype constitutes at least two isoforms,
generated by differential promoter usage and alternative splicing [41].
In 1987, two independent groups had reported the discovery of RARα , which bound
strongly to RA and transduced signal of RA in a dose-dependent and saturable man-
ner, but did not respond to thyroid hormone, vitamin D, dexamethasone, or testos-
terone [100, 247]. Shortly after the discovery of RARα , two additional RAR isotypes
with similar properties, namely RARβ [33] and RARγ [155], were discovered. The
discovery of a distinct but closely related nuclear receptor, RXRα , was subsequently
reported by Mangelsdorf et al., which responded towards RA treatment in a dose de-
pendent manner but responded poorly towards TTNPB, a pan-RAR agonist [190]. Soon
after, RXRβ and RXRγ were discovered, and the concept of RXRs binding to RARs as
heterodimers that enhance their binding to DNA leading to more efficient signal trans-
duction was introduced [168, 333].
The amino acid sequence of an individual isotype of RAR and RXR is better conserved
across species than that of the three RAR or RXR isotypes in a given species [167].
The RARs shared a similar modular structure, consisting six conserved regions desig-
nated A to F. Regions C and E that encompass DNA binding domain (DBD) and ligand
binding domain (LBD), respectively, are most conserved and play the most important
roles, i.e., DBD recognises specific DNA sequences and served as dimerisation interface,
while LBD comprises ligand binding pockets for ligand binding, a major interface for
1.1. An overview of the retinoid system 44
dimerisation, and the activation function 2 (AF-2) that is required for ligand-dependent
activation [264]. The A/B region represents the N-terminal domain encompassing a
ligand-independent activation function 1 (AF-1) that synergises with AF-2 to activate
transcription; the D region serves mainly as a rotatable hinge between DBD and LBD;
function of F region remains poorly understood but may enhance binding of transcrip-
tion co-repressors in the absence of ligand and may be capable to bind specific mRNA
motifs [221, 264].
RXRs adopt the same modular structure as RARs except that region F is absent [164].
Besides heterodimerising with RARs, RXRs form homodimers and homotetramers, and
also serve as promiscuous binding partner for many other nuclear receptors, such as
PPAR, thyroid hormone receptor (T3R), and vitamin D receptor [164]. A schematic
representation of retinoid nuclear receptor heterodimers and brief description of each
region are depicted in Figure 1.2.
Figure 1.2: Schematic representation of retinoic acid receptor (RAR) and retinoic acid
X receptor (RXR) modular structure. RAR (yellow) and RXR (blue) form heterodimers,
which binds to a specific sequence called retinoic acid response element (RARE) present
on retinoid target genes to modulate gene transcription activity.
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In the context where RXR and RAR function as heterodimer, Forman et al. found that
reporter activity can be induced by RAR ligand but not by RXR ligand [85]. By treat-
ing P19 teratocarcinoma cells and F9 cells with RAR-specific agonists and RXR-specific
agonists individually and in combination, Roy et al. reported that RAR activation but not
RXR activation resulted in induction of gene expression; when given in combination, a
synergistic effect was observed whereby gene expression and cell differentiation were
induced to a greater extent at lower doses of agonists [269]. Subsequent work proposed
that binding of RAR to its ligands has to first take place before RXR can be bound by
its ligand [317]. In a later study, it was reported that both RXR and RAR within the
heterodimer can bind to their respective ligands independently, but their bindings elicit
different responses in terms of co-regulator mobilisation [95], which will be further elu-
cidated in the following subsection.
Several studies had investigated the endogenous ligands of RARs and RXRs. Using
COS-1 African green monkey kidney fibroblast-like cells transfected with individual
isotypes of mouse RARs and RXRs, Allenby et al. reported that tRA and 9cRA bound
to all three isotypes of RARs with high affinity (Kd of 0.2-0.4 nM for tRA and 0.2-0.7
nM for 9cRA) [3]. While the respective 3,4-didehydro form of tRA and 9cRA were also
found to be as effective in receptor binding and activation [3], the role of 3,4-didehydro
form of tRA as endogenous ligand of RARs was better established in avians than in ro-
dents [260, 300]. Retinoids other than RA had also been reported to be natural ligands
of RARs but the results were less definitive. For example, tRol was reported to bind and
activate human RARs but was 4- to 37-fold less potent compared to tRA [259]. On the
other hand, Achkar et al. reported that mouse RARs were not bound to tRol but did bind
to 4-oxo-Rol [2]. Based on consistent reports derived from binding assays, transactiva-
tion assays, and its abundance detected in vivo, tRA is well acknowledged to be the most
physiologically relevant endogenous ligand of RARs by far.
On the other hand, identification of specific endogenous ligands of RXRs remains a
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great challenge until today [164]. While tRA binds to RARs with high affinity, it does
not bind RXRs [3]. 9cRA binds to RXRs with high affinity (Kd within 14.0-16.0 nM)
and activates the receptors [3] but in vivo, 9cRA was only detected in the pancreas [138].
Moreover, activity of 9cRA in pancreas was found to be rapid and distinct from that of
synthetic RXR agonists [138]. It is worth mentioning that some unsaturated fatty acid
was reported to bind and modulate activities of RXRs, but the binding was not exclusive
as the fatty acid also binds other nuclear receptors, including PPARs [164].
Null mutants of individual retinoid nuclear receptor were soon available and the roles
of the receptors in transducing RA signal have been better elucidated since. Rara-/- mice
develop normally, but exhibited testes degeneration and webbed digits, and more than
90% of the null mutant mice died before the age of two-month-old without obvious spe-
cific lethal lesions [183]. Rarb-/- mice were growth deficient, but were fertile and live as
long as their wild-type counterparts [98, 184]. Rarg-/- mutant mice did not die in utero,
but suffered congenital anomalies such as Harderian gland agenesis, tracheal cartilage
malformations, and homeotic transformations along the rostral axial skeleton; a higher
post-natal mortality rate was noted with less than 40% of Rarg-/- mutant mice surviving
to 3-month-old and the surviving mice were growth deficient and sterile [182]. While
null mutants of a single RAR showed few anomalies, genetic deletion of two or more
RARs resulted in a plethora of developmental defects involving multiple organs with
striking resemblance to VAD syndromes observed in rats with maternal vitamin A de-
ficiency, which were comprehensively summarised in recent reviews [193, 231]. This
leads to the conclusion that RARs are indeed the major players in transducing RA sig-
nalling during development and that the RARs may be functionally redundant or may be
required to act in a cooperative manner.
Genetic deletion of individual Rxrs, except for Rxrg, resulted in a more severe deve-
lopmental defect than that of individual Rars. Rxra heterozygotic null mutants exhibited
growth deficiency, whereas Rxra homozygotic null mutants died in utero at E16.5, and
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exhibited ocular and myocardial anomalies [142]; about 50% of Rxrb-/- mutant mice
died in utero or at birth [144]; Rxrg-/- mutants were viable and fertile [154]. Importantly,
anomalies exhibited by Rxra-/- mice recapitulated VAD syndromes and developmental
defects of Rarb-/- / Rarg-/- double mutants, suggesting the involvement of RXRα in
transducing RA signals [145]. Consistent with the role of RXRs as promiscuous binding
partners for many nuclear receptors such as PPAR and T3R, anomalies not known to be
related to vitamin A deficiency, such as defects in male reproductive organ and metabolic
imbalance, were found in Rxrb-/- and in Rxrg-/- mice, respectively [35, 144, 218]. Com-
pound null mutants of two or more RXRs had then been established to further elucidate
their roles. Rxrg-/- / Rxra-/- mice exhibited similar ocular and cardiac defects as ob-
served in Rxra-/- mice while Rxrg-/- / Rxrb-/- mice and Rxrg-/- / Rxrb-/- / Rxra+/- mice
were viable despite being deficient in growth and exhibited male sterility [154]. These
studies had underscored RXRα as the predominant RXR isotype in mediating embryo-
nic development and that presence of a single allele is sufficient in this regard.
By establishing a battery of Rxr/Rar compound null mutants, Kastner et al. found that
genetic deletion (either single or double alleles) of Rxra together with either of the in-
dividual Rar isotype resulted in a synergism of ocular and myocardial defects observed
in Rxra mutants as well as other developmental defects not seen in Rxra single null mu-
tants and the corresponding single Rar null mutants; compound null mutants of Rxrb
and individual Rar isotype, as well as Rxrg and individual Rar isotype developed nor-
mally [143]. This study strongly suggests RXRα / RAR to be the primary functional unit
in transducing RA signalling during development, consistent with the idea of retinoid re-
ceptors functioning as heterodimers. By treating the Aldh1a2-/- mutant mice that lack
endogenous tRA with an RAR-specific agonist and an RXR-specific agonist, Mic et al.
reported that activation of RARs but not RXRs is sufficient to rescue lethal defects [209],
which is in good agreement with observations by Roy et al. that RAR activation is suf-
ficient to transduce RA signalling [269]. This concept of “RXR subordination” will be
further elucidated in the following subsection.
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Genetic deletion of retinoid nuclear receptors had indeed highlighted the crucial roles
of retinoid nuclear receptors, particularly in development. While the importance of
RXR/RAR heterodimers in transducing RA activity is no longer disputed, their specific
functions remained elusive and are not completely deciphered. The presence of addi-
tional abnormalities observed in compound null mutants of the receptors that are not
noted in VAD animals might be due simply to the fact that some residual RA signalling
might still be operational in animals with vitamin A deficiency whereas genetic deletion
of retinoid receptors resulted in a total inhibition of RA canonical signalling [193]. How-
ever, the observation might also suggest additional functions of these receptors in their
unliganded form. Early lethality in null mutants of retinoid nuclear receptors generated
from germline mutation had also precluded further investigations into the functions of
these genes, particularly during the adult stage. A few conditional knockout models were
reported [193] which should allow better understanding of these receptors, especially on
their roles in post-natal and adult life.
Transcription co-regulators
RXR/RAR-mediated regulation of gene transcription requires coordinated functions of
transcription co-regulators, which bind physically to RXR/RAR heterodimer and act
as “master switch” to switch the receptor heterodimers from an inactive state to an ac-
tive state and vice versa, via multiple biochemical mechanisms [36,104]. The transcrip-
tion co-regulators make up a diverse family of proteins that function with transcription
factors [36]. This section introduces their general functions in modulation of retinoid nu-
clear receptor silencing/activation rather than individual transcription co-regulators and
their respective functions, which have been presented in recent reviews [6, 264].
The transcription co-regulators can be largely categorised into two groups, i.e., (i) tran-
scription co-activators, and (ii) transcription co-repressors [6, 203]. Transcription co-
activators, exemplified by p160 subfamily of steroid receptor co-activators such as N-
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coA1 (nuclear receptor co-activator 1, also known as SRC1), CARM1 (coactivator-
associated arginine methyltransferase 1) and SWI/SNF (switch/sucrose non-fermenting),
bind to AF-2 on region E of retinoid nuclear receptors (Figure 1.2) in the presence of
ligand. Co-activators possess activities such as histone acetyltransferase, histone methyl-
transferase, and ATP-dependent chromosome remodelling, which decompact chromatin
into a more relaxed configuration. The co-activators are then released or degraded, giv-
ing way to the SMCC (Srb and Mediator protein containing complex), which then re-
cruits RNA-polymerase II and general transcription factors, leading to gene transcription
initiation [6, 264]. On the other hand, the transcription co-repressors, such as Nco-R
(nuclear receptor co-repressor) and SMRT (silencing mediator for retinoid and thyroid
hormone receptors), function to recruit big molecules with histone deacetylase activity,
thereby further stabilising the compact chromatin configuration hence silencing gene
transcription [6, 264].
In vitro, binding of transcription co-activators and transcription co-repressors to the
RXR/RAR heterodimer are mutually exclusive and a single co-activator can bind to both
RXR and RAR; binding of RAR to its ligand leads to dissociation of co-repressors but
binding of RXR to its ligand does not [95]. Thus, RARs were deemed “permissive” in
the context of RXR/RAR heterodimers, whereby liganded-RAR is sufficient to initiate
transcription whereas RXR was “subordinated” to their RAR partners [16, 114].
The universal interaction of transcription co-regulators with multiple transcription fac-
tors renders genetic deletion unhelpful in learning their functions. A working model that
briefly elucidates the functions of transcription co-regulators, in the context of their se-
quential interaction with retinoid nuclear receptors, is presented in the short summary at
the end of this subsection.
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RARE
RARE denotes a specific sequence that is present at the regulatory region of retinoid
target genes, which are recognised and bound by the RXR/RAR heterodimers. The clas-
sical RARE comprises direct repeat (DR) of two hexameric motifs, (A/G)G(G/T)TCA,
spaced by 1, 2 or, 5 bases, which are described as DR1, DR2, and DR5, respectively [41].
On DR2 and DR5, the RXR/RAR heterodimers bind in a polarity such that the RXR
binds to the hexameric motif located at the 5’ site while RAR binds at the 3’ site; the
polarity can reverse in the case of DR1, i.e., RAR binds to the 5’ site while RXR binds
to the 3’ site, which switches the role of the receptors from transcription activators into
transcription repressors [158]. In addition, DR1 can also be bound by RXR homodimers.
More recently, Lalevee et al. had performed an in silico whole genome screen for DR5
RARE, and proposed that a more relaxed (A/G)G(G/T)T(C/G)A motif to be the half site
of RARE, hence expanding the repertoire of classical RARE [159].
A gene cannot be defined as retinoid target gene based simply on the presence of nu-
cleotide sequences in the regulatory region that resemble RARE. Functions of RARE are
often examined in an in vitro setting by screening various regions of the gene promoter
using reporter-based assay and by examining the physical binding of RXR/RAR to the
regions determined. Point mutations of one or more nucleotides can also be performed
to further confirm the functions of RARE. Using such strategies, functional RARE was
identified and characterised in some members of the retinoid system, such as the Rarb
gene [54, 289] and the Rbp1 gene that encodes Crbp1 [284] in the early 90s. In fact,
many members of the retinoid system had subsequently been reported to contain one or
more functional RARE in their regulatory region. This phenomenon reflects the presence
of a self-regulatory control mechanism of the retinoid system, which will be further dis-
cussed in Section 1.1.6.
It is important to note that identification of functional RARE in a given gene is not always
as straight forward. RARE determined from reporter-based assay and from DNA-protein
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binding may sometimes produce artificial results, especially in cells over-expressed with
RXR/RAR. Also, RARE that is responsive in a well-controlled in vitro setting may not
be applicable to the dynamic state in vivo, as gene expression is often governed by more
than a single regulatory factor. Another issue complicating determination of RARE is
that RARE can come in far more complex arrangements other than the aforementioned
classical RARE [13, 41, 159], including: (i) The hexameric motif of an RARE can have
an even less rigid sequence, (A/G)G(G/T)(G/T)(G/C)A, (ii) RARE do not necessarily
follow the classical spacing attributes, i.e., 1, 2, and 5, between the DR hexameric mo-
tifs, (iii) presence of RARE is not restricted to the promoter region and can also be
present in the intronic regions, (iv) RARE can be present in both the coding and the
non-coding DNA strands, (v) RARE can be in both forward and reversed orientation.
A short summary of the canonical signalling
The working model described by Bastien and Rochette-Egly [16] is presented here to
summarise the canonical signalling pathway of retinoids:
1. In the absence of ligand, DBD (region C) of retinoid nuclear receptors asso-
ciates with RARE at the regulatory region of retinoid target genes; transcription
co-repressor complexes may be recruited to AF-2 in the LBD (region E) of the
retinoid nuclear receptors if the chromatin configuration is not impeding such in-
teraction.
2. When ligand binds to LBD (region E) resulting in a conformational change to the
nuclear receptors, transcription co-repressors will be released while transcription
co-activators will be recruited to AF-2 in the LBD, leading to a state of decompact
nucleosome ready for transcriptional activity to take place.
3. The transcription co-activators will then dissociate or degrade hence giving way
to SMCC, which facilitates the recruitment of RNA polymerase II and general
transcription factors thereby initiating transcription.
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The canonical signalling is a highly regulated and coordinated event, and much remains
to be learnt about the canonical signalling pathway of retinoids. It is important to note
that concomitant presence of RXR/RAR and transcription co-regulators in cells express-
ing genes that contains one or more RARE(s), are not necessarily indicative of an active
retinoid canonical signalling, until proven otherwise.
1.1.5 The non-canonical signalling
In order to better illustrate the multiplicity of RA signalling, the non-canonical signalling
of retinoids is briefly introduced here focusing on two examples.
Binding and activation of nuclear receptors other than retinoid nuclear receptors
Shaw et al. reported that tRA binds PPARβ /δ with high affinity (Kd of 17 ± 3 nM for
PPARβ /δ compared to Kd of 100-200 nM for PPARα and PPARγ); tRA treatment sta-
bilised binding of transcription co-activator SRC1 to PPARβ /δ and induce PPARβ /δ re-
porter activity [282]. The same group later reported that binding of RA to PPARβ /δ is an
event strictly governed by Fabp5, whereby Fabp5-bound RA was directed to PPARβ /δ
leading to activation of PPARβ /δ -mediated signalling events; in the case where Crabp2
protein exceeds Fabp5 protein, binding of Crabp2 to RA dominates and Crabp2-bound
RA would be channelled to RARs [280]. However, the involvement of RA in activat-
ing PPARβ /δ was defied by two other groups, who reported that RA does not bind to
PPARβ /δ , and does not activate PPARβ /δ -mediated signalling [30,263]. The discrepan-
cies remain unresolved and hence it is difficult to conclude on the relationship between
RA and PPARβ /δ at this stage.
Besides PPARβ /δ , tRA was also reported to bind RORβ , a member of the retinoid
orphan receptors, which are ligand-dependent transcription factor. In this context, tRA
functions as antagonistic ligand in a cell type-specific manner, whereby its binding an-
tagonised transactivation of RORβ activity in several cell types but not the others [288].
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Transrepression of activator protein 1 (AP-1) activity
AP-1 is transcription factor complex comprising a group of structurally and functionally
related members of Jun, Fos, and activating transcription factor ATF, which function
as heterodimers and binds to its putative DNA response element [121]. In the begin-
ning of 1990s, it was reported that RA suppresses gene expression by preventing bind-
ing of AP-1 to its DNA binding site, a process which requires liganded RAR but not
RXR [229, 276]. Of note, the anti-AP-1 activity of retinoids can be dissociated from
RAR-mediated transcriptional activation, ruling out the possibility of anti-AP-1 acti-
vity acting downstream of RA canonical signalling [43]. Many studies had since been
conducted to further elucidate the transrepression activity of AP-1 by retinoids and the
potential mechanisms were summarised in recent reviews [264, 329], which include: (i)
suppression of Jun/Fos family member expression, (ii) direct interaction of RARs with
Jun/Fos family members, (iii) disruption of dimerisation between Jun/Fos family mem-
bers by RARs, and (iv) competition between RARs and AP-1 family members for com-
mon transcription co-activators. On the other hand, transrepression of retinoid canonical
signalling by AP-1 was also reported [41].
Given that knowledge on crosstalk between retinoid system and AP-1 was largely de-
rived from in vitro experiment and in cells over-expressing retinoid nuclear receptors,
their physiological relevance remained questionable [41]. In view of the fact that AP-1
regulates cell oncogenic transformation and proliferation, the anti-proliferative effect of
exogenously administered RA in tumour cells is believed to be mediated, at least in part,
through its antagonisation of AP-1 activity [5].
A short summary on the non-canonical signalling
There are many other examples of the non-canonical signalling pathway of retinoids, all
of which were summarised in recent reviews [6, 264, 302]. For example, liganded RAR
can rapidly activate kinases, which in turn phosphorylate RAR hence modifying its trans-
criptional activity; a direct physical binding of RAR to mRNAs was found, which would
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affect translation of the mRNAs depending on the presence of ligand; the involvement
of Rol and Ral as signalling molecules, which leads to distinct biological events.
1.1.6 Target genes of RA
Many studies have examined the target genes of RA, which had provided some me-
chanistic insights into the biological effects of RA. It has been long appreciated that
regulation of gene expression by RA is cell type-specific and context-dependent [41],
i.e., while RA exerts a positive regulation on a given gene in a given cell type under cer-
tain condition, a neutral or a completely opposite regulatory effect on the same gene is
well possible in another cell type under different context [12]. The cell-type specificity
and context-dependency of RA regulation of gene expression can be, at least in part,
explained by the following:
• The presence of multiple retinoic acid receptor isotypes, of which better conserva-
tion was found for individual isotype across multiple species than for all isotypes
within a single species [167], raises the possibility of isotype-specific regulation
of gene expression. It is thus possible that the varied results exerted by RA is due
to the presence of different receptors and to their isotype-specific functions.
• Using mouse embryonic fibroblasts and mouse embryonic stem cells as in vitro
models, Delacroix et al. showed that occupancy of a given RAR isotype on RA
target genes differs between the two cell types [56]. Therefore, presence of same
sets of retinoid nuclear receptors in two different cells would still result in distinct
biological responses.
• Depending on the cell types and contexts, gene expression regulation by RA might
be mediated via the canonical or the non-canonical pathways, or might be a net
result of the combinatorial effects from crosstalk between the two [264].
In addition to the cell type-specificity and context-dependency, the effects of RA on gene
expression regulation can be rapid and transient depending on which signalling pathways
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dominate. Moreover, due to its pro-differentiative property, RA can induce fundamental
phenotypical changes leading to a knock-on effect on gene expression profile. All the
aforementioned had posed a great challenge in identification of genuine target genes of
RA. In 2002, Balmer and Blomhoff summarised the experimental evidence available for
532 target genes of RA that were published [12]. Among them, only 27 genes (around
5%) were deemed direct target genes of RA (treatment of 1 µM of RA for 6 h or less
was set as the upper limit), which were regulated through canonical signalling pathways
and contain functional RARE(s); the remaining were those regulated by RA directly
but mechanisms not fully elucidated or genes regulated indirectly without conclusive
evidence on transcriptional regulation [12]. An important aspect worth noting is that
although target genes of RA canonical signalling were rather diverse, many members of
the retinoid system are themselves direct target genes of RA [12].
While many studies had focused on identifying target genes of exogenous RA, target
genes of endogenous RA are less well described. Hence, it remains to be established
if exogenous RA and endogenous RA share a similar set of target genes in a given cell
type. Nonetheless, it is conceivable that endogenous RA also exhibits similar multipli-
city and diversity as exogenous RA described earlier.
Self-regulatory system
As mentioned before, many members of the retinoid system are direct target genes of
RA, depicting an exquisite self-regulatory and fine-tuning mechanisms to ensure the
functions of retinoid system be kept in check. Specifically, many members of retinoid
system contain well-characterised and functional RARE(s) in their gene regulatory re-
gion, and their expression has been shown to be regulated by RA, e.g., Rarb (DR5)
[54, 289], in particular, Rarb2 and Rarb4 but not Rarb1 nor Rarb3 [205], Rara2 (DR5)
[171], Rarg2 (DR5) [165], Cyp26a1 (DR5) [338], Rbp1 that encodes Crbp1 (DR2) [284],
Rbp2 that encodes Crbp2 (DR1) [191], Crabp2 (DR1 and DR2) [8, 70], and Stra6 [31].
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The positive regulation of RA on the RARs depicts a positive feedback mechanism to
potentiate RA signalling, while up-regulation of Cyp26a1 in response to RA would pro-
mote RA catabolism as a negative feedback mechanism to prevent excessive RA. In
addition, RA were also reported to down-regulate other members of the retinoid sys-
tem, which do not have classical RARE, via other mechanisms, such as Raldh1 [74] and
Raldh2 [233]. The non-direct negative regulation of these genes suggests a feedback
mechanism to avoid aberrant RA biosynthesis leading to toxicity.
It must be reiterated that cell-specificity and context-dependency of gene expression re-
gulation also apply to members of retinoid system including those with well-characterised
RARE in their regulatory regions. For example, induction of Cyp26a1 mRNA in liver by
tRA was about 20-fold more than that in kidney [338]; high dose of tRA induced rather
than suppressed Raldh2 mRNA in fibrotic kidney of Alb/TGF-β1 transgenic mice [328].
It is thus crucial to always interpret “target genes” of retinoids with caution, by taking
into consideration the full context, under which the gene regulation was examined.
1.1.7 Concluding remarks on the retinoid system
In summary, the retinoid system is highly versatile involving retinoid metabolism, trans-
portation, and signalling. Firstly, availability of endogenous retinoids is dynamically
determined by cellular uptake, as well as the expression and activity of retinoid synthe-
sising and metabolising enzymes. Secondly, the gene expression regulatory function of
retinoids, primarily RA, is governed by multiple factors, such as the binding proteins,
RAR and RXR that come in multiple isotypes and isoforms, and potential crosstalk be-
tween RA with other signalling pathways. The diversity of retinoid system had lead to
multiplicity of RA functions, depending on its target genes in a given cell type under
specific contexts. A brief summary of retinoid system is depicted in Figure 1.3.
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Figure 1.3: A brief overview of retinoid metabolism, transportation, and signalling. Up-
take of extra-cellular Rbp bound-Rol is mediated by Stra6 (Ai) and perhaps via other
mechanisms such as simple diffusion and yet defined mediators (Aii); direct uptake of
extra-cellular RA into the cells is also possible (Aiii). In the cells, Rol is either con-
verted, reversibly, into RE or into Ral; Ral is then converted irreversibly into RA and
subsequently into polar metabolites. The retinoids were bound by various binding pro-
teins to facilitate their intra-cellular transport, i.e., Rol is bound by Crbp1 and Crbp2,
Ral is bound by Crbps, Cralbp, and Irbp, RA is bound by Crabp1, Crabp2, and Fabp5
(B). RA, the most physiologically relevant retinoid compound, mediates many signalling
events with potential cross-modulation among them, such as the canonical signalling
that typically involves the RXR/RAR heterodimers, transcription co-regulators, and the
presence of RARE in the regulatory region of retinoid target genes (C), and the non-
canonical signalling such as activation of nuclear receptors other than retinoid nuclear
receptors, crosstalk with other transcription factors, and activation of kinases (D). Rbp:
retinol binding protein; Rol: retinol; Ral: retinaldehyde; RA: retinoic acid; RE: retinyl
ester; Stra6: stimulated by retinoic acid 6; Lrat: lecithin:retinol acyltransferase; Arat:
acyl-coA acyltransferase; Adhs: alcohol dehydrogenases; Rdhs: retinol dehydrogenases;
Raldhs: retinaldehyde dehydrogenases; Cyp26s: cytochrome P450 26 enzymes; Crbp:
cellular retinol binding protein; Cralbp: cellular retinaldehyde binding protein; Irbp: in-
terphotoreceptor retinoid binding protein; Crabp: cellular retinoic acid binding protein;
Fabp5: fatty acid binding protein 5, RXR: retinoid X receptor; RAR: retinoic acid re-
ceptor; RARE: retinoic acid response element; PPAR: peroxisome-proliferator activated
receptor; ROR: retinoid orphan receptor; AP-1: activator protein 1.
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1.2 The retinoid system in kidneys
Retinoids, particularly RA and its analog, have been tested as therapeutic agents, where
its anti-inflammatory, immune-modulatory, anti-proliferative, and tissue reparative roles
were found to be beneficial in various experimental models of kidney diseases, as sum-
marised in a recent review [329]. While its use appeared promising, retinoid compounds
are double-edged swords whereby under certain circumstances, their use propagates di-
sease progression and leads to severe adverse effects [328, 329].
In order to complement existing knowledge that largely revolves around the use of exo-
genous retinoids in experimental kidney diseases, this section presents a review on the
endogenous retinoid system, which not only focuses on retinoids, but also on retinoid
transport and metabolism as well as their activity in the kidney. The endogenous retinoid
system is presented from two main perspectives, i.e., (i) the retinoid system in embryonic
nephrogenesis and (ii) the retinoid system in the kidney after birth.
1.2.1 The retinoid system in embryonic nephrogenesis
As introduced earlier, a functional retinoid system is required during embryonic deve-
lopment, and is crucial in formation of organs undergoing branching processes such as
the kidney [231]. Many studies have been performed over the last decades on the role
of retinoid system in mediating nephrogenesis. Some of the most relevant studies are
presented here.
Vitamin A is required for nephrogenesis
Rat foetuses with maternal vitamin A deficiency manifested VAD syndromes charac-
terised by severe malformations of many organs, including the kidney. Developmental
defects of the kidney included an abnormal and retarded nephron formation, failure of
renal pelvis and calyx to undergo normal dilatation, and presence of horseshoe kid-
ney [323]. By administering a single dose of vitamin A to pregnant rats during mid-
gestational stage (from E10 to E15), kidney malformation was prevented, either partially
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or completely, depending on the timing of vitamin A administration [322]. In fact, the
developing kidney is highly sensitive towards vitamin A supply that even mild mater-
nal vitamin A deficiency lead to a reduction of glomeruli number, a condition that was
strictly correlated to foetal plasma Rol level [169].
The role of retinoid nuclear receptors in nephrogenesis
The cloning of RARs and RXRs in the late 80s and early 90s had allowed the genera-
tion of RAR and RXR null mutants (as described in Section 1.1.4), which very much
facilitated studies on the roles of retinoid nuclear receptors in mediating embryonic ne-
phrogenesis. Mendelsohn et al. had reported that while null mutants of individual RAR
appeared normal, null mutants of two or more RARs suffered kidney developmental de-
fects including kidney hypoplasia and agenesis [98,206], a condition later reproduced in
Rxra/Rara compound null mutants [143]. The compound null mutants and the associa-
ted kidney developmental abnormalities are summarised in Table 1.3.
Table 1.3: Kidney developmental defects in compound null mutants of retinoic acid
receptor. *: complete penetrance.
Abnormalities Retinoic acid receptor mutant
genotypes





Rara1-/- / Rarg-/- / Rara2+/-
Kidney agenesis/aplasia Rxra-/- / Rara-/-,
Rara-/- / Rarg-/-*
Endogenous RA is the main retinoid compound in nephrogenesis
Vilar et al. reported that adding RA to culture medium stimulated growth and differen-
tiation of E14 rat embryonic metanephro explants in a dose-dependent manner, whereas
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Rol is less effective with two magnitude difference compared to RA [310]. In vivo
experiments had further supported RA as the key retinoid compound mediating nephro-
genesis. Aldh1a2-/- embryos and Rdh10trex/trex mutant embryos, both characterised by a
reduction of RA, suffered kidney development impairment [234, 274]. In a more recent
publication, Rosselot et al. had confirmed Raldh2 that was expressed in the metanephric
stromal cells to be the predominant RA synthesising enzyme required for nephrogene-
sis; during the absence of Raldh2, Raldh3 that was expressed in the ureteric bud can
marginally support RA biosynthesis [267]. On the other hand, horseshoe kidney caused
by an increased endogenous RA level following genetic deletion of Cyp26a1 was par-
tially rescued by heterozygous deletion of Raldh2 to reduce endogenous RA synthe-
sis [230].
Both in vitro and in vivo studies support the fact that RA, rather than its precursor or
its polar metabolites, is the main retinoid compound mediating embryonic nephroge-
nesis. A fine balance of endogenous RA level is exquisitely controlled in this regard,
primarily through collaborative activity of Raldh2, Raldh3, Rdh10, and Cyp26a1 en-
zymes. More interestingly, it was found recently that a genetic variant of ALDH1A2
in human, which is orthologous to mouse Raldh2, was associated with a higher level of
umbilical cord blood RA and with a significantly higher newborn kidney volume (22%
higher compared to newborns of wild-type Aldh1a2 genotype) [141]. Thus, it is very
likely that endogenous RA is indeed the primary retinoid compound in mediating kid-
ney development in rodents and in human.
Target genes and potential mechanisms of endogenous retinoids in embryonic
nephrogenesis
Kidney morphogenesis is initiated by invasion of ureteric bud into its surrounding me-
senchyme, during which signals were transduced into mesenchymal tissues; mesenchy-
mal tissues then differentiate into nephrons and reciprocate by transducing signal back
to the ureteric bud to promote branching processes [212]. Various groups had suggested
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target genes of RA and the potential mechanisms, by which nephrogenesis is mediated.
One of the most established RA target gene is Ret, a proto-oncogene expressed in
the ureteric buds that upon activation by its cognate ligand, glial cell line-derived neu-
rotrophic factor (GDNF), would trigger ureteric bud branching [212]. In 1998, Moreau
et al. reported that tRA up-regulated Ret mRNA expression in cultured metanephroi in
a dose-dependent manner from 1 nM to 1 µM [217]. It was later found that there was a
marked down-regulation of Ret in kidney of Rara-/- / Rarb2-/- mutant mice [204], and rat
embryos of maternal vitamin A deficiency [17]. Of note, forced expression of Ret in the
ureteric bud of Rara-/- / Rarb2-/- mutants rescued the kidney developmental defects [17].
Although it is now well accepted that Ret is the target gene of RA, via which kidney
development is regulated, the exact mechanism of RA in the regulation of Ret expres-
sion remains elusive as functional RARE had not been identified in the 5’-flanking region
of Ret promoter [245]. It is thus still a question whether regulation of Ret by RA is me-
diated via other mechanisms or mediators. It might be possible that Ret contains highly
degenerative RARE rather than the well-defined classical RARE and the RARE might
lie in regions other than the 5’-flanking region of gene promoter.
Based on the observation that both Rara and Rarb are expressed in the stromal cells, and
that Ret is expressed in the ureteric buds, it was initially proposed that the retinoid sys-
tem controlled yet defined signalling molecule(s) in the stromal cells via RARα/RARβ ,
which in turn promotes Ret expression in the ureteric buds either directly or via the sur-
rounding metanephric mesenchyme [17, 204]. However, this proposal was recently re-
vised following a recent publication in GenitoUrinary Development Molecular Anatomy
Project (GUDMAP) consortium (http://www.gudmap.org), which reported presence of
RARα and RARβ transcripts in the ureteric buds. The revised model proposes that
endogenous RA binds to RARs in the ureteric buds and activates RAR-dependent sig-
nalling locally leading to Ret expression, either directly or indirectly [267].
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Besides Ret, other potential RA target genes that mediate nephrogenesis had also been
proposed. These include transcription factors such as the Hox genes and growth factor
receptors such as epithelial growth factor receptor, EGFR [102]. More recent reports had
added additional candidate genes to this list. Specifically, Vilar et al. observed a consis-
tent down-regulation of midkine, Mdk, in E16-E20 foetal kidney of rats with maternal
vitamin A deficiency, and tRA induced Mdk expression in cultured metanephroi [311].
Late-gestation lung protein 1, Lgl1, was also proposed to be another potential target gene
of RA during nephrogenesis as tRA increased both Lgl1 mRNA and gene promoter re-
porter activity in cultured metanephric mesenchymal cells [255].
A brief summary on the retinoid system in embryonic nephrogenesis
A brief summary of the retinoid system in embryonic nephrogenesis is as follow:
1. Endogenous RA rather than its precursors or metabolites is the primary, if not the
only, endogenous retinoid compound that mediates kidney development.
2. Rdh10, Raldh2, Raldh3 (to a lesser extent), and Cyp26a1 are believed to be the
primary enzymes actively involved in the exquisite control of endogenous RA
level.
3. The canonical signalling, which involves retinoid nuclear receptor-mediated sig-
nalling, is essential.
4. Endogenous RA is synthesised mainly in the stromal cells, which was then se-
creted to ureteric buds to bind and activate the RARs; RAR-dependent signalling
in ureteric bud maintains Ret expression, either directly or indirectly.
5. Ret is by far the best characterised target gene of RA in the ureteric buds that
mediates nephrogenesis although functional RARE had not been identified in the
promoter region of Ret.
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1.2.2 The retinoid system in kidneys after birth
As opposed to the well-established role of endogenous RA in nephrogenesis, relatively
little is known about the role of endogenous RA in kidneys after birth. This is in part due
to the early lethality following germline deletions of members of the retinoid system,
precluding investigation into anomalies that may arise later during post-natal develop-
ment and adulthood. However, studies that reported symptoms of post-natal vitamin A
deficiency, as well as reports on the expression of members of the retinoid system and
their alterations in the advent of kidney pathogenesis had provided some valuable in-
sights into the potential roles of endogenous RA in the kidney after birth.
Post-natal vitamin A deficiency and associated renal anomalies
The lack of apparent histological abnormality in the kidney parenchymal tissues follow-
ing post-natal vitamin A deficiency reported during mid 1920s, argues against endoge-
nous RA playing a crucial role in maintaining renal epithelial tissue integrity [106,325].
However, functional defects of kidney and other anomalies, including an increased sus-
ceptibility towards certain challenges, were reported as early as 1917. A summary of
major experimental findings in murine models subjected to post-natal vitamin A defi-
ciency is shown in Table 1.4.
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While there seems to be a large number of reports that associate post-natal vitamin A de-
ficiency to anomalies in the kidney, these studies are not without caveats. For instance,
retinoid profile in kidney was not established in some of the studies while some studies
did not use appropriate control. In addition, some of these studies involved limiting vi-
tamin A supply prior to weaning and during gestation, hence the anomalies observed
may reflect a defect in pre- and post-natal kidney development. Taken together, while
an association has been made, a clear cause-and-effect relationship between post-natal
vitamin A deficiency and anomalies in the kidney remains to be established.
Besides reports from experimental murine models, post-natal vitamin A deficiency in
farm animals and in clinical subjects had also been reported. Specifically, VAD farm ani-
mals were associated with polyuria and an increased incidence of urolithiasis [316,324];
clinical subjects with post-natal vitamin A deficiency were more susceptible towards
urolithiasis [135]. Taken together, conditions such as urolithiasis that are often asso-
ciated with urinary metabolite imbalance and kidney calcification, kidney/urinary infec-
tions, and renal pelvic epithelium keratinisation, are conditions most commonly reported
since 1900s in rodents, farm animals, and human.
In the beginning of the millennium, several groups had started to explore the associa-
tion between post-natal vitamin A deficiency and gene expression, and the potential link
between the dysregulated gene expression and functional outcome. Establishing target
genes of endogenous RA in the kidney should better define the role of retinoid system
in the kidney after birth, and provide a better cause-and-effect link between post-natal
vitamin A deficiency and the aforementioned anomalies.
Bioactive RA in the kidney: a product of local synthesis?
The presence of endogenous RA has been well documented in healthy murine kidney,
with tRA being the most abundant isomer detected [137,139,277,286,328]. The source
of renal tRA has not been investigated in detail but multiple mechanisms seem to be in-
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volved in this regard. Specifically, renal uptake of retinyl ester and Rol [108,246], as well
as tRA [157] were documented. Interestingly, Stra6 expression was found to be abun-
dant in the developing mouse kidney from E12.5 and continue to be highly expressed
until adulthood [31], which may facilitate uptake of RBP-bound Rol. In addition, re-
nal proximal tubules are known to reabsorb RBP-bound Rol that was filtered through
glomeruli, via endocytic receptor, Megalin [46].
The kidney also seems poised for a local biosynthesis of tRA by expressing enzymes
involved in retinoid metabolism. Ang et al. reported the presence of Adh1 mRNA in
adult mouse kidney, localised to the medullary rays and collecting ducts [7]. It was later
found that both Adh1 and Adh3 protein [57, 58, 118], as well as Rdh1 transcript [335]
were detected in adult mouse kidney but their localisation was not commented. Besides
Rol dehydrogenases, Raldh1 and Raldh3 transcripts were detected in post-natal and adult
kidney at a high level, concentrating in the outer medulla and inner medulla, respec-
tively [232]; Alnouti et al. described the presence of Raldh2 and Raldh3 but not Raldh1
transcripts in adult mouse kidney [4]; Lin et al. described the expression of Raldh1 and
Raldh2 proteins in the cortex and medulla, and Raldh4 protein in the cortex of adult
mouse kidney [177]. As for metabolising enzymes of RA, Cyp26a1 transcript was de-
tected at a high level in adult mouse liver, but was not detected in the kidney [45, 258];
Cyp26b1 expression was reported in rat only at birth and at post-natal day 4, localised
to the cortical ureteric bud end and the associating collecting ducts [194]; expression of
Cyp26c1 was not as well established in adult mouse kidney.
It is clear from the aforementioned studies that a detailed description and unequivocal
consensus on the presence and localisation of enzymes involved in retinoid metabolism
in the kidney after birth has not been achieved. More importantly, since kidney-specific
knockout of these enzymes had not been established, their roles in determining the en-
dogenous RA supply in the kidney under normal physiological condition remain to be
established.
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RARs and RXRs in kidney
To date, a systematic analysis examining protein expression of all known isotypes and
isoforms of RAR and RXR in healthy kidney after birth is lacking. This might be due
to the fact that antibodies with good selectivity and sensitivity in detecting all the RARs
and RXRs are not readily available. However, according to datasets generated by the
Nuclear Receptor Signaling Atlas (NURSA) consortium (www.nursa.org/10.1621/
datasets.02001; last accessed on 30.07.2011), transcript of all six retinoid nuclear re-
ceptor isotypes, namely, Rara, Rarb, Rarg, Rxra, Rxrb, and Rxrg were detected in adult
kidney of two strains of mice, C57Bl/6J and 129x1/SvJ (results derived from 38 mice).
Alteration of endogenous retinoid metabolism in experimental models of
kidney diseases
An altered profile of retinoid system, including the level of tRA, expression of Raldhs
and retinoid nuclear receptors, as well as a few well-established RA target genes, has
been reported in a number of experimental models of kidney disease, such as puromycin-
associated nephropathy [291], glomerulonephritis [176], Alb/TGF-β1 transgenic mice, a
kidney fibrosis model characterised by an over-expression of transforming growth factor-
β1 [328], diabetic nephropathy [286], and HIV-associated nephropathy [256]. More im-
portantly, in cases where endogenous RA was reduced, supplementation of exogenous
RA were found to halt disease progression in certain disease models [256, 291] but fur-
ther worsened disease progression in other [328].
Taken together, while these reports might suggest an active participation of RA and the
retinoid system in modulating disease progression, the paradoxical outcomes of exoge-
nous RA supplementation complicate the interpretation of RA effects. Perhaps a non-
specific administration of exogenous RA might not be of advantage in all cases where
endogenous RA was reduced. A direct cause-and-effect relationship between disease
progression and an alteration of endogenous retinoid system remains to be further eluci-
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dated.
A brief summary on the retinoid system in kidneys after birth
The source of endogenous tRA detected in mouse kidney, whether it is a product of
local biosynthesis or whether it is taken up directly from the circulation, remains un-
clear. Nevertheless, the presence of endogenous tRA together with all known isotypes
of RARs and RXRs in healthy kidneys suggests the presence of constitutively active
retinoid canonical signalling. If this is indeed the case, then the renal-associated anoma-
lies observed during post-natal vitamin A deficiency might be at least partially explained
by an attenuated RA canonical signalling, which leads to gene expression dysregulation.
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1.3 Aims of this project
Existing evidence supports the presence of an inbuilt system in healthy murine kidneys
for retinoid synthesis and metabolism, as well as the expression of retinoid nuclear re-
ceptors that are key components to support RA canonical signalling. In addition, tRA,
the most physiological relevant bioactive retinoids, was reported to be present in the
kidney. Thus, it is hypothesised that an RAR-dependent transcriptional activity of endo-
genous RA is present in the kidney after birth, to regulate gene expression.
In order to address this hypothesis, this project was designed to answer the following
questions:
1. Given that all known isotypes of RARs and RXRs, as well as tRA are found in
healthy kidneys, is there a direct evidence of constitutively active retinoid nuclear
receptor-mediated RA canonical signalling?
2. If the canonical signalling is indeed present, does it have a temporospatial-specific
pattern?
3. What are the target genes of canonical signalling of endogenous retinoids in the
cell type(s) identified in (2)?
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Chapter 2
General Materials and Methods
This chapter describes the general materials and methods used for all laboratory work.
Specific protocols and procedures applicable only to specific chapters are described in
the individual chapter.
2.1 Buffers, solutions, and reagents
All buffers, solutions, and reagents were prepared following the recipes and protocols
stated below. Ultrapure water dispensed from a Maxima USF Alga machine was used
for dilution and dissolution of reagents, a Metler toledo AB204-S weighing balance
was used for weighing chemical reagents, a Stuart CB161 magnetic stirrer (with Fisher
Brand® magnetic stir bar) and a Grant Bio PV-1 vortex mixer were used for mixing pur-
pose, a Metler toledo 340 pH meter was used for pH measurement.
All buffers, solutions, and reagents were stored at room temperature in laboratory stan-
dard glass bottles, unless stated otherwise. Suppliers of chemical reagents are listed in
Table 2.1.
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2.1.1 Acid and alkaline solutions for pH adjustment
1 M Hydrochloric acid
5 M Hydrochloric acid 20 ml
Ultrapure water 80 ml
Eighty millilitre of ultrapure water was first measured into a glass bottle, after which
20 ml of 5 M hydrochloric acid was pipetted and gently added into the water. Solution
was mixed well by gentle swirling.
0.5 M Hydrochloric acid
1 M Hydrochloric acid 50 ml
Ultrapure water 50 ml
Fifty millilitre of ultrapure water was first measured into a glass bottle, after which
50 ml of 1 M hydrochloric acid was pipetted and gently added into the water. Solu-
tion was mixed well by gentle swirling.
1 M Sodium hydroxide
Sodium hydroxide 4 g
Ultrapure water To a final volume of 100 ml
Eighty millilitre of ultrapure water was first measured into a glass bottle, after which
4 g of sodium hydroxide was weighed out and added into the water with gentle stirring
on a magnetic stirrer. Ultrapure water was then added to a final volume of 100 ml after
sodium hydroxide was completely dissolved.
2.1. Buffers, solutions, and reagents 74
2.1.2 Buffers and solutions for general use
10x Phosphate-buffered saline (PBS), pH 7.4
(1.37 M NaCl, 27 mM KCl, 81 mM Na2HPO4.2H2O, 17.6 mM KH2PO4)
Sodium chloride 80 g
Potassium chloride 2 g
Disodium hydrogen phosphate dihydrate 14.4 g
Potassium dihydrogen phosphate 2.4 g
Ultrapure water To a final volume of 1 L
Eight hundred millilitre of ultrapure water was first measured into a glass bottle, af-
ter which all reagents were weighed out and added into the water with gentle stirring
on a magnetic stirrer. pH was adjusted to 7.4 using 1 M sodium hydroxide or 1 M hy-
drochloric acid after all reagents were completely dissolved. Ultrapure water was then
added to a final volume of 1 L.
1x PBS, pH 7.4
(137 mM NaCl, 2.7 mM KCl, 8.1 mM Na2HPO4.2H2O, 1.76 mM KH2PO4)
10x PBS 200 ml
Ultrapure water 1.8 L
Two hundred millilitre of 10x PBS and 1.8 L of ultrapure water were measured into
a glass bottle, and the solution was mixed well by inverting the bottle.
0.1 % Tween® 20 in 1x PBS (0.1 % PBST)
Tween® 20 2 ml
1x PBS 2 L
Two litre of 1x PBS was first measured into a glass bottle, after which 2 ml of Tween® 20
was pipetted directly into the PBS. Solution was mixed well by shaking the bottle vigo-
rously.
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1.5 M Tris, pH 8.0
Tris 181.71 g
Ultrapure water To a final volume of 1 L
Eight hundred millilitre of ultrapure water was first measured into a glass bottle, after
which tris was weighed out and added into the water with gentle stirring on a magnetic
stirrer. pH was adjusted to 8.0 using 5 M hydrochloric acid after tris was completely
dissolved. Ultrapure water was then added to a final volume of 1 L.
100 mM Ethylenediaminetetraacetic acid (EDTA), pH 8.0
EDTA disodium salt dihydrate 1.861 g
Ultrapure water To a final volume of 50 ml
Forty millilitre of ultrapure water was first measured into a conical tube, after which
1.861 g of EDTA was weighed out and added into the water. The solution was mixed
briefly by gentle vortexing. pH was adjusted to 8.0 using 1 M sodium hydroxide (a pH
value of 8.0 was required for complete dissolution). Ultrapure water was then added to
a final volume of 50 ml and the solution was sonicated until complete dissolution was
achieved. Aliquots of 1 ml was prepared and stored at -20 °C.
2.1.3 Buffers and solutions for cell staining
0.01 M Citric acid buffer, pH 6.0
Citric acid monohydrate 2.1 g
Ultrapure water To a final volume of 1.5 L
One litre of ultrapure water was first measured into a glass bottle, after which citric
acid monohydrate was weighed out and added into the water with gentle stirring on a
magnetic stirrer. pH was adjusted to 6.0 using 1 M sodium hydroxide after citric acid
monohydrate was completely dissolved. Ultrapure water was then added to a final vo-
lume of 1.5 L.
Note: After being used once for antigen retrieval, citric acid buffer was cooled to room
temperature and stored in a glass bottle at room temperature. The solution was re-used
2.1. Buffers, solutions, and reagents 76
once, after which fresh buffer was prepared.
0.1 M Glycine in 1x PBS
Glycine 0.075 g
1x PBS 10 ml
Ten millilitre of 1x PBS was first measured into a conical tube, after which 0.075 g
of glycine was weighed out and added into the PBS. Solution was then mixed well by
gentle vortexing until glycine was completely dissolved. Solution was prepared fresh
before use.
1% Bovine serum albumin (BSA) in 1x PBS
BSA 0.1 g
1x PBS 10 ml
Ten millilitre of 1x PBS was first measured into a conical tube, after which 0.1 g of
BSA was weighed out and added into the PBS. Solution was then mixed well by gentle
vortexing until BSA was completely dissolved. Solution was prepared fresh before use.
Ice-cold 10% formalin in 1x PBS
100% Formalin 5 ml
1x PBS 45 ml
Forty-five millilitre of 1x PBS was first measure into a 50 ml conical tube, after which 5
ml of 100% formalin was pipetted and added into the PBS. Solution was mixed well by
inverting the conical tube and kept on ice until use.
Note: Handling of formalin was performed in a fumigated hood and the solution was
prepared fresh before use.
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Ice-cold 5% formalin in 1x PBS
100% Formalin 1 ml
1x PBS 19 ml
Nineteen millilitre of 1x PBS was first measure into a 50 ml conical tube, after which
1 ml of 100% formalin was pipetted and added into the PBS. Solution was mixed well
by inverting the conical tube and kept on ice until use.
Note: Handling of formalin was performed in a fumigated hood and the solution was
prepared fresh before use.
5% Formalin and 0.2% glutaraldehyde in 1x PBS
100% Formalin 1 ml
25% Glutaraldehyde 160 µl
1x PBS To a final volume of 20 ml
Seventeen millilitre of 1x PBS was first measure into a 50 ml conical tube, after which
1 ml of 100% formalin and 160 µl were pipetted and added into the PBS. PBS was then
added to a final volume of 20 ml. Solution was mixed well by inverting the conical tube.
Note: Handling of formalin and glutaraldehyde was performed in a fumigated hood and
the solution was prepared fresh before use.
0.1% Triton X-100 in 1x PBS
Triton X-100 10 µl
1x PBS 10 ml
Ten millilitre of 1x PBS was first measured into a conical tube, after which 10 µl of
Triton X-100 was pipetted and added into the PBS. Solution was then mixed well by
gentle vortexing. Solution was prepared fresh before use.
2.1. Buffers, solutions, and reagents 78
2.1.4 Buffers and solutions for X-gal histochemistry and cytochemistry
X-gal dilution buffer
(5 mM K3Fe(CN)6, 5 mM K4Fe(CN)6.3H2O, 2 mM MgCl2)
Magnesium chloride 0.01 g
Potassium ferricyanide cystalline 0.08 g
Potassium ferrocyanide trihydrate 0.105 g
1x PBS To a final volume of 50 ml
Forty millilitre of 1x PBS was first measured into a conical tube, after which all reagents
were weighed out and added into the PBS. Solution was mixed well by gentle vortexing.
PBS was then added to a final volume of 50 ml.
Note: The prepared X-gal dilution buffer was then wrapped in aluminium foil and stored
at 4 °C to a maximum of four weeks prior to use.
X-gal staining solution (1 mg/ml X-gal)
X-gal stock solution (50 mg/ml) 1 ml
X-gal dilution buffer 49 ml
Forty-nine millilitre of X-gal dilution buffer was first measured into a conical tube and
pre-warmed in water bath to 37 °C before 1 ml of X-gal stock solution was added. X-gal
staining solution was prepared fresh before use.
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2.1.5 Buffers and solutions for plasmid preparation
3 M Sodium acetate
Sodium acetate 4.08 g
Ultrapure water 10 ml
Five millilitre of ultrapure water was first measured into a conical tube, after which
sodium acetate was weighed out and added into the water. The solution was mixed well
by gentle vortexing. Ultrapure water was then added to a final volume of 10 ml and was
stored at 4 °C until use.
Ice-cold 70% ethanol
100% Ethanol 7 ml
Ultrapure water 3 ml
Seven millilitre of 100% ethanol and 3 ml of ultrapure water were measured into a coni-
cal tube. Solution was mixed well by inverting the tube and stored at -20 °C until use.
Tris-EDTA (TE) buffer (sterile), pH 8.0
(10 mM Tris, 1 mM EDTA)
1.5 M Tris 100 µl
100 mM EDTA 150 µl
Ultrapure water To a final volume of 15 ml
Fourteen millilitre of ultrapure water was first measured into a conical tube, after which
1.5 M tris and 100 mM EDTA were pipetted and added into the water. pH was adjusted
to 8.0 using a few drops of 0.5 M hydrochloric acid. Solution was then filter-sterilised
into a sterile conical tube using a Whatman® PuradiscTM 25 syringe filter.
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Table 2.1: Suppliers of chemical reagents. *Suppliers: Hayman: Hayman Ltd., Es-
sex, UK; Merck: Merck Chemicals Ltd., Nottingham, UK; Promega: Promega UK,
Southampton, UK; S-A: Sigma-Aldrich Company Ltd., Dorset, UK; VWR: VWR Inter-
national Ltd., Leicestershire, UK.
Reagents *Suppliers
Bovine serum albumin S-A
Citric acid monohydrate VWR
Disodium hydrogen phosphate dihydrate VWR





Hydrochloric acid (5 M) VWR
Magnesium chloride S-A
Potassium chloride VWR
Potassium dihydrogen phosphate VWR
Potassium ferricyanide crystalline S-A







X-gal stock solution (50 mg/ml in dimethylformamide) Promega
2.2. Cell culture 81
2.2 Cell culture
The mouse inner medullary cell line, mIMCD-3, was obtained from LGC Standards,
Middlesex, UK at passage (P) 11. The P11 cells were reassigned as P1 upon receipt at
King’s College London and were stored in liquid nitrogen tank in the original cryotube
supplied by LGC Standards. In order to propagate mIMCD-3 cells for storage and fu-
ture use, cells were brought out of liquid nitrogen and thawed in water bath at 37 °C.
Thawed cells were then immediately plated on a 75 cm2 tissue culture flask containing
DMEM-F12 culture medium with penicillin (100 IU/ml), streptomycin (100 µg/ml), and
amphotericin B (2.5 µg/ml), supplemented with 5% foetal bovine serum (FBS), which
were pre-warmed and equilibrated with CO2 for at least 15 min in a Techne incubator.
Tissue culture medium, antibiotics, and FBS were from PAA Laboratories Ltd., Somer-
set, UK, and amphotericin B was from Invitrogen Ltd., Paisley, UK.
Cells were routinely cultured in a Techne incubator (with a setting of 37 °C and 5% CO2).
For passaging cells, adherent cells were first washed twice with PBS and incubated in
2 ml trypsin (0.5 mg/ml)-EDTA (0.22 mg/ml) (PAA Laboratories Ltd., UK) for 3 min at
37 °C. Complete trypsinisation was confirmed by examining the cells under microscope.
Eight millilitre of culture medium was then added to the trypsinised cells and cells were
titurated up and down a few times to break up cell clumps. Cells were passaged when
near confluent at a ratio of 1:4 to 1:8 as recommended by LGC Standards.
In order to store cells for future use, cells were trypsinised and resuspended in cul-
ture medium as described before, after which cell number was counted using hemocy-
tometer. Cell suspension was then centrifuged for 5 min at 328 g at 25 °C. Cell pellet
was resuspended in 95% culturing medium and 5% dimethly sulfoxide (DMSO, Sigma-
Aldrich Company Ltd., UK) to a final concentration of 1x106 cells/ml, and 1 ml cell
suspension was pipetted into each pre-labled cryotube. Cryotubes were then wrapped in
multiple layers of paper towel, placed in a well-insulated polystyrene box, and kept at
-80 °C overnight before being transferred into the liquid nitrogen tank. Cells at P2 and
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P3 were stored. All tissue culture flasks and dishes were from Falcon (Marathon La-
boratory Supplies, London, UK), and pipette tips were from Starlab (UK) Ltd., Milton
Keynes, UK.
2.2.1 Reagents used for cell treatment
tRA
Stock solution of tRA (Sigma-Aldrich Company Ltd., UK) was prepared by dissolv-
ing the powder in 100% ethanol to a stock concentration of 10 mM (prepared by Dr.
Q Xu). Aliquots of 40 µl 10 mM tRA solution were prepared in 500 µl microtubes,
wrapped individually in aluminium foil, and sealed with Parafilm® (Starlab (UK) Ltd.,
UK). Aliquots were then stored at -80 °C.
Following prolonged storage at -80 °C , tRA precipitated out of ethanol forming a yellow
colour precipitant. Thus, before using, aliquots of tRA were vortex-mixed briefly, and
were warmed to 37 °C for about 15 min, with vortex-mixing in between, to redissolve
the precipitant. Please note that prolonged vortex-mixing might increase the risk of tRA
being oxidised.
Antagonists of RARs
Two antagonists of RARs were used in this project: (i) AGN193109, an antagonist of
RARα , RARβ , and RARγ [134] (a kind gift from Allergan Pharmaceuticals, Irvine,
California, USA), and (ii) BMS189453, an antagonist of RARα and RARγ , and a mixed
agonist/antagonist of RARβ [43] (a kind gift from Dr. J Corcoran at King’s College
London Wolfson Centre for Age Related Diseases).
Stock solution of AGN193109 was dissolved in DMSO to a concentration of 2 mM
(prepared by Dr. Q Xu). Aliquots of 40 µl 2 mM AGN193109 solution were prepared in
500 µl microtubes, wrapped individually in aluminium foil, and stored at -80 °C. Stock
solution of BMS189453 was dissolved in DMSO to a concentration of 1 mM (prepared
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by Dr. J Corcoran). Aliquots of 40 µl 1 mM BMS189453 solution were prepared in
500 µl microtubes and stored at -80 °C (prepared by Dr. A Rankin).
Inhibitors of RA synthesising enzymes
Two inhibitors of retinoic acid synthesising enzymes were used in this project: (i) 4-
(diethylamino)benzaldehyde (DEAB) [272], reconstituted in DMSO to a concentration
of 25 mM, and (ii) tetraethylthiuram disulfide (also known as disulfiram) [75], reconsti-
tuted in DMSO to a concentration of 10 mM. Both DEAB and disulfiram were purchased
from Sigma-Aldrich Company Ltd., UK. Aliquots of 40 µl 25 mM DEAB solution and
40 µl 10 mM disulfiram were prepared in 500 µl microtubes and stored at -80 °C.
2.3 Microscopy and digital imaging
All microscopic examinations were performed on a Nikon Eclipse TE2000-S epifluores-
cence microscope equipped with a mercury arc lamp and a standard RGB (FITC, G-2A,
and UV-2A) filter wheel. Signal of AlexaFluor 488 (absorption max: 496 nm, emis-
sion max: 519 nm) was examined with the FITC filter, AlexaFluor 555 (absorption max:
555 nm, emission max: 565 nm) and AlexaFluor 568 (absorption max: 578 nm, emission
max: 603 nm) was examined with the G-2A filter, and 4’,6’-diamidino-2-phenylindole
(DAPI; absorption max: 358 nm, emission max: 461 nm) was examined with the UV-2A
filter.
In order to differentiate specific fluorescence signal from that given rise by non-specific
staining, tissue sections or cells stained with non-immune IgG were first examined, and
the exposure time was adjusted until only background signal was barely observed. Us-
ing the same exposure time, sections or cells stained with corresponding antibodies were
then examined. Signals beyond the background signal on the non-immune IgG-stained
sections/cells were deemed genuine signal given rise by antibody-antigen binding. Im-
ages were captured with a DXM1200F Nikon digital camera using the NIS-element
software. The images were then processed and merged with Adobe® Photoshop®.
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Chapter 3
Constitutive Retinoic Acid Response Element
Activity in Mouse Kidney Collecting Ducts
3.1 Introduction
The project started off with examining the presence and temporospatial localisation of
RARE activity in healthy kidney using reporter mice. This chapter describes the obser-
vation of a constitutively active RARE activity in healthy kidney and its predominant
localisation in the renal collecting ducts.
Detection and localisation of RA pose great challenge to researches. Specifically, given
that RA is not a nucleotide-based molecule and is non-immunogenic on its own, classical
techniques such as in situ hybridisation and immunohistochemistry cannot be applied to
detect RA. While HPLC-based assay represents the gold standard in quantifying RA, lo-
calising bioactive RA at the tissue or cellular level requires a robust and efficient method
of isolating samples containing specific populations of tissues/cells, as well as a highly
sensitive HPLC-based assay.
Localising RA synthesising enzymes may provide clues on site of endogenous RA pro-
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duction. However, the presence of multiple synthesising enzymes of RA makes loca-
lisation of individual enzyme difficult. Moreover, there is still a big knowledge gap in
the predominant enzyme(s) involve in biosynthesis of RA and the potential functional
redundancy among them. In addition, since RA steady state is also governed by the
Cyp26a1-c1 enzymes, their expressions have to be taken into account. Equally impor-
tant is that existing evidence suggests RA can be delivered from adjacent tissues and
circulation in a paracrine and autocrine manner [67, 157, 231].
There had been attempts in the past to generate antibodies recognising RA, by conju-
gating a larger protein to RA to confer immunogenic property to this small molecule
[297,341]. However, the antibody was found to also react towards Rol and Ral [297], as
well as towards retinoid esters, β -carotene, and other polar derivatives of RA, especially
the -oxo derivatives [341].
In order to get better insights on the actual sites of endogenous RA exerting its effect, it
would be more meaningful to determine not only the presence of RA per se but also the
presence of retinoid nuclear receptors. However, since there are multiple RA receptor
isotypes and they function as heterodimers, examining the concomitant presence of indi-
vidual receptor and RA would be arduous. More importantly, the concomitant presence
of both RA and retinoid nuclear receptors does not necessarily mean that the receptors
are constitutively activated by RA, unless proven otherwise.
In the early 90s, the use of transgenic mice as reporters of endogenous RA activity had
been introduced by several groups. These reporter mice harbour a reporter transgene
containing RARE cloned into heterologous promoters to drive the expression of bacteria
derived-lacZ gene. For example, RARE-TKpr-lacZ mice, which the expression of re-
porter transgene was driven by the herpes simplex virus thymidine kinase promoter [11],
and the RARE-hsp68-lacZ mice, which the expression of reporter transgene was driven
by the hsp68 minimal promoter [266]. There are also transgenic mice that the expres-
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sion of reporter transgene is driven by natural RARE-containing regulatory elements
in the promoter of RARβ2 [207, 262]. Expression of reporter transgene in these mice
were found to largely overlap with the expression of endogenous RARβ2 [207, 262],
hence representing reporter for presence and activation of RARβ2. More recently, other
reporter mice of RA activity were described. In a crossed bred of RARE-hsp68-lacZ-
cre and ROSA26R mice, cells would be permanently labelled in the presence of RA,
therefore representing a more sensitive method to detect transient presence of RA acti-
vity [61]. However, the permanent labelling of the cells will not allow dynamic monitor-
ing of RA activity. The use of DR5-luciferase reporter mice were also recently reported,
which has the advantage of allowing dynamic monitoring of RA activity without the
need of sacrificing animals [250].
3.1.1 RARE-hsp68-lacZ transgenic mice
The RARE-hsp68-lacZ transgenic mice [266], herein referred as transgenic mice, were
used in this project. This model was chosen as it has been widely employed since its
establishment, particularly in examining RA activity in developing embryos, some of
which has been presented in Chapter 1 [69,76,198,199,208,209,211,216,230,234,273,
274, 306, 331]. More importantly, these mice had been used to describe endogenous RA
activity in developing kidneys [235, 267] and in the thymus after birth [149].
The transgenic mice harbour a transgene that contains 32-bp oligonucleotides defining
three copies of RARE derived from RARβ , which is placed upstream of a mouse hsp68
minimal promoter that does not contain sequences determining site-specific expression
[150], to drive the expression of a lacZ reporter gene derived from E. coli [266]. In cells
where RXR/RAR heterodimers were activated by ligands such as RA, co-activators will
be recruited to the RARE on the transgene resulting in expression of β -galactosidase (β -
gal) protein encoded by the lacZ reporter gene. β -gal protein expression can then be de-
termined by performing an X-gal (5-bromo-4-chloro-3-indolyl-β -D-galactopyranoside)
assay (Figure 3.1) and by immunostaining.
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Figure 3.1: Reporter transgene activation and X-gal enzymatic reaction. In the presence
of functional RXR/RAR heterodimer and their putative ligands such as RA, transcrip-
tional co-activators will be recruited to the RARE (1), leading to activation of the lacZ
reporter gene producing β -galactosidase protein (2). By performing an X-gal assay, β -
galactosidase oxidised X-gal (5-bromo-4-chloro-3-indolyl-β -D-galactopyranoside) into
insoluble blue X-gal product (5,5’-dibromo-4,4’-dichloro-1H,1’H-(2,2’)biindolylidene-
3,3’-dione) (3). Note that the construct of transgene is not drawn to scale and lacZ trans-
gene was driven by a minimal hsp68 promoter rather than a full hsp68 promoter. coA:
transcriptional co-activators; RA: retinoic acid; RXR: retinoic acid X receptor; RAR:
retinoic acid receptor.
In view of the complexity of RA signalling involving both canonical and non-canonical
pathways, “RARE activity” would be used to describe the expression of reporter trans-
gene. In order to have better insights on the temporospatial pattern of reporter trans-
gene activation, kidneys from 1-, 2-, 3-, 5-, and 8-week-old mice were examined; livers,
known to be the major storage of retinoids, were examined alongside kidneys. When in-
dicated, tissues from wild-type mice and transgenic mice were examined concurrently to
differentiate endogenous β -gal from transgenic β -gal. X-gal signal observed in tissues
of both wild-type and transgenic mice was attributed to background signal given rise by
endogenous β -gal activity; X-gal signal that was detected only in tissues of transgenic
mice was considered as specific induction of reporter transgene (Figure 3.2).
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Figure 3.2: Endogenous β -galactosidase and transgenic β -galactosidase. Wild-type
mice served as control to differentiate endogenous β -galactosidase from transgenic β -
galactosidase.
3.2 Materials and methods
3.2.1 Animals
Both transgenic and wild-type mice were fed a standard chow and maintained at the ani-
mal facilities at Biological Services, Institute of Child Health (ICH), University College
London. The transgenic mice, which were originally established on an outbred CD-1
background, had been bred onto a C57BL/6 background for at least four generations
upon arrival at ICH. Animal handling, including animal housing and care, animal sacri-
fice, and harvest of kidneys and livers were performed by Dr. C Roberts at ICH.
3.2.2 Tissue preparation
Tissues from 7-16 mice in each age group were obtained. Kidneys and livers were cut
transversely into halves, of which half was subjected to wholemount X-gal assay. The
remaining half was divided further into two quarters, to be processed for paraffin sec-
tions and cryosections, respectively.
Tissue preparation for cryosectioning
Freshly harvested tissue was first submerged in 30% sucrose (Sigma-Aldrich Company
Ltd., UK) in ultrapure water overnight at 4 °C, which is a dehydration step to prevent ice
crystal artefact in cryosections and to minimise fracturing during cryosectioning. The
tissue was then submerged in a mixture of 30% sucrose in water and Optimum Cutting
Temperature (OCT) compound (VWR International Ltd., UK) at a ratio of 1:1 for 2 h
at 4 °C, before being transferred into OCT compound. In order to embed tissue in OCT
compound, tissue was first positioned with the cutting side facing upwards, on a piece
of soft card board rested on a metal chuck. OCT compound was then slowly squeezed,
3.2. Materials and methods 89
avoiding bubbles, over the tissue to cover it completely. The bottom of metal chuck was
then slowly dipped into liquid nitrogen, during which OCT compound would freeze.
Finally, the OCT embedded tissue was removed from the metal chuck using a blade,
transferred immediately into a pre-chilled 1.5 ml cryotube, and stored at -80 °C.
A Microm HM560 cryostat machine (temperature set to -20 °C) was used to section
OCT embedded tissues. The tissues were sectioned at 5 µm and were mounted on
polysine® microscope slide (VWR International Ltd., UK). The sections were then air
dried at room temperature for 2 min, before storing at -80 °C.
Tissue preparation for paraffin sectioning
Tissues were fixed and embedded in paraffin wax by the histopathology department of
King’s College Hospital. Briefly, freshly harvested tissues were fixed with 10% formol
saline for 24-48 h, to protect tissues from proteolytic enzymes and microorganism, as
well as to allow formation of cross-linking between protein thereby preserving tissue
structure [125]. The tissues were then subjected to dehydration step by going through
a series of graded ethanol, ending with 100% ethanol, and then through xylene before
being embedded in paraffin wax.
A Reichert Jung 2030 microtome was used to section paraffin embedded tissues. The
tissues were sectioned at 4 µm, and section ribbons were laid on a Raymond A Lamb
mounting water bath (temperature set to 45 °C) until the creases flatten. The section
ribbons were then lifted from the water bath with microscope slides and left to drip dry.
Slides were placed on a Raymond A Lamb hot plate (temperature set to 80 °C) to melt
the wax. The slides were then lifted off the hot plate and allowed to cool to room tem-
perature, during which the paraffin wax solidified. The slides were stored in slide boxes
at room temperature.
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3.2.3 Detection of β -gal activity and expression
X-gal assay on wholemount kidneys and livers and semi-quantitative scoring
The halved tissues were fixed with PBS containing 2% paraformaldehyde and 2 mM
MgCl2 (pH 7.4) for 10 min, then rinsed with 2 mM MgCl2 in PBS twice before incuba-
tion in X-gal staining solution in PBS (pH 7.4) containing 20 mM K3Fe(CN)6, 20 mM
K4Fe(CN)6.3H2O, 2 mM MgCl2, 0.01% sodium deoxycholate, 0.02% tergitol NP-40,
and 1 mg/ml X-gal substrate overnight for 16 h at 37 °C, until desired staining devel-
oped. The X-gal assay on wholemount tissues were performed by Dr. C Roberts at ICH,
and microphotography was performed by Dr. Q Xu.
A total of 5-13 kidneys from transgenic mice in each age group were examined for the
intensity of X-gal signal. The kidneys were first divided into two regions, i.e., (i) cor-
tex and outer medulla, and (ii) inner medulla, following the description by Wallace et
al. [315]. The intensity of the X-gal signal in renal tubules within each region was de-
termined with naked eyes; an average score was given to renal tubules with X-gal signal
within each region. A score of “1” represents the least intense signal and a score of
“4” represents the most intense signal.
X-gal assay on kidney and liver cryosections
Kidney and liver cryosections were equilibrated to room temperature for 20 min, after
which the sections were fixed briefly by submersion in ice-cold 10% formalin in PBS
in a Coplin jar for 10 min. Sections were then washed with three changes of PBS with
gentle rocking on a table top rocker, 5 min each wash, to remove the excess formalin
solution. After fixation, the slides were submerged in X-gal staining solution (pH 7.4)
in PBS (formula stated in Section 2.1.4) at 37 °C. Kidney and liver cryosections were
incubated in X-gal staining solution for 7 h and 25 h, respectively. At the end of the in-
cubation period, sections were washed with two changes of PBS that was pre-warmed to
37 °C, 5 min each wash, and rinsed briefly with ultrapure water before counter-staining.
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Kidney cryosections were subjected to periodic acid-Schiff (PAS) counter-staining. The
staining procedure involved incubating cryosections in 1% periodic acid solution for
15 min, followed by thorough rinsing with ultrapure water. Sections were then incu-
bated in Schiff reagent for 15 min followed by 5 min washing in running tap water. Peri-
odic acid selectively oxidises glucose residues, which are abundant in the brush borders
of proximal tubules, into aldehyde that subsequently reacts with Schiff reagent form-
ing purple-magenta colour. Liver cryosections were counter-stained with 0.1% nuclear
fast red solution in 0.5% aluminium sulfate (Sigma-Aldrich Company Ltd., UK), which
stains the nuclei red, for 20 min. After counter-staining, liver sections were rinsed briefly
in ultrapure water. Both kidney and liver cryosections were then mounted directly with
Glycergel® (Dako UK Ltd., Ely, UK) using cover glass.
β -gal immunofluorescence
A standard indirect immunofluorescence technique [213] was employed to detect β -gal.
Kidney and liver paraffin sections were first dewaxed in three changes of xylene, 2 min
each, and rehydrated in three changes of graded ethanol starting from 100% ethanol,
1 min each, then immersed in ultrapure water.
Due to potential masking of antigen sites by formalin cross-linking impeding their recog-
nition by antibodies, paraffin sections were subjected to heat-induced antigen retrieval
to unmask the antigenic epitopes. The slides were boiled in 0.01 M citric acid buffer
(pH 6) using a domestic pressure cooker for 3 min at full pressure. Slides were then
cooled to room temperature while submerged in citric acid buffer, after which they were
transferred immediately into a Coplin jar containing ultrapure water, avoiding sections
going dry. In order to reduce fixative induced auto-fluorescence, sections were incubated
with 0.1 M glycine in PBS for 20 min, followed by 5 min PBS washing. The sections
were then incubated with 1% BSA in PBS for 2 h at room temperature to reduce non-
specific antibody binding. The excess BSA was tipped off the slides and a paper towel
was used to wipe off residual BSA around the sections. A Dako pen (Dako UK Ltd.,
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UK) was used to draw a circle around the sections to create a water-repellent barrier so
that antibody can stay on the sections.
In order to establish the optimum signal to noise ratio, sections were incubated with
chicken anti-β -gal IgY primary antibody (1 mg/ml) at different concentrations (dilution
1:50, 1:100, 1:200; Abcam Inc., Cambridge, UK) or non-immune chicken IgY 400 µg/ml
at similar concentrations to that of the primary antibodies (dilution 1:20, 1:40, 1:80; In-
sight Biotechnology Ltd., Wembley, UK) as negative controls. After 1 h of incubation
at room temperature, sections were washed in five changes of 0.1% PBST with gentle
rocking, 5 min each wash, and incubated with goat anti-chicken secondary antibody con-
jugated with AlexaFluor 488 (2 mg/ml) (dilution 1:1000; Invitrogen Ltd., UK) for 1 h
at room temperature. Sections were then washed in three changes of 0.1% PBST with
gentle rocking. Finally, coverslip was mounted onto the sections with ProLong® Gold
mounting medium (Invitrogen Ltd., UK).
After coverslipping, nail varnish was applied to four corners of the coverslip and the
slides were left at room temperature on a flat surface, in an opaque box. After 24 h,
nail varnish was applied around the edges of the coverslip and the slides were examined
under the epifluorescence microscope. The slides were then stored in an opaque box at
4 °C and microscopy was performed within the next 48 h.
As shown in Figure 3.3, a 1:200 dilution of chicken anti-β -gal IgY (working concentra-
tion 5 µg/ml) gave an optimum signal-to-noise ratio of β -gal signal. Thus, subsequent
immunostaining for β -gal was performed using 5 µg/ml chicken anti-β -gal; section
stained with 5 µg/ml non-immune chicken IgY served as a negative control.
3.2.4 Antibodies used as markers for kidney tubules and cells
An anti-Tamm-Horsfall protein (THP) antibody was used to label the thick ascending
limbs and part of the ascending thin limbs of Henle’s loop; an anti-calbindin D28K
(CD28K) antibody was used to label the distal convoluted tubules and connecting tubules;
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Figure 3.3: Optimisation of β -galactosidase (β -gal) antibody. In kidney sections of a 2-
week-old transgenic mouse, 20 µg/ml anti-β -gal IgY gave rise to a poor signal-to-noise
ratio, with a relatively high background signal that was also observed in section stained
with 20 µg/ml non-immune chicken IgY. A better signal-to-noise ratio was achieved by
using 10 µg/ml and 5 µg/ml anti-β -gal IgY, with the latter giving minimum signal in
the wild-type mouse kidney section. Structural-specific signal was not observed in kid-
ney section from wild-type mouse stained with equivalent concentration of antibodies.
β -gal signal that was noted on kidney sections from both transgenic mouse and wild-
type mouse were attributed to endogenous β -gal expression. Original magnification was
100x.
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an anti-aquaporin 2 (AQP2) antibody was used to label the collecting duct principal cells
and inner medullary collecting duct cells; an anti-vacuolar H+-ATPase B1 (V-ATPase)
antibody was used to label the intercalated cells (Figure 3.4). Anti-AQP2 antibody was
from Millipore, Watford, UK. All other antibodies were from Insight Biotechnology
Ltd., UK.
Figure 3.4: Antibodies employed as markers to identify various segments of nephron
and different cell types in collecting ducts. Anti-Tamm-Horsfall protein (THP) antibody
labels the thick ascending limbs and a portion of ascending thin Henle’s loop (red); anti-
calbindin D28K (CD28K) antibody labels the distal convoluted tubules and connecting
tubules (blue); anti-aquaporin 2 (AQP2) antibody labels the collecting duct principal
cells and inner medullary collecting duct cells; anti-vacuolar H+-ATPase B1 (V-ATPase)
antibody labels the collecting duct intercalated cells (green).
Optimisation of antibody concentration
Preliminary experiments were first performed following protocol described in Section
3.2.3 by staining kidney section with individual antibody at three different dilutions
(1:100, 1:200, and 1:500) to determine the optimum concentrations giving the best
signal-to-noise ratio. Non-immune goat IgG and non-immune rabbit IgG (Insight Bio-
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technology Ltd., UK) at concentrations similar to that of primary antibodies served as ne-
gative controls. Sections were then incubated with the corresponding anti-rabbit or anti-
goat secondary antibodies conjugated with AlexaFluor 488 (2 mg/ml), AlexaFluor 555
(2 mg/ml), or AlexaFluor 568 (2 mg/ml) (dilution 1:1000, Invitrogen Ltd., UK).
The primary antibodies used to identify the specific segments/cells of kidney tubules
and their optimum concentrations are summarised in Table 3.1. The microscopic images
for each antibody with optimum signal-to-noise ratio and their respective negative con-
trols are shown in Figure 3.5.
Table 3.1: Primary antibodies used as markers of specific segments/cells of kidney
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collecting duct cells of
collecting ducts
1:150 (4 µg/ml)
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Figure 3.5: Optimum concentrations for marker antibodies. Concentrations of marker
antibodies that gave optimum signal-to-noise ratio were as follow: rabbit anti-aquaporin
2 (AQP2) IgG at 4 µg/ml, goat anti-calbindin D28K (CD28K) IgG at 1 µg/ml, rabbit
anti-Tamm-Horsfall protein (THP) IgG at 2 µg/ml, and goat anti-vacuolar H+-ATPase
B1 (V-ATPase) IgG at 0.4 µg/ml. At a similar exposure time, signal on sections stained
with non-immune rabbit IgG and non-immune goat IgG was minimum, if any. Original
magnification was 100x.
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Specificity of antibodies in identifying kidney tubules and cells
In order to confirm the specificity of the antibodies serving as markers of renal tubules
and cells, a double immunofluorescence staining was performed using different combi-
nations of two of the antibodies, as follow:
1. THP and CD28K
Thick ascending limbs and thin loops of Henle stain positive for THP [94]; distal
convoluted tubules and connecting tubules stain positive for CD28K [94]. Thus
the two immunostaining signals were expected to be mutually exclusive.
2. CD28K and AQP2
In kidney cortex, distal convoluted tubules and connecting tubules stain positive
for CD28K [94], although cortical collecting ducts were also reported to have
weak CD28K staining [151]; principal cells of connecting tubules and collecting
ducts stain positive for AQP2 [94]. Thus, distal convoluted tubules were expected
to stain positive solely for CD28K, connecting tubules to stain positive for both
CD28K and AQP2, whereas collecting ducts to stain positive for AQP2 and very
weakly for CD28K.
3. AQP2 and V-ATPase
In collecting ducts, principal cells and inner medullary collecting duct cells stain
positive for AQP2 [80, 94], whereas intercalated cells stain positive for V-ATPase
[82]. The principal cells and the intercalated cells were expected to be present
within the cortical collecting ducts while the late portion of distal convoluted
tubules were expected to have only the intercalated cells; inner medullary col-
lecting duct cells were expected to largely stain positive for AQP2.
Kidney paraffin sections of a 2-week-old wild-type mouse were used for this purpose.
Sections were first dewaxed and rehydrated as described in Section 3.2.3. Double im-
munofluorescence staining was performed sequentially, i.e., after incubation with 1%
BSA to block non-specific binding, sections were stained with one primary antibody
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followed by the corresponding fluorophore conjugated-secondary antibody; upon com-
pletion of the first cycle of immunostaining, sections were stained with the second cycle
of primary and secondary antibodies. After completing the first cycle of immunostain-
ing, the sections were examined briefly under the epifluorescence microscope to ensure
successful immunostaining, before proceeding to the second cycle of immunostaining.
Whilst antigen retrieval with citric acid buffer heating and glycine incubation were per-
formed only once before the first cycle of immunostaining, blocking non-specific bind-
ing with 1% BSA was performed before sections were incubated with primary antibodies
of the first cycle and again before sections were incubated with primary antibodies of the
second cycle. Washing steps were as described in Section 3.2.3. Finally, sections were
incubated with DAPI (dilution 1:2000) before coverslip was mounted onto the slide.
The main procedures and steps involved in performing double immunofluorescence
staining are summarised in Table 3.2.
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Table 3.2: Main procedures of double immunofluorescence staining
Procedure Temperature Duration
1. Pressure cook section in 0.01 M citric





2. Incubate section in 0.1 M glycine to
reduce fixative-induced
auto-fluorescence
Room temperature 20 min
3. Rinse glycine off the section and
incubate section in PBS
Room temperature 5 min
4. Incubate section in 1% BSA to reduce
non-specific binding of antibody
Room temperature 2 h
5. Incubate section in primary antibody
A that detects protein A
Room temperature 1 h
6. Rinse antibody off section and wash
section in 0.1% PBST
Room temperature 5 x 5 min
7. Incubate section in secondary
antibody conjugated to flurophore X that
detects primary antibody A
Room temperature 1 h
8. Rinse antibody off section and wash
section in 0.1% PBST
Room temperature 3 x 5 min
9. Incubate section in 1% BSA to reduce
non-specific binding of antibody
Room temperature 2 h
10. Incubate section in primary antibody
B that detects protein B
4 °C Overnight
11. Repeat washing step “6”
12. Incubate sections in secondary
antibody conjugated to flurophore Y that
detects primary antibody B
Room temperature 1 h
13. Repeat washing step “8”
14. Counter-staining with DAPI Room temperature 5 min
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Primary antibodies raised in goat were selected for first round of immunostaining to
avoid cross-reactivity during the second round of immunostaining. The sequence for
double immunostaining is shown in Table 3.3.
Table 3.3: Double immunofluorescence sequence for characterisation of antibodies.
Double immunofluorescence was performed sequentially according to the sequence be-
low. AF: AlexaFluor.
Primary Antibody Secondary Antibody
THP and CD28K
First Goat anti-CD28K Donkey anti-goat AF 555
Second Rabbit anti-THP Goat anti-rabbit AF 488
CD28K and AQP2
First Goat anti-CD28K Donkey anti-goat AF 555
Second Rabbit anti-AQP2 Goat anti-rabbit AF 488
AQP2 and V-ATPase
First Goat anti V-ATPase Donkey anti goat AF 555
Second Rabbit anti-AQP2 Goat anti-rabbit AF 488
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As shown in Figure 3.6, results of double immunofluorescence were congruent with
their reported histological localisation, demonstrating their appropriateness as markers
for specific segments of renal tubules and the two cell types in the collecting duct system.
It was also noted that the number of V-ATPase-positive cells were higher in the kidney
cortex compared to that in the medulla and only a few V-ATPase-positive cells were
noted in the inner medulla, in concordance with common feature of intercalated cells in
mammalian kidney [80].
Figure 3.6: Please refer to the following page for figure legend.
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Figure 3.6: Characterisation of antibodies for their specificity in labelling nephron and
collecting ducts. Antibodies were used to identify thick ascending limbs, distal con-
voluted tubules, as well as principal cells, inner medullary collecting duct cells, and
intercalated cells of collecting ducts. Ai. (Merged image): CD28K signal (red) was
observed only in the cortex, whereas THP signal (green) was detected in both cortex
and outer medulla, but not in deep inner medulla. Original magnification was 100x;
Aii. (Merged image): CD28K (red) and THP (green) signals were mutually exclusive.
Original magnification was 400x. Bi. (Merged image): CD28K (red) was detected only
in the cortex whereas AQP2 (green) was more abundant in the outer medulla and in-
ner medulla. Original magnification was 100x; Bii. (merged image): distal convoluted
tubules stained exclusively and intensely for CD28K (double arrow); tubules stained
positive for both CD28K and AQP2 were the connecting tubules (arrowhead) whereas
those showing weak or negative CD28K but a positive AQP2 signal were the cortical col-
lecting ducts (arrow). Original magnification was 400x. Ci. Principal cells that stained
positive for AQP2 (green) and intercalated cells that stained positive for V-ATPase (red)
co-localised to the same tubules in the cortical collecting ducts (arrow). Cii. In the inner
medullary collecting ducts, most cells stained positive for AQP2 (green) whereas there
was minimum, if any, cells that stained positive for V-ATPase (red); one cell with pos-
itive V-ATPase signal was noted (arrow), which might be an intercalated cell. Original
magnification was 400x. Nuclei were visualised with DAPI (blue) counterstaining. C:
cortex; OM: outer medulla; IM: inner medulla; G: glomeruli.
3.2.5 Localisation of β -gal
AQP2 immunofluorescence and X-gal assay on kidney cryosection
Following the protocol described in Section 3.2.3, cryosection was fixed briefly in for-
malin, then incubated in rabbit anti-AQP2 IgG for 1 h at room temperature, followed
by goat anti-rabbit IgG conjugated to AlexaFluor 488 overnight at 4 °C. Upon confirm-
ing the success of immunostaining under epifluorescence microscope, cryosections were
subjected to X-gal assay and then mounted with coverslip directly with ProLong® Gold
mounting medium.
Double immunofluorescence for β -gal and marker antibodies
Double immunofluorescence was performed for β -gal and the marker antibodies se-
quentially, following the protocols described in Section 3.2.4. The sequence of antibody
incubation is shown in Table 3.4.
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Table 3.4: Double immunofluorescence sequence for localisation of β -galactosidase (β -
gal). Double immunofluorescence was performed sequentially according to the sequence
below. AF: AlexaFluor.
Primary Antibody Secondary Antibody
AQP2 and β -gal
First Rabbit anti-AQP2 Goat anti-rabbit AF 568
Second Chicken anti-β -gal Goat anti-chicken AF 488
V-ATPase and β -gal
First Goat anti-V-ATPase Donkey anti-goat AF 555
Second Chicken anti-β -gal Goat anti-chicken AF 488
CD28K and β -gal
First Goat anti-CD28K Donkey anti-goat AF 555
Second Chicken anti-β -gal Goat anti-chicken AF 488
THP and β -gal
First Goat anti-THP Donkey anti-rabbit AF 568
Second Chicken anti-β -gal Goat anti-chicken AF 488
3.2.6 Immunostaining for RARβ , RARβ2, Raldh1, and Raldh3
A double immunostaining between β -gal and RARβ , RARβ2, or Raldh3 was performed
sequentially following the protocols described in Section 3.2.4. Immunostaining for β -
gal protein was performed during the second cycle using the same concentration stated
before; dilutions for other antibodies were as follow: rabbit anti-RARβ antibody (1
mg/ml) (dilution 1:100; Abcam Inc., UK), rabbit anti-RARβ2 antibody (200 µg/ml)
(dilution 1:100; Insight Biotechnology Ltd., UK), and goat anti-Raldh3 antibody (200
µg/ml) (dilution 1:100; Insight Biotechnology Ltd., UK).
Immunostaining for Raldh1 was performed on kidney sections from a 3-week-old mouse
using a rabbit anti-Raldh1 antibody (Abcam Inc., UK); liver sections from an 8-week-old
mouse was used as a positive control for the antibody, following the company’s recom-
mendation. The concentration of this antibody was not stated in the data sheets as it is
a monoclonal antibody derived from tissue culture supernatant, which contains culture
medium foetal calf serum. According to the company’s technical support personnel, the
concentration of this antibody was estimated to be around 1-3 mg/ml. Hence, for a pre-
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liminary test, the concentration was assumed to be 3 mg/ml and the antibody was diluted
1:100 (working concentration: 30 µg/ml) for immunostaining. A non-immune rabbit
IgG diluted to similar working concentration was used as a negative control. As shown
in Figure 3.7, there was hardly any discernible Raldh1 signal in both kidney and liver
sections. However, given that the actual concentration of this antibody remains ques-
tionable and that no specific signal was detected even in the liver, which was meant to
serve as positive control, localisation of Raldh1 protein was not pursued any further.
In order to confirm its specificity, anti-Raldh3 antibody was pre-adsorbed to an excess
amount of Raldh3 antigen (Insight Biotechnology Ltd., UK) before being incubated with
section. While the section was incubated in 1% BSA to block non-specific binding,
4 µl of anti-Raldh3 antibody was mixed together with 20 µl of Raldh3 antigen in a
microtube and was left at room temperature for 2 h. At the end of the incubation, the
pre-adsorbed antibody was diluted with 1% BSA to a final working concentration of
2 µg/ml before being pipetted onto the section and incubated for 1 h at room temperature.
The other sections were either incubated with non-pre-adsorbed anti-Raldh3 antibody or
non-immune goat IgG for the same period of time.
3.2.7 Statistical analysis for X-gal semi-quantitative scoring
A Kruskal-Wallis one-way analysis of variance (ANOVA) test with a Dunns post-test
was performed for the semi-quantitative scores of X-gal signal observed in kidney tubules
using GraphPad Prism, Version 4.0. Separate comparison was made between kidney
tubules within the cortex and outer medulla, and between kidney tubules within the in-
ner medulla. A value of p<0.05 was taken as a statistically significant difference.
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Figure 3.7: Immunostaining for retinaldehyde dehydrogenase 1 (Raldh1) in kidney and
liver. In kidney sections from a 3-week-old mouse, no discernible Raldh1 immunostain-
ing signal was observed in the cortex (C) and outer medulla (OM) (Ai, original magni-
fication was 100x), as well as inner medulla (Aii, original magnification was 200x). No
Raldh1 immunostaining signal was observed in liver section from a 8-week-old mouse
either (B, original magnification was 100x).
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3.3 Results
3.3.1 Reporter signal observed in the kidney but not in the liver
Results of X-gal assay on wholemount kidneys and livers are shown in Figure 3.8. Kid-
neys of 1- and 2-week-old wild-type mice had weak and ubiquitous cortical staining
whereas kidney cortex of 3-, 5-, and 8-week-old wild-type mice showed no signal. In
contrast, there was a conspicuous pattern of X-gal signal in kidneys of both male and
female transgenic mice in all age groups. X-gal signal in the kidneys of transgenic mice
was highly concentrated in the medulla, whereas in kidney cortex, X-gal signal was re-
stricted to certain renal tubules. No specific signal was noted in livers of both wild-type
mice and transgenic mice.
Following the description by Wallace et al. [315] (Figure 3.9Ai), kidney tissue was di-
vided into two regions: (i) cortex and outer medulla region, and (ii) inner medulla region
(Figure 3.9Aii). Intensity of X-gal signal in kidney tubules within each region was scored
semi-quantitatively. In both regions, kidney tubules of 1-, 2-, and 3-week-old transgenic
mice had a stronger intensity of X-gal signal compared to those in kidneys of 5- and
8-week-old transgenic mice (Figure 3.9B).
Results of X-gal assay on kidney cryosections were congruent with those on whole-
mount kidneys (Figre 3.8), whereby kidney sections of wild-type mice did not have
discernible signal but a conspicuous structural-specific X-gal signal was detected in kid-
neys of transgenic mice. The X-gal signal was noted to be more abundant in kidneys of
young mice compared to that in kidneys of older mice, in good agreement with results
of wholemount X-gal assay (Figure 3.10). In addition, the signal was observed only in


































Figure 3.8: X-gal assay on wholemount kidneys and livers of transgenic (TG) and wild-
type (WT) mice. Conspicuous X-gal signal (blue) was observed in kidneys of TG mice.
Shown here are representative images taken from tissues of 5-13 TG mice and 1-7 WT
mice from different age groups. Pictures were taken freshly after X-gal assay for 1-
week (A), 2-week (B), 5-week (C), and 8-week (D) groups; tissues of the 3-week (a) (E)
group were stained and fixed in formalin overnight before pictures were taken. Absence
of endogenous X-gal signal in 3-week-old WT kidney was confirmed by repeating X-
gal assay on freshly harvested and stained 3-week-old tissues (shown in 3-week (b) (F)),
after which picture was taken immediately. TG-K and WT-K: kidney of TG and WT
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Figure 3.9: X-gal signal in different regions of kidney from transgenic mice and semi-
quantitative scoring of X-gal signal intensity. Following the description by Wallace et
al., who divided rat kidney into cortex, outer medulla, and three inner medulla regions
(Figure adapted from [315]) (Ai), the transgenic mouse kidneys were divided into cortex
and outer medulla region, and inner medulla region (Aii). B. Tubules with positive X-
gal signal was scored semi-quantitatively on a scale of 1 to 4, with 1 representing weak
signal and 4 representing very strong signal; an average score of X-gal signal intensity
was given to all tubules with X-gal signal within the cortex and outer medulla region
(orange triangle), and to all tubules with X-gal signal within the inner medulla region
(blue triangle). Within each region, a statistical difference (p<0.0001) was found in the
X-gal intensity among the five groups. However, no difference was found between the
signal in kidney of 1-week to 3-week group, nor between those of 5-week and 8-week
group. Each triangle represents signal from kidney of one transgenic mouse. 1-w, 2-w,
3-w, 5-w, and 8-w represents 1-week, 2-week, 3-week, 5-week, and 8-week-old kidneys,
respectively; n=12 for 1-week, n=9 for 2-week, n=5 for 3-week, n=13 for 5-week, and
n=6 for 8-week; n.s.: not statistically significant.
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Figure 3.10: X-gal assay on kidney cryosections of transgenic (TG) and wild-type (WT)
mice. X-gal signal (blue) was detected in kidneys of TG mice but not in WT mice.
X-gal signal was restricted to renal tubules, and was noted to be more abundant in 1-
week-old TG mice, especially in medulla, than in 5- and 8-week-old TG mice. Original
magnification was 100x. C: cortex; M: medulla.
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3.3.2 Reporter signal in a subset of kidney tubules but not in glomeruli
In all age groups, glomeruli and proximal tubules were devoid of X-gal signal; X-gal sig-
nal was present in a subset of renal tubules, in which some cells exhibited higher staining
intensity than others (Figure 3.11A). The histological orientation of these tubules that
were composed of large and cuboidal cells indicated that those tubules were not thin
limbs of Henle’s loop but were likely to be collecting ducts (with the consultation from
King’s College Hospital Histopathologist, Dr. N Dutt).
The tubular pattern of X-gal signal and its absence from the glomeruli were confirmed
with β -gal immunohistochemistry (Figure 3.11B and Figure 3.11C).
3.3.3 Absence of reporter signal from the liver
In good concordance with X-gal assay on wholemount livers, no signal was observed
in liver sections subjected to X-gal assay (Figure 3.12A) and to β -gal immunostaining
(Figure 3.12B), suggesting the lack of reporter transgene activation in the liver. The lack
of signal in liver section was not due to any experimental fault, as positive X-gal signal
was observed in a kidney section stained alongside.
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Figure 3.11: X-gal assay and β -galactosidase (β -gal) immunohistochemistry on kidney
sections of transgenic (TG) and wild-type (WT) mice. X-gal signal (blue) was observed
in a subset of tubules but was not observed in the proximal tubules (arrow, with distinct
luminal brush border stain) nor in the glomeruli, in kidney sections of 1-week-old (Ai),
5-week-old (Aii), and 8-week-old (Aiii) transgenic mice. Original magnification was
400x. β -gal (green) immunostaining on kidney paraffin section of 1-week-old TG mice
showed a similar tubular pattern (Bi). The background signal that was also noted in
kidney section of 1-week-old WT mice might be attributed to endogenous β -gal (Bii).
Original magnification was 100x. C. Merged image: β -gal signal (green) was observed
in tubules, whereas no signal was detected in glomeruli. Nuclei were visualised with
DAPI (blue) counter-staining. Original magnification was 400x. No specific signal was
noted on sections incubated with non-immune IgG in place of primary antibody (data
not shown). C: cortex; M: medulla; G: glomeruli.
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Figure 3.12: X-gal assay and β -galactosidase (β -gal) immunohistochemistry on liver
sections of transgenic (TG) and wild-type (WT) mice. Reporter signal was not observed
in liver sections of 2-week-old (Ai) and 8-week-old mice (Aii) subjected to X-gal assay.
Similarly, signal was not observed in liver sections of 2-week-old (Bi) and 8-week-old
mice (Bii) stained with anti-β -gal antibody. Original magnification was 100x.
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3.3.4 Reporter signal in principal cells, inner medullary collecting duct cells, and
intercalated cells of collecting ducts
The histological orientation and cellular morphology of tubules stained positive for X-gal
and β -gal signals were suggestive of collecting ducts. Hence, initial attempt of localis-
ing reporter transgene activation was focused on examining the presence of X-gal and
β -gal signals in the collecting duct.
X-gal assay and immunostaining for AQP2
The staining patterns of X-gal and AQP2 closely resembled each other (Figure 3.13Ai);
only X-gal signal but not fluorescence signal was observed in section stained with non-
immune IgG in place of anti-AQP2 IgG (Figure 3.13Aii), thus ruling out the possibility
of auto-fluorescence given rise by X-gal signal. At higher magnification, X-gal and
AQP2 signals co-localised to the same renal tubules (Figure 3.13B).
Double immunostaining for AQP2 and β -gal
In concordance with the results shown in Figure 3.13, the immunostaining pattern of
β -gal and AQP2 in kidneys from young mice closely resembled each other and both
signals co-localised to the same renal tubules (Figure 3.14A). At the cellular level,
cells that stained positive for both β -gal and AQP2 were observed in most instances
(Figure 3.14B). β -gal expression was more extensive in kidneys of young mice, evident
by the presence of many cells that appeared as yellow/orange colour; in kidney of older
mice, β -gal expression was less widespread, which was largely localised to cells with













































































































































































































































































































































































































































































Figure 3.15: Localisation of aquaporin 2 (AQP2) and β -galactosidase (β -gal) signals in
renal tubules of an adult mouse. In kidneys of 8-week-old mice, β -gal (green) signal
was less abundant, which was largely localised to tubules that also stained positive for
AQP2 (red). Insets showed the enlarged figure of signal co-localisation. Note that co-
localisation of β -gal with AQP2 signals to the same renal tubules was more apparent
in the inner medulla (Bi) than in the cortex (Ai). Original magnification was 200x. No
specific signal was detected on sections incubated with non-immune IgGs in place of
primary antibodies (Aii and Bii).
3.3. Results 117
Double immunostaining for V-ATPase and β -gal
While most β -gal-positive cells express AQP2, β -gal signal was also detected in some
cells stained positive for V-ATPase (Figure 3.16).
Figure 3.16: Localisation of vacuolar H+-ATPase B1 (V-ATPase) and β -galactosidase
(β -gal) signals in renal tubules. β -gal signal (green) was detected in some cells that
stained positive for V-ATPase (red) in kidney cortex (Ai) and medulla (Aii) of 2-week-
old mice, as well as in inner medulla of 8-week-old (B) mice. Original magnification
was 400x. No specific signal was detected on sections incubated with non-immune IgGs
in place of primary antibodies (data not shown).
Collectively, the observation confirms the presence of reporter transgene activation in
principal cells and inner medullary collecting duct cells, which expressed AQP2, and in
intercalated cells, which expressed V-ATPase. In older mice, reporter transgene activa-
tion was found to largely localised to inner medullary collecting duct cells (Figure 3.15).
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3.3.5 Absence of reporter signal from thick ascending limbs
In kidneys of both young and adult mice, β -gal signal was not detected in THP-positive
thick ascending limbs (Figure 3.17).
Figure 3.17: Mutually exclusive β -galactosidase (β -gal) and Tamm-Horsfall protein
(THP) signals. Tubules stained positive for β -gal (green) and THP (red) were mutually
exclusive in kidneys of 2-week-old (A) and 8-week-old (B) mice. Original magnification
was 200x. No specific signal was detected on sections incubated with non-immune IgGs
in place of primary antibodies (data not shown). C: cortex; M: medulla.
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3.3.6 Absence of reporter signal from distal convoluted tubules
β -gal signal was not observed in tubules with intense CD28K signal, but was detected
in some tubules with intermittent and relatively weak CD28K signal (Figure 3.18).
Figure 3.18: Partial overlapping of β -galactosidase (β -gal) and calbindin D28K
(CD28K) signals in renal cortex. In renal cortex of 2-week-old (A) and 8-week-old (B)
mice, tubules with intense CD28K signal (arrow) did not stain positive for β -gal protein.
Whereas, some tubules with intermittent CD28K showed positive β -gal signal (double
arrow). Original magnification was 400x. No specific signal was detected on sections
incubated with non-immune IgGs in place of primary antibodies (data not shown).
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The results suggest that the reporter transgene activation was absent from distal convo-
luted tubules with an intense CD28K signal, but was likely to be present in connecting
tubules or cortical collecting ducts with intermittent CD28K signal, consistent with the
presence of CD28K-negative intercalated cells in these segments [151].
3.3.7 Expression of Raldh3 and RARβ2 proteins in the kidney
A kidney section stained with anti-Raldh3 IgG showed predominant signal in the inner
medulla region, partially overlapping with tubules stained positive for β -gal, as shown
in Figure 3.19A. The specificity of anti-Raldh3 IgG was questionable as section stained
with anti-Raldh3 IgG pre-adsorbed with Raldh3 antigen resulted in a similar staining
pattern as section stained with anti-Raldh3 IgG (Figure 3.19B).
As shown in Figure 3.20, RARβ protein was not detected in tubules expressing reporter
transgene. Whereas, RARβ2 protein was found to be present only in a few tubules
expressing reporter transgene (Figure 3.21).
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Figure 3.19: Expression of retinaldehyde dehydrogenase 3 (Raldh3) and β -galactosidase
(β -gal) protein. In kidney section of a 5-week-old transgenic mouse, Raldh3 was lo-
calised predominantly to the inner medulla; no specific signal was detected on sections
incubated with non-immune IgGs in place of primary antibodies (Ai). Original mag-
nification was 100x. C: cortex; IM: inner medulla. At higher magnification, Raldh3
protein expression was found to be partially overlapped with β -gal protein expression
(Aii). Original magnification was 200x. B. Whereas no apparent signal was observed in
kidney section stained with non-immune IgG (middle panel), section stained with anti-
Raldh3 IgG pre-adsorbed with Raldh3 antigen (right panel) showed a similar staining
pattern as section stained with anti-Raldh3 IgG (left panel). Original magnification was
200x.
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Figure 3.20: Expression of retinoic acid receptor β (RARβ ) and β -galactosidase (β -gal)
protein. In kidney section of a 3-week-old transgenic mouse, expression of RARβ (B)
was not observed in tubules with positive β -gal signal (A). Original magnification was
200x.
Figure 3.21: Expression of retinoic acid receptor β2 (RARβ2) and β -galactosidase (β -
gal) protein. In kidney section of a 1-week-old transgenic mouse, many tubules stained
positive only for β -gal, while only a few stained positive for both β -gal and RARβ2.
Original magnification was 400x.
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3.4 Discussions
3.4.1 Methodology used in detecting and localising reporter transgene expression
An X-gal assay was first performed on wholemount kidney and liver tissues to get a ge-
neral idea on expression of reporter transgene. In order to avoid the possibility of poor
penetration of X-gal into the tissues, X-gal assay was subsequently performed on kidney
and liver cryosections to localise reporter transgene expression.
Although X-gal assay was a quick and convenient way of examining reporter trans-
gene expression, it involved an enzymatic reaction that relies on functionality of the
β -gal protein, which would be affected by tissue fixation [185]. Thus, X-gal assay had
to be performed on cryosections that were only briefly fixed. The short fixation period
did not allow precise X-gal localisation due to suboptimal histological detail. Moreover,
diffusion of X-gal product to adjacent cells [266] and the inherent difficulties during sec-
tioning that subjected tissues to multiple freeze-thaw cycles also hampered localisation
of X-gal signal at the cellular level. Therefore, reporter transgene expression was further
confirmed with immunostaining of β -gal protein, using an optimised concentration of
antibody, performed on paraffin sections.
Localisation of reporter transgene expression was determined based on the advice from
King’s College hospital consultant histopathologist, Dr. N Dutt. In addition, a double
immunostaining was performed for β -gal protein and a series of marker antibodies, of
which their optimum concentrations and specificity were carefully examined and vali-
dated (Figure 3.6). Taken together, the expression of reporter transgene and its locali-
sation were examined using more than one method and similar conclusions were drawn
from different methodologies.
3.4.2 Expression of reporter transgene in the kidney but not in the liver
X-gal signal in kidneys of 1-, 2-, and 3-week-old transgenic mice was rather similar in
intensity, and was higher compared to that in kidneys of 5- and 8-week-old transgenic
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mice (Figure 3.8 and Figure 3.9), consistent with the pattern of immature and mature
kidneys, respectively. The exact half-life of β -gal protein in these reporter mice is not
known, but Rossant et al. had described a day-to-day variation (both increase and de-
cline) of the reporter transgene activation from E7.5 until E12.5 [266], indicating a dy-
namic activation of reporter transgene and a relatively rapid turn-over of β -gal protein.
Given that no apparent difference in the intensity of X-gal signal was observed in 1- to
3-week-old kidney and that the signal was still consistently observed in 5- and 8-week-
old kidney, albeit at lower intensity, the signal was suggestive of a constant activation
of reporter transgene rather than an accumulation of β -gal protein from embryonic stage.
The positive signal of reporter transgene expression observed in the kidney of trans-
genic mice from all age groups indicates a constitutively active RARE activity. In vitro,
the RARE-hsp68-lacZ construct was activated by RA but not by thyroid hormone [266].
When metanephric kidney of RARE-hsp68-lacZ mice was cultured in vitro for 72 h with-
out tRA, there was a complete loss of reporter transgene expression, whereas a conspi-
cuous and intense signal continued to be present in the ureteric bud tips and trunks of
wholemount kidney cultured in medium containing tRA for the same duration [267].
Administration of exogenous RA to pregnant RARE-hsp68-lacZ mice resulted in an ele-
vation of reporter transgene expression in domains where reporter transgene expression
was normally present, as well as in novel domains where transgene expression was not
originally detected in mouse foetus [266]. Similar observation of an enhanced transgene
expression was reported in mice deficient in Cyp26 when mated to RARE-hsp68-lacZ
reporter mice [273]. Collectively, these results showed that the reporter transgene is
responsive towards both exogenous and endogenous RA, as well as ruling out the possi-
bility of site-specific silencing, at least during embryonic development. Thus, it is very
likely that the constitutive RARE activity observed in the kidney of RARE-hsp68-lacZ
transgenic mice indicated the presence of endogenous RA and activation of retinoid nu-
clear receptor that leads to reporter transgene expression.
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On the other hand, there was no indication of reporter transgene expression in the liver.
This might be due to an absence of bioactive RA or other components of retinoid sys-
tem, i.e., functional RXR/RAR heterodimers and transcription co-regulators, necessary
to support reporter transgene expression. Indeed, Xu et al. found that endogenous tRA
was not detected in liver of 3-week-old C57BL/6 mice despite the presence of abundant
tRol [328], which might explain the lack of reporter transgene expression in the liver of
transgenic mice. However, absence of tRA in the liver is not unequivocal. Other groups
had reported the presence of tRA in adult murine liver at a level higher than that mea-
sured in the kidney [137,139,277]. The discrepancy might be due to numerous variables
including dietary vitamin A content, tissue preparation and retinoid extraction methods,
sensitivity of assays employed, and animal strain or age difference, all of which might
have an impact on tRA metabolism and detection. On the other hand, according to the
NURSA database, the mRNA level of all three isotypes of “permissive” RARs, i.e.,
RARα , RARβ , and RARγ , in the liver are at least 2-fold lower compared to those in the
kidney of C57Bl/6J and 129x1/SvJ mice (www.nursa.org/10.1621/datasets.02001; last
accessed on 30.07.11), which may account for the absence of reporter transgene expres-
sion in the liver. Nevertheless, presence of RARs with functional evidence had been
reported in the past [60, 283]. Taken together, the presence of endogenous RA and its
RAR-dependent activity in the liver is not as clear-cut at this stage and further studies
are required to reconcile these discordance.
3.4.3 Expression of reporter transgene in the principal cells, inner medullary
collecting duct cells, and intercalated cells of renal collecting ducts
The nephron, comprising the glomeruli, proximal tubules, Henle’s loops, distal tubules,
and connecting tubules, was originated from the metanephric mesenchyme, whereas
the collecting duct is derived from ureteric bud [80]. In this project, reporter trans-
gene expression was consistently detected in renal collecting ducts from 1-8 weeks of
age, but not in glomeruli, proximal tubules, Henle’s loops, and distal convoluted tubules
(Figure 3.8). In rodents, AQP2-positive principal cells are found mainly in the collecting
duct although some connecting tubule cells also express AQP2 protein [49]; V-ATPase-
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positive cells first arise from the late portion of distal convoluted tubules [39], and are
also found in the connecting tubules and collecting ducts [148]. Thus, some of the AQP2-
and V-ATPase-positive cells observed in the cortical region might reside within the con-
necting tubules. However, it is difficult to conclude on whether the reporter transgene
expression was localised to connecting tubules in the absence of a marker that specifi-
cally labels this segment [181].
Using the same reporter mice, Dr. A Yoshifusa at the National Institute of Health,
Bethesda, had also detected a similar pattern of reporter transgene expression in neona-
tal kidneys at 1-2 days of age, whereby signal was observed in the ureteric bud tips and
collecting ducts [327]. These observations closely reminisce that of Rosselot et al., who
reported positive signal of reporter transgene expression in the ureteric bud tip and trunk
of developing kidney at E12-E14 [267]. Hence, it is evident that the reporter transgene
expression in the ureteric bud during nephrogenesis had persisted in the ureteric bud-
derived collecting ducts, in principal cells, inner medullary collecting duct cells, and
intercalated cells after birth.
3.4.4 Expression of RARβ , RARβ2, and reporter transgene
In RARE-hsp68-lacZ, domains of reporter transgene expression [266] closely resem-
bled that of RARβ transcript [62] from developmental stage E11.5 onwards, suggesting
that RARβ might be the main RAR that mediates embryonic development. It was thus
speculated that reporter transgene expression observed in kidney collecting ducts might
overlap with that of RARβ and RARβ2.
In kidney of a 3-week-old transgenic mouse, RARβ protein was not detected in tubules
expressing reporter transgene (Figure3.20) while RARβ2 protein was detected only
in a few collecting ducts that expressed reporter transgene in kidney of a 1-week-old
mouse (Figure 3.21). The discrepancy between the immunostaining results of RARβ and
RARβ2 might be due to the age difference. The lack of RARβ and RARβ2 immunos-
taining signal also raised the issues of specificity and sensitivity of these antibodies in
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detecting the respective protein. However, these issues were failed to be addressed due to
the lack of controls such as tissues known to express a high level of RARβ and RARβ2,
and lack of RARβ and RARβ2 antigens that antibodies could be pre-adsorbed with.
While it remains inconclusive whether the reporter transgene activation in collecting
ducts were mediated by RARβ , it is important to note that the RARE on reporter trans-
gene, although derived from RARβ , can be activated by all three RAR isotypes, i.e.,
RARα , RARβ , and RARγ [266]. More studies such as kidney-specific genetic ablation
of individual or compound RARs and RXRs are required to determine the mediator of
reporter transgene activation.
3.4.5 Expression of Raldh3 and reporter transgene
Transcript of Raldh3 was reported to be present predominantly in the inner medulla
of adult mouse kidney [232] but expression of Raldh3 protein in the kidney has not
been reported thus far. It was found in this study that the expression pattern of Raldh3
closely resembled that of Raldh3 transcript, which was primarily in the inner medulla
(Figure 3.19A). The partial overlapping between Raldh3 and reporter transgene expres-
sion might suggest both autocrine and paracrine action of Raldh3 in generation of bioac-
tive RA to activate reporter transgene in the collecting duct. However, when kidney
section was incubated with anti-Raldh3 IgG pre-adsorbed with Raldh3 antigen, a similar
staining pattern as the section that was stained with anti-Raldh3 IgG alone was observed
(Figure 3.19B). The situation could be due to suboptimal binding between antibody and
blocking antigen hence not all antigen binding sites were blocked, or could be due to
an inherent fault in either the anti-Raldh3 IgG or the Raldh3 blocking antigen. Fur-
ther testing including prolonged pre-incubation of antibody and Raldh3 antigen, as well
as a higher ratio of Raldh3 antigen to antibody are required to achieve a solid conclusion.
Taken together, although Raldh3 immunostaining showed a pattern similar to the Raldh3
transcript reported before, it remains inconclusive if the immunostaining signal was in-
deed Raldh3. Even if Raldh3 protein did indeed overlap with reporter transgene expres-
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sion, further testing such as knock down of Aldh1a3 that encodes Raldh3 is required to
confirm its contribution towards generating RA for reporter transgene activation.
3.4.6 Concluding remarks
In this study, constitutive RARE activity was observed in principal cells, inner medullary
collecting duct cells, and intercalated cells, which might indicate constitutive RAR ac-
tivation by endogenous RA in these cells as discussed before. Nevertheless, there is a
possibility whereby the reporter transgene was activated by other elements in addition
to RA. In fact, it was reported that RARE-hsp68-lacZ transgene could be activated by
heat shock and by arsenite [150]. While the reporter mice were not exposed to either
of these elements, it remains unknown if the RARE activity was given rise by other yet
identified elements. However, based on the observation of reporter transgene expression
in the ureteric buds of developing kidneys, which are dependent on RA [267], the RARE
activity observed in the ureteric bud-derived collecting duct in this study was very likely
to be mediated by a constitutive activation of RAR/RXR by endogenous RA. On the
other hand, sites devoid of reporter signal could be a result of site-specific transgene si-
lencing that might have happened during the transition from embryo to adulthood [51].
Thus, whether the lack of reporter signal in sites other than the collecting duct, such as
glomeruli and proximal tubules, was due to site-specific silencing would require further
confirmation.
The RARE-hsp68-lacZ reporter mice have been widely employed to study the role of
RA activity during embryonic development but have not been extensively used at post-
natal and adult stages. Thus, it would be of great interest to further characterise the
reporter mice after birth, in terms of its sensitivity and specificity in reporting RAR-
dependent endogenous RA activity. This can be achieved by altering the availability
and level of endogenous RA in the reporter mice, e.g., by subjecting the mice to diet
containing varied amount of vitamin A, or by administrating chemical reagents that in-
hibit RA biosynthesis or that antagonise retinoid nuclear receptors. In addition, by mat-
ing RARE-hsp68-lacZ mice to conditional knockout mutants of individual or compound
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RARs/RXRs, as well as of retinoid synthesising and metabolising enzymes, would allow
the identification of mediators of reporter transgene activation.
Collecting ducts are the final renal tubular segment that connects the renal tubules to
the bladder and are the only renal tubules that spans across the whole kidney from cortex
to inner medulla. It is well acknowledged that collecting ducts are made up of a heteroge-
neous population of cells with distinct features and functions. Classically, the principal
cells are known to be regulating Na+ and water reabsorption, while intercalated cells that
are subdivided into at least three subtypes, i.e., α-, β -, and non-α- non-β -intercalated
cells, are thought to be regulating acid/base balance; a third distinct cell type, designated
inner medullary collecting duct cells, are present in the collecting duct of inner medullary
region 2 (middle) and 3 (terminal), which possess some characteristics of both principal
cells and intercalated cells, as well as mediate urea transport [73,80]. Emerging publica-
tions are challenging the classical views on functions of collecting ducts, and have shown
evidence of their novel properties, such as: (i) involvement of intercalated cells in regu-
lation of Na+/K+ exchange and in paracrine communication with principal cells [73], (ii)
defence against bacterial infection [42], (iii) regulation of tubulointerstitial inflammatory
processes and fibrogenesis via Kru¨pel-like factor 5 [91], and (iv) epithelial-mesenchymal
transition leading to fibrotic changes [37, 130].
Considering its multifaceted functions, the collecting duct is indeed highly versatile. If
the reporter transgene activation indeed represents a constitutive activation of RAR/RXR
by endogenous RA, it might play a role in mediating some of the known and perhaps
other as yet unknown functions of collecting ducts. Finally, it must be reiterated that the
presence of a constitutive activation of RAR/RXR by endogenous RA in the collecting
duct does not negate the fact that other RAR-independent signalling mechanisms of RA





Endogenous Retinoic Acid Activity in a
Mouse Collecting Duct Cell Line
4.1 Introduction
While the presence of RARE activity was observed in kidney collecting ducts of RARE-
hsp68-lacZ mice, a direct evidence of it being a result of retinoid nuclear receptor ac-
tivation by endogenous RA is lacking. In order to address this issue, the presence of
RARE activity was examined in an in vitro model of collecting duct cells. This chapter
describes the presence of constitutive retinoid nuclear receptor activation by endogenous
RA in a well-established collecting duct cell line.
4.1.1 mIMCD-3 as an in vitro model
Although primary cultures derived from mouse collecting ducts would be more phy-
siologically relevant, establishment of highly enriched primary cultures of collecting
duct cells that maintain high level of epithelial differentiation and collecting duct cells-
specific characteristics would be laborious and technically challenging. An alternative
to primary cultures is to employ cell lines derived from collecting ducts. Mouse inner
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medullary collecting duct cells, mIMCD-3 cells, were chosen as a cell model for this
purpose.
The mIMCD-3 cells were derived from the terminal one third of inner medullary col-
lecting ducts of a mouse transgenic for the early region (large T antigen) of simian virus
40, Tg(SV40E)Bri/7 [257]. The original founder reported that mIMCD-3 cells retain
many characteristics of the inner medullary collecting duct cells observed in vivo, in-
cluding high transepithelial resistance, presence of amiloride-sensitive sodium channel
with luminal-to-basolateral sodium flux that was blocked by both amiloride and atrial
natriuretic peptide, and the ability to grow in hypertonic medium up to 900 mOsmol/kg
H2O [257].
Ever since its establishment, mIMCD-3 cells have been employed as an in vitro model
in various studies, which are highly relevant to functions and activities of collecting duct
principal cells and inner medullary collecting duct cells, such as ion channel signalling
[105, 285], signalling during osmotic and hypertonic stress [38], and urea signalling
[47]. In addition, mIMCD-3 cells undergo branching morphogenesis when grown on
3-dimensional gel matrix [162], a unique feature of the ureteric bud cells in developing
embryonic kidney. Therefore, as a starting point, mIMCD-3 cells should serve as a good
in vitro model of collecting duct principal cells, inner medullary collecting duct cells,
and ureteric bud cells, for examination of RARE activity.
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4.2 Materials and methods
4.2.1 Cell culture and cell morphology
The basic maintenance and culturing of mIMCD-3 cells was described in Chapter 2,
Section 2.2. Cell morphology at different passages was examined under phase contrast
microscopy and microscopic photos were taken for future reference.
At low confluence, mIMCD-3 cells had slightly spindled morphology; when near con-
fluent, mIMCD-3 cells had an uniform cuboidal morphology (Figure 4.1A). A change in
cell morphology was noted by around P9-P10 (Figure 4.1B), during which the cells were
growing very quickly. The phenomenon might be due to a permanently high level of un-
controlled large T antigen expression leading to cell dedifferentiation [21]. Thus, all
experiments employing mIMICD-3 cells were performed within P3-P8, and cells were
discarded as soon as morphological change was observed.
Figure 4.1: Morphology of mICMD-3 cells. The figure shows mIMCD-3 cells at P3
and P9 cultured for 48 h. At the end of 48 h, mIMCD-3 cells of P3 achieved 80% to
100% confluent and had a uniform cobblestone-like morphology with distinct cell-cell
boundary (A). Whereas, mIMCD-3 cells of P9 were over-confluent; some cells were
elongated with less apparent cell-cell boundary (B). Original magnification was 100x.
4.2.2 Immunocytochemistry for E-cadherin and AQP2
Since a detailed characterisation of mIMCD-3 cells had already been performed by the
original founder of this cell line [257], a basic characterisation was performed to confirm
the identity of mIMCD-3 cells. Expression of E-cadherin (E-cad), a marker of epithelial
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cells, and AQP2, a marker of collecting duct principal cells and inner medullary collect-
ing duct cells, were examined with indirect immunocytochemistry.
Cells were seeded at 6 x 105 cells/35 mm2 dish in 2 ml DMEM-F12 medium containing
antibiotics and anti-fungal, supplemented with 5% FBS. After an overnight culture until
confluent, cells were fixed with ice-cold 5% formalin for 15 min on ice, followed by
washing with three changes of PBS, 5 min each wash. Cells were then permeabilised
with 0.1% Triton X-100 for 3 min and washed with three changes of PBS, 5 min each
wash. After fixation and permeabilisation, cells were incubated with 1% BSA for 2 h
at room temperature to reduce non-specific antibody binding, followed by 1 h incuba-
tion of rabbit anti-AQP2 IgG (dilution 1:150), or mouse anti-E-cad IgG2a (dilution 1:50,
BD Biosciences, Oxford, UK), at room temperature. Cells incubated with non-immune
rabbit IgG and non-immune mouse IgG2a (Insight Biotechnology Ltd., UK) at the same
concentrations served as negative controls for anti-AQP2 IgG and for anti-E-cad IgG2a,
respectively. Cells were then washed with three changes of PBS, 5 min each wash,
and were incubated with goat anti-rabbit conjugated with AlexaFluor 488 (2 µg/ml) for
AQP2 detection or goat anti-mouse conjugated with AlexaFluor 555 (2 µg/ml) for E-
cad detection, for 1 h at room temperature. At the end of secondary antibody incubation,
cells were washed with three changes of PBS, 5 min each wash. One millilitre of fresh
PBS was then pipetted onto the cell monolayer and fluorescence microscopy was per-
formed immediately. For all washing steps, PBS was pipetted gently onto cells from the
side of dishes, after which dishes were shaken at low speed on a table top rocker.
As shown in Figure 4.2, both E-cad and AQP2 protein were detected in mIMCD-3 cells.
The morphology of mIMCD-3 cells (Figure 4.1), as well as the presence of E-cad and
AQP2 protein in this cell line (Figure 4.2) were consistent with it being of epithelial and
of principal cell/inner medullary collecting duct cell origin.
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Figure 4.2: E-cadherin (E-cad) and aquaporin 2 (AQP2) protein expression in mIMCD-3
cells. Ai. Expression of E-cad protein was predominantly localised to cell membrane.
Bi. Expression of AQP2 protein was more intense in cell membrane and was also noted
in cell cytoplasm. No specific signal was detected in mIMCD-3 cells stained with non-
immune IgGs (Aii and Bii). Original magnification was 100x.
4.2.3 Reporter assay
The presence of RARE-activity in mIMCD-3 cells was examined in reporter assay with
transient transfection of RA reporter plasmid. Plasmids used are as follow:
1. pmaxGFP in TE buffer (Lonza Wokingham Ltd., Berkshire, UK): A plasmid that
constitutively expresses green fluorescent protein (GFP) when transfected into the
cells. pmaxGFP plasmid was used to assess transfection efficiency in the first
instance. Map of pmaxGFP plasmid is shown in Appendix A.1.
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2. pGL3-RARE-luciferase in TE buffer (a kind gift from Dr. T M Underhill [124]
and prepared by Dr. Y Abe): A plasmid that expresses firefly luciferase in the
presence of RA, functional RAR heterodimers, and transcription co-activators,
similar to the principle of transgene activation in RARE-hsp68-lacZ transgenic
mice as described in Section 3.1.1. Map of pGL3-RARE-luciferase plasmid is
shown in Appendix A.2.1.
3. pCI-β -galactosidase in CsCl2 (a kind gift from Promega, Madison, USA, and
prepared by Dr. Q Xu): A plasmid that constitutively expresses β -gal when trans-
fected into the cells, and hence was co-transfected with pGL3-RARE-luciferase
plasmid to serve as a control for transfection efficiency. Map of pCI-vector is
shown in Appendix A.2.2.
Plasmid DNA precipitation
Before first use, pCI-β -galactosidase plasmid was precipitated and resuspended in ste-
rile TE buffer. A volume of 125 µl pCI-β -galactosidase plasmid DNA was pipetted into
a 1.5 ml microtube, following which 12.5 µl of 3 M sodium acetate buffer (pH 5.2)
was added. The positively charged sodium (Na+) acts to neutralise the negative charges
on phosphate groups (PO3-) of the DNA, rendering the DNA less hydrophilic and less
soluble in water. The interaction between Na+ and PO3- was further accomplished by
adding 343.75 µl of ice cold 100% ethanol, which has a much lower dielectric constant,
to the plasmid DNA sodium acetate mixture. The mixture was then kept at -20 °C for 2
h, after which microtube was centrifuged at 24,100 g in a Mikro 24-48R microcentrifuge
for 15 min at 4 °C, with hinge of microtube facing outward. After centrifugation, super-
natant was carefully decanted, after which 200 µl of ice cold 70% ethanol was pipetted
into the microtube without resuspending the precipitated plasmid DNA, to wash away
residual salt from DNA pellet. Microtube was again centrifuged at 24,100 g for 5 min
and supernatant was removed with a 200 µl pipette, avoiding the pelleted plasmid DNA.
Finally, the microtube was left in a tissue culture hood for about 15 min with the lid
opened to allow evaporation of residual ethanol. Plasmid DNA pellet was then resus-
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pended in 60 µl of sterile TE buffer and stored at 4 °C until use.
Supernatant was removed in a tissue culture hood throughout the procedure to ensure
sterility of the plasmid DNA preparation. The final concentration of plasmid DNA was
determined using a NanoDrop® ND-1000 machine, with TE buffer set as blank measure-
ment. A ratio of ≈1.80 for A260/280 and a ratio of ≈2.0 for A260/230 were routinely
obtained, confirming the purity of plasmid DNA.
Other reagents used for transfection
Lipofectamine™ LTX and Plus™ reagents (Invitrogen Ltd., UK) were used as trans-
fection reagents following the company’s product manual1. Lipofectamine™ LTX is a
liposome formulation containing the polycatinoic lipid, DOSPA, and the neutral lipid,
DOPE, at a ratio of 3:1 (w/w). The positive charges of the lipid will associate with the
negatively charged plasmid DNA and form liposome/DNA complexes. The resulting
lower net negative charges on the plasmid DNA encourages closer association between
plasmid DNA and the negatively charged cell membrane, thereby facilitating transfer of
plasmid DNA into the cell via endocytosis. Plus™ reagent functioned as an adjuvant
that forms pre-complex with plasmid DNA to enhance DNA transfection. Opti-MEM®
I Reduced Serum Medium (Invitrogen Ltd., UK) was used as a medium to dilute plasmid
DNA and for formation of lipid-DNA complex.
Examination of transfection efficiency and plasmid functionality
Cells were seeded into a 24-well plate at 4 x 104 cells/well in 500 µl of DMEM-F12
medium supplemented with 5% FBS, without antibiotics and anti-fungal. Cells were
cultured overnight for 16-24 h until about 60% to 80% confluent before being transfected
with 1 µg pmaxGFP plasmid. Cells were then incubated for an additional 5 h before the
medium was changed to fresh DMEM-F12 medium supplemented with 1% FBS. Cells
were incubated overnight before being examined under the epifluorescence microscope
1Invitrogen Lipofectamine™ LTX and Plus™ Reagents, edition 08/2008, P/N: 15338.pps
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for presence of GFP-positive cells.
Transfection was performed in duplicates. A volume containing 1 µg of pmaxGFP plas-
mid DNA, 2 µl of Lipofectamine™ LTX, and 1 µl of Plus™ Reagent were prepared
in 100 µl Opti-MEM® I for each well. pmaxGFP plasmid DNA was first diluted in
Opti-MEM® I and mixed well, after which Plus™ reagent was added directly into the
diluted plasmid DNA and incubated for 10 min at room temperature. Lipofectamine™
LTX was then added directly to the plasmid DNA-Plus™ mixture and incubated at room
temperature for 30 min to allow formation of DNA-lipid complexes. Without removing
the culture medium, 100 µl of DNA-lipid complexes was added directly, drop-wise, to
each well, followed by gentle rocking of the plate. As a negative control for background
signal, a mixture of Lipofectamine™ LTX and Plus™ reagents in Opti-MEM I prepared
the same way but without plasmid DNA was added to cells in another well. By using
the Matlab Image Processing Toolbox version 7.2, around 65% of the total number of
cells expressed GFP (Figure 4.3). The algorithm used for image analysis is shown in
Appendix A.3.
In order to determine functionality of pCI-β -galactosidase plasmid and to determine if
endogenous β -gal was present in mIMCD-3 cells at a high level that would preclude
its use for normalising pGL3-RARE-luciferase reporter activity, mIMCD-3 cells were
transfected with 1 µg of pCI-β -galactosidase plasmid following the protocol described
before for pmaxGFP plasmid transfection. At the end of transfection, cells were stained
with X-gal staining solution (the same staining solution used for tissue cryosection) to
determine β -gal expression. Medium was first removed and cells were washed once with
PBS before being fixed in 5% formalin and 0.2% glutaraldehyde in PBS for 10 min at
room temperature. Cell monolayer was then washed twice with PBS, 5 min each wash,
and incubated in 150 µl of X-gal staining solution for 2 h at 37 °C with occasional rock-
ing of the plate. At the end of 2 h incubation, X-gal solution was washed off with PBS
and microscopic photos were taken immediately.
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Figure 4.3: Transfection efficiency assessed from green fluorescent protein (GFP) ex-
pression. A. In cells where only transfection reagents were added, no GFP expression
was observed. Bi. GFP expression was observed in cells transfected with pmaxGFP
plasmid. Bii. Image analysis revealed that 65.25% of the total mIMCD-3 cells expressed
GFP (green). Original magnification was 100x.
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X-gal product was detected in transfected cells, confirming the functionality of pCI-
β -galactosidase plasmid; no apparent signal was detected in non-transfected cells, indi-
cating the absence of high endogenous β -gal (Figure 4.4). The observation suggest the
presence of minimum, if any, endogenous β -gal in mIMCD-3 cells, hence permitting its
use as normalisation control for transfection efficiency.
Figure 4.4: Validation of pCI-β -galactosidase plasmid as normalisation control for trans-
fection efficiency. An intense signal of X-gal product (blue) was detected in mIMCD-3
cells transfected with pCI-β -galactosidase plasmid (left panel). No signal of X-gal prod-
uct was noted in cells where only transfection reagents were added (right panel). Original
magnification was 100x.
Co-transfection of pGL3-RARE-luciferase and pCI-β -galactosidase plasmids
Co-transfection of pGL3-RARE-luciferase and pCI-β -galactosidase plasmids were per-
formed following the same protocol described for pmaxGFP transfection. The ratio
(in µg) of pGL3-RARE-luciferase plasmid DNA : pCI-β -galactosidase plasmid DNA
was 5:1, and the ratio of plasmid DNA (total of pGL3-RARE-luciferase plasmid DNA
and pCI-β -galactosidase plasmid DNA in µg) : Lipofectamine™ LTX (in µl) : Plus™
Reagents (in µl) was 1:2:1. The actual amount used for transfection in individual expe-
riment is described in Section 4.2.4.
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Cell lysis for examination of plasmid expression
Cells were lysed in Reporter Lysis Buffer (RLB) (Promega UK, UK), which is a lysis
buffer compatible with both pGL3-RARE-luciferase and pCI-β -galactosidase plasmids.
Culture medium was first removed with a 1 ml pipette and the cell monolayer was care-
fully washed once with 600 µl of Ca2+- and Mg2+-free PBS per well. After removing
the PBS from cell monolayer, 150 µl of 1x RLB (prepared by diluting 5x RLB with
H2O) was pipetted directly onto cells in each individual well. In order to ensure com-
plete lysis, the 24-well plate containing cells in 1x RLB was kept at -80 °C for at least
2 h and then thawed at room temperature. The RLB cell lysate was then pipetted into
a 1.5 ml microtube and centrifuged at 12,000 g in a Mikro 24-48R microcentrifuge for
2 min at 4 °C. The supernatant was transferred to a new 1.5 ml microtube and stored at
-80 °C if not analysed immediately. Cell lysate was divided into two separate portions,
to be examined for the expression of firefly luciferase and β -gal, respectively.
Substrates for examination of plasmid expression
Expression of firefly luciferase and β -gal was detected by production of luminescence.
A Luciferase Assay System (Promega UK, UK), which contains lyophilised Luciferase
Assay Substrate and Luciferase Assay Buffer, was used to examine expression of firefly
luciferase following the company’s technical bulletin2. The Luciferase Assay System
contains beetle luciferin and other co-factors that are substrates for firefly luciferase, the
product of luc+ gene contained in the pGL3-RARE-luciferase plasmid. The lyophilised
Luciferase Assay Substrate was first reconstituted in 10 ml of Luciferase Assay Buffer.
The reconstituted Luciferase Assay Substrate was then dispensed into aliquots of 3 ml or
4 ml, and stored at -80 °C until use. The reagent was equilibrated to room temperature
before use.
A Beta-Glo® Assay System (Promega UK, UK), which contains lyophilised Beta-Glo®
Assay Substrate and Beta-Glo® Assay Buffer, was used to examine the expression of
2Luciferase Assay System Technical Bulletin, edition 03/2009, P/N: TB281
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pCI-β -galactosidase plasmid, following the company’s technical manual3. The Beta-
Glo® Assay System contains 6-O-β -galactopyranosyl-luciferin that acts as a substrate
for β -gal, the product of lacZ gene contained in the pCI-β -galactosidase plasmid, to
yield D-luciferin, which was subsequently converted into oxyluciferin by firefly lu-
ciferase and other co-factors present in the assay reagent.
The basic principles of transfection and chemical reactions involved in detecting plasmid
expression are illustrated in Figure 4.5.
Detection of luminescent signal
The luminescent signal was detected with a DTX880 multimode detector. The multi-
mode detector was programmed to perform linear shaking at a moderate speed for 5 sec
prior to reading, and to analyse the wells from left to right in a horizontal manner. The
integration time was set at 1 sec for luminescence generated from both pGL3-RARE-
luciferase plasmid and from pCI-β -galactosidase plasmid. Readings generated from
non-transfected cells (cells treated with transfection medium without plasmid DNA)
were set as background that were subtracted from all other readings generated from
transfected cells. Result was expressed as Relative Light Unit (RLU), which is a ratio
of light produced from pGL3-RARE-luciferase plasmid : light produced from pCI-β -
galactosidase plasmid.
For the detection of light produced from pGL3-RARE-luciferase plasmid, 20 µl of cell
lysate from each microtube was pipetted into individual well of an opaque black 96-well
plate (Greiner Labortechnik Ltd., UK). As soon as 100 µl/well of Luciferase Assay Sub-
strate was added to the cell lysate, light with a relatively short half-life of about 10 min
will be produced, which will remain constant for about 1 min. Therefore, 100µl of Lu-
ciferase Assay Substrate was added to cell lysate in each well of a single row on the
96-well plate using multi-chamber pipette, after which reading was performed immedi-
3Promega Beta-Glo® Assay System Technical Manual, edition 09/2009, P/N: TM239
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Figure 4.5: Plasmid transfection and detection. The negatively charged pGL3-RARE-
luciferase and pCI-β -galactosidase plasmid DNA were first incubated with the positively
charged Lipofectamine™ LTX to form complex (1). The lower repelling force between
the negatively charged cell membrane and the DNA-Lipofectamine™ LTX complex with
a lower net negative charge enhance plasmid DNA delivery into the cells (2). Cells were
lysed and divided into two separate portions subjected to different chemical reactions:
(i) Reaction A, where beetle luciferin was converted into oxyluciferin accompanied by
light production catalysed by firefly luciferase (encoded by pGL3-RARE-luciferase plas-
mid), and (ii) Reaction B, where 6-O-β -galactopyranosyl-luciferin was converted into
D-luciferin catalysed by β -gal (encoded by pCI-β -galactosidase plasmid), and subse-
quently into oxyluciferin accompanied by light production.
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ately.
Unlike the light produced from Luciferase Assay System, light produced from Beta-
Glo® Assay System has a long half-life and the signal intensity remains constant over a
period of 4 h. Fifty microlitre of cell lysate from each individual microtube was pipetted
into individual well of an opaque black 96-well plate, to which 50 µl/well of Beta-Glo®
substrate were added. The 96-well plate was then agitated for 30 sec at moderate speed
on an IKA MS1 minishaker to mix the reagents, after which it was left at room tempe-
rature covered in aluminium foil for 30 min before reading was performed.
Preliminary tests showed that luminescence generated from pCI-β -galactosidase plas-
mid was very high, which might saturate the detection capacity of the machine. In order
to avoid saturation of luminescent signal, a serial dilution of cell lysate (from transfected
cells treated with vehicle) was prepared with 1x RLB, and was analysed for luminescent
signal. As shown in Figure 4.6, a near linear luminescent signal was produced by cell
lysate at 102x-105x dilutions. Thus, in all subsequent assays, cell lysate was diluted
1000x with 1x RLB to avoid saturation of luminescent signal.
The workflow of detecting and interpreting luminescent signal is summarised in Figure 4.7.
4.2.4 Experimental protocols for reporter assay
tRA treatment in cells cultured in medium supplemented with normal FBS
Cells were seeded into a 24-well plate at 4 x 104 cells/well in 500 µl of DMEM-
F12 supplemented with 5% FBS without antibiotics and anti-fungal. Cells were cul-
tured overnight for 16-24 h until about 70% confluent before transfection was com-
menced. Cells were then incubated for an additional 5 h before medium was changed to
fresh DMEM-F12 medium supplemented with 1% FBS with antibiotics and anti-fungal.
Cells were incubated overnight before medium was again changed to fresh DMEM-F12
medium supplemented with 1% FBS containing 0.001 µM, 0.01 µM, or 0.1 µM tRA,
and cultured for 24 h.
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Figure 4.6: Serial dilution of Reporter Lysate Buffer cell lysate and luminescent signal.
A near linear luminescent signal was achieved at 102x to 105x dilution of cell lysate.
For transfection, cells in each well were transfected with 0.25 µg pGL3-RARE-luciferase
plasmid DNA, 0.05 µg pCI-β -galactosidase plasmid DNA, 0.6 µl Lipofectamine™ LTX,
and 0.3 µl Plus™ Reagents, prepared in 100 µl of Opti-MEM® I.
tRA treatment in cells cultured in medium supplemented with charcoal-stripped FBS
Cells were seeded into a 24-well plate at 8 x 103 cells/well in 500 µl of DMEM-F12
medium supplemented with 5% charcoal-stripped FBS (PAA laboratories Ltd., UK) to
limit the supply of lipid-soluble retinoids, with antibiotics and anti-fungal. Cells were
cultured for 72 h until about 70% confluent, and medium was then changed to fresh
DMEM-F12 medium supplemented with 1% charcoal-stripped FBS without antibiotics
and anti-fungal before transfection was commenced. Cells were incubated overnight
before medium was again changed to fresh DMEM-F12 medium supplemented with
1% charcoal-stripped FBS containing 0.001 µM, 0.01 µM, or 0.1 µM tRA, and cultured
for 24 h.
For transfection, cells in each well were transfected with 0.2 µg pGL3-RARE-luciferase
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Figure 4.7: Workflow for luminescent signal detection. Cells were lysed with 1x Re-
porter Lysis Buffer (RLB) and subjected to one freeze-thaw cycle to ensure complete cell
lysis. For the detection of light produced from pGL3-RARE-luciferase plasmid activa-
tion, 20 µl of undiluted cell lysate was pipetted into individual well of an opaque black
96-well plate (1). A volume of 100 µl/well of Luciferase Assay Reagent was added to
wells of a single row containing cell lysate using a multi-chamber pipette (2). The light
produced was analysed immediately after substrate addition to obtain a luminescent sig-
nal value designated “X”. For the detection of light produced from pCI-β -galactosidase
plasmid activation, cell lysate was first diluted 1000x with 1x RLB (3). The diluted cell
lysate was pipetted into each well of an opaque black 96-well plate at 50 µl/well (4), to
which 50 µl/well of Beta-Glo® substrate was added (5). The mixture was mixed well by
shaking the 96-well plate on a minishaker for 30 sec, followed by a 30 min incubation at
room temperature. The light produced was then analysed to obtain a luminescent signal
value designated “Y”. The Relative Light Unit (RLU) was calculated by dividing “X” by
“Y”.
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plasmid DNA, 0.04 µg pCI-β -galactosidase plasmid DNA, 0.48 µl Lipofectamine™
LTX and 0.24 µl Plus™ Reagents, prepared in 100 µl of Opti-MEM® I.
AGN193109 and BMS189453 treatment with and without tRA
Cells were seeded into a 24-well plate at 4 x 104 cells/well in 500 µl of DMEM-F12
medium supplemented with 5% FBS without antibiotics and anti-fungal. Cells were
cultured overnight for 16-24 h until about 70% confluent before transfection was com-
menced. Cells were then incubated for an additional 5 h before medium was changed
to fresh DMEM-F12 medium supplemented with 1% FBS with antibiotics and anti-
fungal. Cells were incubated overnight before medium was again changed to fresh
DMEM-F12 medium supplemented with 1% FBS containing 1 µM AGN193109 or
1 µM BMS189453, with and without 0.01 µM, 0.1 µM, or 1 µM tRA, and cultured
for 24 h.
For transfection, cells in each well were transfected with 0.25 µg pGL3-RARE-luciferase
plasmid DNA, 0.05 µg pCI-β -galactosidase plasmid DNA, 0.6 µl Lipofectamine™ LTX,
and 0.3 µl Plus™ Reagents, prepared in 100 µl of Opti-MEM® I.
DEAB and disulfiram treatment with and without tRA
Cells were seeded into a 24-well plate at 2 x 104 cells/well in 500 µl of DMEM-F12
medium supplemented with 5% FBS without antibiotics and anti-fungal. Cells were
cultured overnight for 16-24 h, and medium was changed to fresh DMEM-F12 medium
supplemented with 1% FBS, without antibiotics and anti-fungal, containing DEAB or
disulfiram, or vehicle. Optimum doses for DEAB and disufiram were determined in
the first instance by adding DEAB to final concentration of 1 µM, 5 µM, or 25 µM,
and disulfiram to final concentrations of 0.1 µM, 1 µM, or 10 µM. Cells were then
cultured for 16-24 h until about 70% confluent. Medium was changed to fresh DMEM-
F12 medium supplemented with 1% FBS, without antibiotics and anti-fungal, contain-
ing DEAB or disulfiram at the aforementioned concentrations, after which transfection
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was commenced. After an overnight incubation, medium was again changed to fresh
DMEM-F12 medium supplemented with 1% FBS with antibiotics and anti-fungal, con-
taining DEAB or disulfiram at the aforementioned concentrations, and cells were cul-
tured for an additional 16-24 h, so that cells were exposed to DEAB and disulfiram for a
total of 72 h.
For experiments involving aforementioned enzyme inhibitors and tRA, the protocol was
similar as described above, except that during the last 24 h, medium was changed to
fresh DMEM-F12 medium supplemented with 1% FBS with antibiotics and anti-fungal
containing enzyme inhibitors, with and without 0.0001 µM, 0.001 µM, 0.01 µM, or
0.1 µM tRA.
For transfection, cells in each well were transfected with 0.15 µg pGL3-RARE-luciferase
plasmid DNA, 0.03 µg pCI-β -galactosidase plasmid DNA, 0.36 µl Lipofectamine™
LTX, and 0.18 µl Plus™ Reagents, prepared in 100 µl of Opti-MEM® I.
Dilutions of reagents for cell treatment and experimental replicates
All reagents used for cell treatment were 1000x higher than the final working concen-
trations. The reagents were then diluted 1000x with cell culture medium to achieve
the desired working concentration, immediately before adding to cells. Cells in vehicle
control group were treated with ethanol and/or DMSO at a final concentration of 0.1%.
Microtubes and culture plates were covered in aluminium foil whenever possible and
transferring of reagents was performed quickly to minimise light exposure.
Three independent experiments, in triplicates or quadruplicates, were performed for all
the reporter assays aforementioned, except for the charcoal-stripped FBS experiment,
which was performed only once in triplicates.
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4.2.5 Data normalisation and statistical analysis
Readout of reporter assay was referred as “RARE-luciferase activity”. An average value
of RLU was first calculated for the triplicated or quadruplicated wells in each individual
experiment. The average value of RLU for vehicle-treated group was set as “1”; average
values of RLU of all other treatment groups were compared to the vehicle-treated groups
and expressed as “RLU fold-change”.
The fold-change values derived from three independent experiments were then grouped
together for statistical analysis. Due to the intrinsic asymmetric distribution of data ex-
pressed as fold-changes, fold-change values were first log-transformed, after which a
Repeated Measure One-way Analysis of Variance (ANOVA) test with a Tukey post-test
was performed on the log-transformed values using GraphPad Prism, Version 4.0. Please
note that owing to the small sample size (n=3), the p value computed may not be precise.
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4.3 Results
4.3.1 Poor inducibility of RARE-luciferase activity by exogenous RA
It was hypothesised that if mIMCD-3 cells are expressing functional RAR heterodimers
and transcription co-activators, exogenous tRA would induce RARE-luciferase activity.
However, although a slight trend of dose-dependent increase in RARE-luciferase activity
was noted following tRA treatment at 0.001-0.1 µM, the difference was not statistically
significant (Figure 4.8).
Figure 4.8: Poor inducibility of RARE-luciferase activity in mIMCD-3 cells treated
with all-trans retinoic acid (tRA). Despite a slight dose-dependent increase of RARE-
luciferase activity following 24 h of tRA treatment at the doses indicated, the difference
was not statistically significant. Each dot represents mean value of triplicates or quadru-
plicates from a single biological experiment.
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4.3.2 Basal RARE-luciferase activity induced by endogenous RA
Following the results of poor inducibility of RARE-luciferase activity by tRA, it was
hypothesised that mIMCD-3 cells have high basal RARE-luciferase activity given rise
by constitutive RAR activation. If such is the case, the transcriptional machineries might
already be fully occupied therefore mIMCD-3 cells might have been “desensitised” to-
wards exogenous tRA treatment. In order to address this hypothesis, mIMCD-3 cells
were subjected to culture condition or treatments that reduced or blocked endogenous
RARE-luciferase activity.
As illustrated in Figure 4.9, mIMCD-3 cells were (i) cultured in medium supplemented
with charcoal-stripped FBS in place of normal FBS for 72 h to reduce retinoid supply,
or (ii) treated with antagonists of RARs, AGN193109 and BMS189453, to inhibit RAR-
mediated signalling, or (iii) treated with inhibitors of Raldhs, DEAB and disulfiram, to
reduce cell-autonomous synthesis of RA.
Figure 4.9: Strategies used to inhibit RARE-luciferase activity in mIMCD-3 cells. Cells
were either cultured in charcoal-stripped FBS for 72 h to limit the supply of lipid-soluble
retinoids, including Rol, Ral, and RA (1), or treated with DEAB and disulfiram to in-
hibit biosynthesis of RA (2), or treated with AGN193109 and BMS189453, to block
the receptors from activating RARE-luciferase plasmid (3). Rol: retinol; Ral: retinal;
RA: retinoic acid; RARs: functional retinoic acid receptors; RARE-luciferase plasmid:
pGL3-RARE-luciferase plasmid.
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Cells cultured in medium supplemented with charcoal-stripped FBS
Cells were treated with tRA for 24 h after 72 h of culture in medium supplemented with
charcoal-stripped FBS. As shown in Figure 4.10, tRA treatment did not induce RARE-
luciferase activity under such culture condition.
Figure 4.10: Non-inducible RARE-luciferase activity in mIMCD-3 cells cultured with
charcoal-stripped foetal bovine serum (FBS) and treated with exogenous all-trans
retinoic acid (tRA). Preliminary investigation performed in triplicates showed that 24
h tRA treatment did not induce RARE-luciferase activity in mIMCD-3 cells at the doses
tested, after the cells were cultured in medium supplemented with charcoal-stripped FBS
for 72 h. Results shown are triplicates from a single biological experiment.
Cells treated with antagonists of RARs
In cells treated with 1 µM AGN193109 or 1 µM BMS189453 for 24 h, there was a re-
duction of RARE-luciferase activity compared to cells treated with vehicle (Figure 4.11).
When exogenous tRA was added simultaneously with the antagonists, the reduction of
RARE-luciferase activity was at least partially abolished in a dose-dependent manner.
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Figure 4.11: RARE-luciferase activity in mIMCD-3 cells treated with AGN193109 and
BMS189453 with and without all-trans retinoic acid (tRA). Treating mIMCD-3 cells
with 1 µM AGN193109 (A) or BMS189453 (B) for 24 h reduced the RARE-luciferase
activity to about 50% of that of the vehicle control group. The reduction of basal RARE-
luciferase activity by the two antagonists of RARs was at least partially abolished with
simultaneous addition of exogenous tRA, in a dose-dependent manner. Each dot repre-
sents mean value of triplicates or quadruplicates from a single biological experiment.
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Cells treated with inhibitors of RA synthesising enzymes
In cells treated with disulfiram, a reduction in cell number was observed at the lowest
dose tested (0.1 µM); at 10 µM, all cells were detached. The cytotoxicity caused by
disulfiram renders it unsuitable for cell treatment and hence was not used in subsequent
experiments.
Treating cells with DEAB caused a dose-dependent decrease in RARE-luciferase ac-
tivity (Figure 4.12), without any indication of cytotoxicity.
Figure 4.12: RARE-luciferase activity in mIMCD-3 cells treated with DEAB. RARE-
luciferase activity was suppressed by DEAB in a dose-dependent manner after 72 h
treatment. Each dot represents mean value of triplicates or quadruplicates from a single
biological experiment.
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The experiment involving DEAB treatment was then repeated with tRA added to the
cells during the last 24 h. As shown in Figure 4.13, tRA treatment induced the RARE-
luciferase activity in a dose-dependent manner, saturating at 0.001 µM.
* = p<0.05 vs vehicle; ** = p<0.01 vs vehicle; *** = p<0.001 vs vehicle.    
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Figure 4.13: RARE-luciferase activity in mIMCD-3 cells treated with DEAB with and
without all-trans retinoic acid (tRA). Treating cells with 25 µM DEAB resulted in a
suppression of RARE-luciferase activity to about 50% of that of vehicle control group.
In cells treated with 25 µM DEAB with tRA added during the last 24 h, the suppression
of RARE-luciferase activity was reversed to a level similar to vehicle control group at
0.0001 µM tRA; RARE-luciferase activity was saturated by 0.001 µM tRA, which was
about 1.75-fold of that of vehicle control group and about 3.5-fold of that of DEAB




4.4.1 Poor inducibility of RARE-luciferase activity by exogenous tRA
When mIMCD-3 cells were treated with tRA at 0.001-0.1 µM, induction of RARE-
luciferase activity was not statistically significant (Figure 4.8). The poor inducibility of
RARE-luciferase activity by tRA might be due to several reasons. Firstly, given the rela-
tively short half-life (about 3 h) of luciferase protein in mammalian cells [303], it might
be possible that an increase of RARE-luciferase activity had taken place earlier on fol-
lowing tRA treatment, and most luciferase protein were degraded after 24 h. Secondly,
there might be an inherent fault in the pGL3-RARE-luciferase plasmid that renders it
unresponsive towards tRA. However, a 3-fold to 6-fold increase of RARE-luciferase ac-
tivity was detected in primary cultures derived from mouse podocytes transiently trans-
fected with the same plasmid, after a 48 h treatment of 1 µM tRA (personal commu-
nication with Dr. A Yoshifusa). The results suggest that the pGL3-RARE-luciferase
plasmid is indeed functional, and detection of luciferase protein was possible even after
48 h tRA treatment. The third possibility would be that RARE-luciferase activity was
already maximally induced once entered the cells therefore rendering further induction
unachievable.
In cells cultured in vitro, supply of lipid-soluble retinoids comes solely from FBS added
to the cell culture medium. In order to reduce retinoid supply to increase their sensitivity
towards exogenous tRA, mIMCD-3 cells were cultured in medium supplemented with
charcoal-stripped FBS in place of normal FBS for 72 h prior to tRA treatment. However,
even under such culture condition, tRA treatment still failed to induce RARE-luciferase
activity (Figure 4.10). This might be due to the fact that charcoal stripping is not efficient
enough to remove all RA and RA precursors such as Rol that could be converted into
RA upon entering the cells (personal communication with Dr. J Corcoran). In addition,
if mIMCD-3 cells have a high level of intra-cellular retinoid storage, 72 h of culture in
charcoal-stripped FBS-supplemented medium might not be long enough to deplete the
cells of intra-cellular retinoid storage.
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4.4.2 Suppression of RARE-luciferase activity by antagonists of RARs
While exogenous tRA failed to induce RARE-luciferase activity, treating cells with
AGN193109 and BMS189453 resulted in a 50% reduction of RARE-luciferase activity
compared to that of the vehicle control groups (Figure 4.11). The results indeed support
the presence of basal RARE-luciferase activity in mIMCD-3 cells.
AGN193109 binds to all three isotypes of RAR, i.e., RARα , RARβ , and RARγ with
high affinity (Kd=2-3 nM for each RAR isotype), but does not activate the RARs [134].
Instead, AGN193109 acts as an inverse agonist of RARs, which upon binding to RARs
further stabilises the binding between RARs and transcription co-repressors leading to
transcription repression [14]. BMS189453 has similar affinity as tRA towards all three
isotypes of RARs [43]. In the absence of tRA, BMS189453 moderately transactivated
RARβ (about 30% relative to that of tRA) but had minimum, if any, agonistic ef-
fect on RARα and RARγ; in the presence of tRA, BMS189453 weakly antagonised
tRA-induced transactivation mediated by RARβ and strongly antagonised tRA-induced
transactivation mediated by RARα and RARγ [43]. In addition to its mixed agonis-
tic/antagonistic activity on RARs, BMS189453 also possess anti-AP1 activity, similar to
tRA [43]. Although activity of BMS189453 was more diverse compared to AGN193109,
suppression of RARE-luciferase activity by two distinct antagonists of RARs strongly
supports the presence of constant pGL3-RARE-luciferase plasmid activation mediated
by ligand-activated RARs in cultured mIMCD-3 cells. Of note, neither AGN193109 nor
BMS189453 binds to RXRs [43, 134], hence ruling out the possibility of these reagents
inhibiting signal transduction of other nuclear receptors bound to RXRs.
While no obvious signs of cytotoxicity such as cell detachment was observed in cells
treated with AGN193109 and BMS189453, it might be possible that these chemicals
were mildly toxic hence lead to a reduction of RARE-luciferase activity. In addition,
a suppression of RARE-luciferase activity might also be a non-specific phenomenon
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rather than a result of RAR blockage. In order to rule out these possibilities, RARE-
luciferase activity was examined in mIMCD-3 cells treated with the antagonists and tRA
simultaneously. It was found that 0.1 µM and 1 µM of tRA completely overcame sup-
pression of RARE-luciferase activity by 1 µM AGN193109, and partially overcame that
by 1 µM BMS189453 (Figure 4.11). Although binding affinities of these antagonists
and tRA to each individual RAR isotype in mIMCD-3 cells are not known, the competi-
tive nature between these antagonists and tRA had been clearly demonstrated [43, 134].
Thus, the diminution of RARE-luciferase activity suppression confirmed the specificity
of AGN193109 and BMS189453 in inhibiting pGL3-RARE-luciferase activation via
RAR blockage, which was relieved by increasing doses of exogenous tRA. Although
BMS189453 might have suppressed basal RARE-luciferase activity via its anti-AP-1
activity, the diminished rather than additive or synergistic effect of RARE-luciferase ac-
tivity suppression by simultaneous treatment of tRA argued against AP-1 playing a role
in this regard.
4.4.3 Suppression of RARE-luciferase activity by inhibitors of RA
synthesising enzymes
The presence of a basal RARE-luciferase activity in mIMCD-3 cells suggested not only
the presence of functional RARs and transcription co-activators but also bioactive RA
that constantly activates the receptors. In order to investigate the source of bioactive RA,
mIMCD-3 cells were treated with DEAB and disulfiram, which are inhibitors of Raldhs,
to inhibit RA biosynthesis. While disulfiram treatment was cytotoxic at the doses tested
precluding its use, DEAB treatment caused a dose-dependent suppression of RARE-
luciferase activity (Figure 4.12).
The dose-dependent suppression of RARE-luciferase supported the presence of an ac-
tive biosynthesis of RA in mIMCD-3 cells but given that DEAB inhibits all class I
Aldhs [272], which includes but not limited to Raldh1-3 [4], the suppression of RARE-
luciferase activity by DEAB might be a non-specific phenomenon. When exogenous
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tRA was added to mIMCD-3 cells pre-treated with DEAB, RARE-luciferase activity
was induced in a dose-dependent manner, and the activity was saturated at 1 nM tRA
(Figure 4.13). The reversal of RARE-luciferase activity by exogenous tRA not only sup-
ports the fact that suppression of RARE-luciferase activity was a result of diminished
intra-cellular RA following Raldh inhibition by DEAB, but further strengthened the pre-
sence of basal RARE-luciferase activity, in keeping with the results of RAR antagonist
experiments (Figure 4.11).
Interestingly, while at least 0.1 µM tRA was required to abolish, in part or in full, the
inhibitory effects of AGN193109 and BMS189453 on RARE-luciferase activity, 0.1 nM
of exogenous tRA was sufficient to reverse RARE-luciferase activity back to basal level
when endogenous RA was depleted from mIMCD-3 cells. Moreover, RARE-luciferase
activity was maximally induced by 1 nM tRA to about 1.75-fold compared to the basal
level. The relatively low dose of tRA needed to activate RARE-luciferase activity was
in good concordance with low serum level of tRA, which is in nano molar ranges [139].
In in vitro experiments, a potent effect of RA, with an ED50 as low as 0.01 nM, had also
been described [14]. The exact mechanism of tRA inducing RARE-luciferase activity
beyond basal level only when endogenous RA biosynthesis was inhibited was not clear.
An enhanced cellular uptake of exogenous tRA from culture medium driven by attenu-
ated endogenous RA supply might be a possible explanation.
4.4.4 Concluding remarks
In aggregate, a constitutively active RAR-dependent endogenous RA activity was present
in mIMCD-3 cells, which was likely given rise by cell-autonomous synthesis of RA that
constantly activates the RARs. This observation further supports that the RARE activity
observed in collecting duct principal cells, inner medullary collecting duct cells, and
ureteric bud cells of RARE-hsp68-lacZ mice might indeed be, at least in part, a result of
constitutive retinoid nuclear receptor activation by endogenous RA.
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Given that pan-antagonists of RARs were used and that expression of the individual iso-
types of RAR and RXR had not been examined, the actual functional RARs and RXRs
mediating the RARE-luciferase activity in mIMCD-3 cells remains unknown. Simi-
larly, since DEAB inhibits the activity of all Raldh isoforms, it is not known whether
RA biosynthesis in mIMCD-3 cells was attributed to a particular Raldh isoform. These
issues could be addressed in the future, e.g., by using RAR and RXR isotype-specific
antagonists or small interference RNA targeting specific RARs or Raldhs.
Finally, since the mIMCD-3 cell line is not a model of the collecting duct intercalated
cells, it remains unknown if the intercalated cells would also demonstrate a similar pat-
tern of constitutively active RAR-dependent endogenous RA activity. It is hoped that
the reporter assay utilising RARE-reporter plasmid can be applied to intercalated cells
when a good cell model of intercalated cells is available.
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Chapter 5
Pan-genomic Study: Target Genes of
Endogenous Retinoic Acid and its
Receptors in mIMCD-3 Cells
5.1 Introduction
In view of the presence of constitutively active RAR-dependent endogenous RA acti-
vity in mIMCD-3 cells, the primary aim of this part of the work is to identify candidate
target genes dependent on endogenous RA and RARs, herein referred as endogenous
RA/RAR, in mIMCD-3 cells. Given that AGN193109 and DEAB were found to sup-
press RARE-luciferase activity, these inhibitors were employed in this study.
Two sets of experiment were designed as summarised in Figure 5.1. In the first set
of experiment, mIMCD-3 cells were treated with AGN193109 to block RARs. In order
to confirm the specificity of regulation, exogenous tRA was added simultaneously with
AGN193109 in another experimental group to determine if regulation by AGN193109
were abolished or diminished. In the second set of experiment, mIMCD-3 cells were
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Figure 5.1: Regulation of gene expression by AGN193109 and DEAB with and without
exogenous all-trans retinoic acid (tRA). AGN193109 and DEAB were used to inhibit
endogenous RA/RAR signalling (blue box) at different stages. AGN193109 competes
with endogenous RA for RARs while DEAB inhibits biosynthesis of endogenous RA.
Since the effects of AGN193109 and DEAB on gene expression might be mediated
via other non-specific mechanisms (X), exogenous tRA was added simultaneously to
AGN193109 and DEAB to determine if the effects of AGN193109 and DEAB were
abolished or diminished.
A gene was regarded as candidate target of endogenous RA/RAR if all following criteria
were fulfilled: (i) regulated by AGN193109 and the regulation was abolished or dimi-
nished in the simultaneous presence of exogenous tRA, (ii) regulated by DEAB and the
regulation was abolished or diminished in the simultaneous presence of exogenous tRA,
(iii) the direction of regulation by AGN193109 and by DEAB was the same, i.e., either
up-regulated by both or down-regulated by both.
5.1.1 Transcriptomic-based study for target gene examination
Various omics-based technologies, e.g., transcriptomics, proteomics, and metabolomics
studies, have been introduced over the years. Given the role of RARs as transcription
factors, transcriptomic-based study, i.e., microarray study covering the whole mouse
genome, was deemed the most sensitive approach to identify target genes of endogenous
RA/RAR in mIMCD-3 cells.
A small pilot study was first performed to examine the expression of a few genes of
interest in order to verify the effectiveness of treatment as well as to guide the process of
shortlisting target genes in the ensuing microarray studies. Genes were selected based on
two criteria: (i) genes reported to be regulated by RA with or without known functional
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RARE, and/or (ii) genes that play specific functions of special interest, in particular, wa-
ter transport, defence/protection mechanism against fibrogenesis and high osmolality of
the inner medullary environment, as well as kidney development.
Five genes were selected, i.e., Foxa1, Rarb, Bmp7, Wnt7b, and Pax2, which fulfil the
above two criteria based on published literature. Foxa1, Rarb, Bmp7, and Wnt7b fulfil
criterion (i). Specifically, Foxa1 and Rarb genes are well-known target genes of RA that
contain functional DR5 RARE and are rapidly induced by RA in many cell types [12];
Bmp7 and Wnt7b had been reported to be induced by RA in human osteosarcoma cell
line [243] and in adult neural stem cells [131], respectively, and a recent genome-wide in
silico study had reported the presence of DR5 RARE in introns of these genes [159]. As
for criterion (ii), Foxa1 is a transcription factor that plays an important role in maintain-
ing water balance as Foxa1-/- mice suffered polyuria [19]. Bmp7 controls collecting duct
proliferation and apoptosis during branching morphogenesis [251] and protects against
fibrogenesis [334]. Pax2 was reported to play a crucial role in protecting collecting duct
cells from high sodium chloride concentration-induced apoptosis [38]. Both Rarb and
Wnt7b play an essential role in mediating early and late kidney developmental events,
respectively [204, 332].
The first part of this chapter comprises the aforementioned pilot study, in which gene
expression was examined by reverse transcription-quantitative polymerase chain reac-
tion (RT-qPCR). The second part describes the microarray experiments, in which candi-
date target genes of endogenous RA/RAR were identified at the pan-genomic level. The
third part constitutes validation of candidate target genes shortlisted from the microarray
experiments with RT-qPCR.
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5.2 Material and methods
5.2.1 Experimental protocols for mIMCD-3 cell treatment
AGN193109 treatment with and without tRA
Cells were seeded at 2 x 105 cells/35 mm2 dish in 2 ml DMEM-F12 medium contain-
ing antibiotics and anti-fungal supplemented with 5% FBS. After an overnight culture,
medium was changed to fresh DMEM-F12 medium supplemented with 1% FBS contain-
ing antibiotics and anti-fungal. After an overnight culture, medium was again changed to
fresh DMEM-F12 medium supplemented with 1% FBS containing 1 µM AGN193109,
with and without 0.2 µM tRA, and cultured for 24 h. For control group, medium was
changed to fresh DMEM-F12 medium supplemented with 1% FBS containing 0.1%
ethanol and 0.1% DMSO, and cultured together with the treatment groups. At the end
of treatment, medium was aspirated off, and culture dishes were stored in -80 °C if total
RNA extraction was not performed immediately.
DEAB treatment with and without tRA
Cells were seeded at 1.2 x 105 cells/35 mm2 dish in 2 ml DMEM-F12 medium contain-
ing antibiotics and anti-fungal supplemented with 5% FBS. After an overnight culture,
medium was changed to fresh DMEM-F12 medium supplemented with 1% FBS contain-
ing antibiotics and anti-fungal. After an overnight culture, medium was again changed
to fresh DMEM-F12 medium supplemented with 1% FBS containing 25 µM DEAB,
with and without 0.01 µM tRA, and cultured for 24 h. For control group, medium was
changed to fresh DMEM-F12 medium supplemented with 1% FBS containing 0.1%
ethanol and 0.1% DMSO, and cultured together with the treatment groups. At the end
of treatment, medium was aspirated off, and culture dishes were stored in -80 °C if total
RNA extraction was not performed immediately.
The doses of AGN193109, DEAB, and tRA used in the aforementioned experiments
were selected based on the results of reporter assays in Chapter 4, Figures 4.11 and 4.13.
Dilutions of reagents used in the aforementioned experiments are as described in Chap-
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ter 4, Section 4.2.4. One 35 mm2 dish was prepared per experimental condition in a
single experiment, and three independent experiments were performed.
5.2.2 Examination of gene expression with RT-qPCR
Total RNA Extraction
Prior to RNA extraction, work bench and pipettes were cleaned with RNaseZap® (Ap-
plied Biosystems, Warrington, UK) to minimise RNase contamination. QIAshredder
spin column (Qiagen Ltd., West Sussex, UK) was used to shear high molecular weight
genomic DNA and other cellular components, which reduced viscosity and created a
homogenous cell lysate. RNeasy® Mini Kit (Qiagen Ltd., UK) was used for RNA ex-
traction, following the protocol provided by the company1. RNeasy® Mini Kit contains
the following reagents and components:
• RNeasy mini column, which is a silica-gel-based membrane that allows binding
of RNA while removing genomic DNA and other contaminants.
• Buffer RLT, a cell lysis buffer containing 25-50% guanidium thiocyanate as chao-
tropic reagent that completely denatures RNase. Before used, β -mercaptoethanol
(β -ME) was added to buffer RLT at a ratio of β -ME:buffer RLT = 1:100.
• Buffer RW1, a washing buffer containing 2.5-10% guanidium thiocyanate and
2.5-10% ethanol that was used to wash the RNA-bound membrane.
• Buffer RPE, a washing buffer containing 20% ethanol that was used to wash the
RNA-bound membrane. Before used, 100% ethanol was added to buffer RPE at a
ratio of ethanol:buffer RPE = 4:1.
Medium was first aspirated off from culture dishes and 350 µl of RLT buffer (containing
β -ME) was pipetted onto the cell monolayer directly. If culture dishes were stored at
-80 °C, RLT buffer was pipetted onto cell monolayer shortly after culture dishes were
taken out from the freezer. Cell lysate was then collected with cell scraper (Greiner
1Qiagen RNeasy® Mini Handbook, edition 04/2006, P/N: 1035969
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Labortechnik Ltd., Tyne and Wear, UK) and pipetted into 1.5 ml microtube. The lysate
was pipetted up and down a few times to ensure complete cell lysis before being trans-
ferred into QIAshredder spin column placed in a 2 ml collection tube, and centrifuged at
21,100 g for 2 min for homogenisation. After centrifugation was completed, one volume
of 70% ethanol (prepared as described in Section 2.1.5) was added to the homogenised
lysates in the collection tube and mixed well by pipetting. The mixture was then trans-
ferred to RNeasy column placed in a 2 ml collection tube and centrifuged at 8,000 g
for 15 s. Total RNA bound to the membrane on RNeasy column was subjected to three
washing steps in the following order:
1. 700 µl of RW1 buffer with 15 s centrifugation at 8,000 g;
2. 500 µl of RPE buffer (containing ethanol) with 15 s centrifugation at 8,000 g;
3. 500 µl of RPE buffer (containing ethanol) with 2 min centrifugation at 8,000 g.
The RNeasy column was then transferred to a new 2 ml collection tube and centrifuged
for 1 min at 21,100 g to eliminate ethanol that may be retained on the RNeasy mem-
brane. Finally, RNeasy column was transferred to a clean 1.5 ml collection tube, follow-
ing which 40 µl of RNase-free water was pipetted directly onto the RNeasy membrane.
After a 1 min centrifugation at 21,100 g, the RNeasy column was discarded and the
eluted total RNA was stored at -80 °C until use. A Thermo Scientific Heraeus Pico 21
centrifuge was used for all centrifugation.
Total RNA Measurement
Concentration and purity of total RNA were determined using a NanoDrop® ND-1000
machine (Labtech International Ltd., East Sussex, UK), with RNase-free water set as
blank measurement. Presence of impurities such as protein and solvent in RNA was
determined from the absorbance ratio A260/280 and A260/230. A ratio of 1.9 to 2.1 for
A260/280 and a ratio of 1.8 to 2.2 for A260/230 were considered as RNA of good quality.
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Reverse transcription of RNA into cDNA
Reverse transcription was performed using Oligo-dT primer and Omniscript® Reverse
Transcription Kit (both from Qiagen Ltd., UK) following the company’s protocol2.
Omniscript® Reverse Transcription Kit contains the following reagents:
• RT buffer (10x stock concentration).
• dNTP mix, containing 5 mM of dATP, dCTP, dGTP, and dTTP, respectively.
• Omniscript Reverse Transcriptase (deoxynucleoside-triphosphate:DNA deoxynu-
cleotidyltransferase (RNA-directed)), with three distinct activities: (i) RNA-depen-
dent DNA polymerase, (ii) hybrid-dependent exoribonuclease (RNase H), and (iii)
DNA-dependent DNA polymerase.
Reverse transcription reaction was set up in 1.5 ml no-stick microtube (Alpha Labora-
tories, Hampshire, UK) on ice, by adding 2 µg of RNA in 26 µl of RNAse-free water,
4 µl of RT buffer, 4 µl of dNTP mix, 4 µl of Oligo-dT primer, and 2 µl of Omniscript®
Reverse Transcriptase. Microtube was then incubated at 37 °C for 60 min. At the end of
reverse transcription, 160 µl of RNAse-free water was added to the reverse-transcribed
cDNA and stored at -80 °C.
Pilot study
Quantitative PCR was performed using TaqMan® Gene Expression Assays and TaqMan®
Universal PCR Master Mix (Applied Biosystems, UK). Each assay comes in 20x stock
concentration containing two unlabelled primers (18 µM, respectively) and one TaqMan®
minor groove binder (MGB) probe (5 µM). The MGB probe consists of an oligonu-
cleotide with a fluorescein amidite (FAM) reporter dye covalently linked to its 5’-end,
and a non-fluorescent quencher dye at its 3’-end. TaqMan® Universal PCR Master Mix
(2x stock concentration) contains the following components:
• AmpliTaq Gold® DNA Polymerase, which is a thermal stable DNA polymerase
that has a 5’ to 3’ nuclease activity but lacks a 3’ to 5’ exonuclease activity.
2Qiagen Omniscript® Reverse Transcription Handbook, edition 05/2004, P/N: 1026831
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• AmpErase® uracil-N-glycosylase (UNG), which prevents reamplication of carry
over PCR products by removing uracil incorporated into single- or double-stranded
DNA.
• dNTPs containing dATP, dCTP, dGTP, and dUTP.
• ROX dye as passive reference.
• Optimised buffer components.
Pre-validated TaqMan® Gene Expression Assays used were as follow:
1. Bmp7: Mm00432101 m1 (amplicon length: 82)
2. Foxa1: Mm00484713 m1 (amplicon length: 68)
3. Pax2: Mm01217939 m1 (amplicon length: 55)
4. Rarb: Mm01319675 mH (amplicon length: 88)
5. Wnt7b: Mm00437357 m1 (amplicon length: 88)
6. Gapdh: Mm99999915 g1 (amplicon length: 107) (used as endogenous control)
Work bench was cleaned with detergent before PCR reactions were set up. PCR reaction
components, including TaqMan® Universal PCR Master Mix, TaqMan® Gene Expres-
sion Assays, and cDNA template, were first prepared in 1.5 ml no-stick microtubes and
pre-mixed with finger-flicking before being pipetted into optical 384-well reaction plate
(Applied Biosystems, UK). Each reaction was set up in triplicated wells and each well
contains a total volume of 12.5 µl comprising 6.25 µl of TaqMan® Universal PCR Mas-
ter Mix, 3.125 µl of RNase-free water, 0.625 µl of TaqMan® Gene Expression Assays,
and 2.5 µl of cDNA. Gapdh TaqMan® Gene Expression Assay was set up in triplicates
on each PCR plate; a non-template control, which contains same reaction components
except that RNase-free water was used in place of cDNA template, was also set up in
triplicates on each PCR plate. Microtubes containing PCR reaction components and
cDNA mixture were kept on ice throughout the course of setting up the PCR plate.
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The PCR plate was sealed well with PCR-compatible adhesive film (Alpha Laborato-
ries, UK) to prevent evaporation of reaction components during PCR reaction. PCR
plate was then centrifuged at 1,500 rounds per minute for 5 min at 15 °C before being
loaded into an ABI Prism 7900 HT detection system. Condition for PCR was as follow:
1. Stage I: 50 °C for 2 min to activate AmpErase® UNG.
2. Stage II: 95 °C for 10 min to activate AmpliTaq Gold® enzyme and to inactivate
AmpErase® UNG enzyme.
3. Stage III: 40 cycles of 95 °C for 15 s for denaturing double stranded DNA into
single strands, and 60 °C for 1 min for annealing of primers and extension.
Filtered pipette tips (Starlab (UK) Ltd.) were used for RNA extraction, reverse tran-
scription, and setting up PCR plates. The procedures and basic principles of reverse
transcription and qPCR are summarised in Figure 5.2.
Expression of Gapdh was first examined to determine its suitability as endogenous con-
trol gene. As shown in Figure 5.3, Gapdh expression did not vary much following a 24
h treatment of AGN193109 and DEAB, in the absence and presence of tRA, suggesting
it to be an appropriate endogenous control.






Figure 5.2: Please refer to the following page for figure legend.
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Figure 5.2: Reverse transcription and quantitative polymerase chain reaction (RT-qPCR).
A. RNA was first reversed transcribed into cDNA using Oligo-dT primers that anneal to
the poly-A cap presents at the 3’-end of mRNA, in the presence of RNA dependent-
DNA polymerase and dNTP mix (1). mRNAs hybridised to their complimentary cDNA
were then degraded by RNase H (2), leaving only cDNA (3). B. The cDNA was then sub-
jected to PCR with real-time fluorescence detection. AmpErase® uracil-N-glycosylase
(UNG) was first activated to break down carry-over PCR products containing uracil (dot-
ted box), after which double-stranded cDNA would de-anneal following temperature rise
to 95 °C (4). When temperature fell to 60 °C, forward/reverse primers would anneal
to complimentary target sequences, while an intact minor groove binder (MGB) probe
(with low fluorescence emission due to proximity of fluorescein amidite (FAM) with a
non-fluorescing quencher (NFQ)) would anneal to its complimentary sequence down-
stream of one of the primers (5). While promoting primer elongation in the presence of
dNTP mix (with dUTP), the 5’-nuclease activity of AmpliTaqGold® DNA polymerase
would cleave the MGB probe off separating FAM from NFQ hence emitting fluores-
cence signal (6). The fluorescence signal from FAM was then detected on a real-time
basis by a detector (7) while the reaction (steps 4-7) was repeated for 40 cycles, during
which number of amplicons would increase exponentially. C. The fluorescence signal
was translated into amplification plot and expressed as threshold cycle, i.e., the number
of cycle required to reach the threshold level (red horizontal line).
Analysis of relative gene expression and statistical analysis
The results were analysed using an Applied BiosystemTM Sequence Detection System
version 2.3 software. The amplification efficacy for all TaqMan® Gene Expression As-
say was assumed to be close to 100%. The relative changes in gene expression was
determined using the comparative threshold cycle (CT) method, as described by Livak
et al. [178]. The comparative CT method involves calculating the fold-change of gene
expression using the formula 2-∆∆CT , i.e., by normalising the CT of genes of interest to
that of Gapdh, and the values were then normalised to a calibrator, which was the vehicle
control group.
The relative mRNA expression was first calculated for individual experiment, by taking
mean values of the technical triplicates for each treatment group, and expressed as fold-
changes compared to vehicle control group that was set as “1”. Fold-changes derived
from three independent experiments were then grouped together for statistical analysis.
A Repeated Measure One-way ANOVA test with a Tukey post-test was performed on
log-transformed fold-change values using GraphPad Prism, Version 4.0. Please note
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that owing to the small sample size (n=3), the p value computed may not be precise.
A B 
Figure 5.3: Amplification plot of Gapdh in mIMCD-3 cells treated with AGN193109
and DEAB, with and without all-trans retinoic acid (tRA). Expression of Gapdh did
not vary much following 24 h treatment of AGN193109 with and without tRA (A), and
of DEAB with and without tRA (B), evident by a tight overlapping amplification plots
across all the samples. Shown here are representative amplification plots derived from
technical triplicates of a single biological experiment.
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5.2.3 Microarray experiment
Two sets of microarray experiments, i.e., AGN193109 experiment and DEAB experi-
ment, were performed in two separate batches, each consist of samples from three in-
dependent biological replicates. The first set of microarray experiment comprises sam-
ples treated with: (i) vehicle, (ii) 1 µM AGN193109, and (iii) 1 µM AGN193109 with
0.2 µM tRA; the second set of microarray experiment comprises samples treated with:
(i) vehicle, (ii) 25 µM DEAB, and (iii) 25 µM DEAB with 0.01 µM tRA.
The array used for microarray experiments was Affymetrix® GeneChip® Mouse Gene
1.0 ST Array (Affymetrix UK Ltd., High Wycombe, UK) that enables whole-genome
gene-level expression examination, using sense cDNA as target. The array contains
about 27 probes (of 25-mer oligonucleotides) per gene and an estimated 28,853 genes
were examined.
Quality and integrity of RNA samples
Total RNA samples were transferred on dry ice to King’s College London Genomics
Centre. All subsequent work related to microarray was performed at the Genomics Cen-
tre under the supervision of Dr. E Aldecoa-Otalora Astarloa and Dr. M Arno.
The integrity of RNA samples is a critical factor that would affect the downstream pro-
cedures in microarray experiments. Thus, the integrity of RNA was first examined using
an Agilent 2100 Bioanalyser and an Agilent RNA 6000 Nano Kit (Agilent Technologies,
Berkshire, UK) following the company’s protocol3. The Agilent RNA 6000 Nano Kit
contains RNA Nano Chip, electrode cleaner, spin filter, and the following reagents:
1. RNA 6000 Nano Ladder, which contains six RNA fragments of 200, 500, 1,000,
2,000, 4,000 and 6,000 nucleotides. The ladder was pipetted into RNase-free mi-
crotubes and heat denatured for 2 min at 70 °C before used.
3Agilent RNA 6000 Nano Kit Guide, edition 08/2006, P/N: G2938-90034
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2. RNA 6000 Nano Gel Matrix, a sieving polymer matrix that separates RNA frag-
ments by their sizes, i.e., smaller RNA fragments migrate through the gel matrix
faster than the larger RNA fragments. Gel matrix was prepared by pipetting 550 µl
of RNA 6000 gel matrix into the top receptacle of a spin filter that comes with the
kit and was centrifuged for 10 min at 1,500 g. The filtered gel was stored at
4 °C and was used within one month of preparation.
3. RNA 6000 Nano Dye Concentrate, which intercalates into RNA/DNA strands,
allowing them to be detected by the laser in bioanalyser. Gel-dye matrix was
prepared by adding 1 µl of RNA 6000 Nano dye concentrate to 65 µl of filtered
gel in a RNase-free microtube. The gel-dye mix was then vortexed thoroughly and
centrifuged at 13,000 g for 10 min at room temperature. The prepared gel-dye mix
was concealed from light and used within one day.
4. RNA 6000 Nano Marker, a 25 nucleotide fragment that was run with each sample
to serve as a reference compensating for possible drift effect during running.
The 16-pin electrodes of the bioanalyser were first cleaned using an electrode cleaner,
filled with 350 µl of fresh RNase-free water. The water-filled electrode cleaner was
placed on the receptacle of bioanalyser and the lid was closed for at least 1 min. The lid
was then opened and the electrode cleaner was removed. Water was allowed to evaporate
from the electrodes for about 30 sec before used.
An RNA Nano Chip, as illustrated in Figure 5.4, was first placed on a chip priming
station. A volume of 9 µl gel-dye mix was drawn from the tube, avoiding the sediments
at the bottom of the tube, and loaded into the bottom of the well with a mark of white
colour “G” against a black colour circle. The plunger on the chip priming station was
first positioned at 1 ml, and was then closed until a “click” sound was heard. The plunger
was pushed downwards until it was held by the clip for a 30 sec period to disperse the
gel-dye mix through the micro-channels within the chip. The clip was then released and
5 sec later, the plunger was slowly pulled back to the 1 ml position. The chip priming
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station was opened and another 9 µl of gel-dye mix was loaded into both wells with the
mark of black “G”. A volume of 5 µl RNA 6000 Nano Marker was then loaded into
the well with the ladder symbol, and each of the 12 sample wells. Subsequently, 1 µl of
heat-denatured RNA sample (2 min at 70 °C) was pipetted into each sample well (1 µl
of RNase-free water into wells without RNA sample), and 1 µl of RNA 6000 Nano lad-
der was pipetted into the ladder well. The RNA Nano Chip was vortexed for 60 sec at
2,400 rpm using an IKA® vortex mixer, before being placed onto the receptacle of bio-
analyser. The lid was closed gently and samples were analysed using an Agilent Expert
2100 software.
Figure 5.4: RNA Nano Chip. A. An RNA Nano chip, which contains micro-channels
for capillary electrophoresis. Sample wells were indicated with numbers 1-12, “G” in-
dicated wells for gel-dye mix and ladder symbol indicated well for RNA 6000 Nano
ladder. Chip was not drawn to scale. B. Reagents and samples were loaded into the
bottom of each well, as illustrated.
Following the same principle of gel electrophoresis, charged RNA or DNA molecules
with a constant mass-to-charge ratio will be separated based on their sizes, except that the
process took place in micro-channels fabricated within the RNA Nano Chip. As shown
in Figure 5.5, all RNA samples had two sharp major peaks corresponding to the 18s
and 28s ribosomal RNA, respectively, with RNA Integrity Number (RIN) [279] values
ranging from 9.70 to 10.00, suggesting minimum degradation of RNA molecules.
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Figure 5.5: Integrity of RNA samples. Integrity of RNA samples from AGN193109
experiment (A) and DEAB experiment (B) was examined. The two sharp major peaks
correspond to 18s and 28s ribosomal RNA, respectively. The high RNA Integrity Num-
ber (RIN) values, within the range of 9.70-10.00, suggest a good quality of RNA samples
with minimum degradation of RNA molecules. The absence of additional peaks in be-
tween 18s and 28s RNA peaks, baseline dips, and broad peaks, also confirm the absence
of genomic DNA in the RNA samples.
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Generation of sense cDNA from RNA samples
Sense cDNA target was generated using Ambion® WT Expression Kit (Life Technolo-
gies Ltd., Paisley, UK) following the company’s protocol4. The workflow started with
synthesis of first-strand cDNA (first cycle), followed by synthesis of second-strand cDNA,
synthesis of cRNA, and finally synthesis of sense cDNA (second cycle). The amount of
reagents used described below is for one set of experiment containing nine samples.
All RNA samples were first normalised to the least concentrated sample with nuclease-
free water. A volume containing 500 ng RNA, the maximum recommended starting
material, was measured into RNase-free microtube. Nuclease-free water was added to a
final volume of 3 µl, after which 2 µl of Poly-A RNA Controls was added. A volume
of 5 µl First-Strand Master Mix (containing an engineered primers with a T7 promoter
sequence) was then added and the mixture was mixed well with gentle finger-flicking.
After a brief centrifugation, the mixture was incubated for 1 h at 25 °C, 1 h at 42 °C, then
for at least 2 min at 4 °C. At the end of incubation, microtubes containing the mixture
were centrifuged briefly and kept on ice.
The Poly-A RNA Controls are in vitro synthesised polyadenylated transcripts for the
Bacillus subtilis genes at a staggered concentration of dap>thr>phe>lys. These genes
are absent from eukaryotic samples, but would hybridise to the Bacillus subtilis probe
sets on the array. Poly-A RNA Controls spiked into the total RNA samples would be
amplified and labelled together with total RNA thus help monitoring the labelling pro-
cess independently from the quality of the RNA samples. Poly-A RNA Controls were
prepared by serial dilution of Poly-A RNA Control Stock and Poly-A Control Dilution
Buffer (both from Affymetrix® GeneChip® Poly-A RNA Control Kit), as follow:
4Ambion® WT Expression Kit for Affymetrix® GeneChip® Whole Transcript (WT) Expression Arrays,
edition 05/2009, P/N:4425209 Rev. B
5.2. Material and methods 177
Poly-A RNA Dilution buffer Dilution
2 µl (from stock) 38 µl 1:20 (1st dilution)
2 µl (from 1st dilution) 98 µl 1:50 (2nd dilution)
2 µl (from 2nd dilution) 98 µl 1:50 (3rd dilution)
20 µl (from 3rd dilution) 20 µl 1:2 (4th dilution)
A volume of 2 µl Poly-A RNA Controls from the 4th dilution was added to each RNA
sample, mixed with gentle finger-flicking and centrifuged briefly to collect samples at
the bottom of microtube. The final concentrations of Poly-A RNA Controls when added
to the RNA samples were as follow:





First-Strand Master Mix contained the following components and volumes per reaction:
First-Strand Buffer Mix 4 µl
First-Strand Enzyme Mix 1 µl
Total volume 5 µl
A total of 10 reactions was prepared at room temperature and the mixture was mixed
well with gentle finger-flicking. After a brief centrifugation, 5 µl of First-Strand Master
Mix was dispensed into each 5 µl of RNA sample (containing the Poly-A RNA Con-
trols).
When the incubation was completed, second-strand cDNA was generated from the newly
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synthesised first-strand cDNA by mixing Second-Strand Master Mix (containing DNA
polymerase I and RNase H) to the first-strand cDNA, and incubated for 1 h at 16 °C,
10 min at 65 °C, then for at least 2 min at 4 °C. At the end of the incubation, microtubes
containing the mixture were centrifuged briefly and kept on ice.
Second-Strand Master Mix contained the following components and volumes per re-
action:
Nuclease-free water 32.5 µl
Second-Strand Buffer Mix 12.5 µl
Second-Strand Enzyme Mix 5 µl
Total volume 50 µl
A total of 10 reactions was prepared on ice, and the mixture was mixed well with gentle
finger-flicking. After a brief centrifugation, 50 µl of Second-Strand Master Mix was
dispensed into each 10 µl of first-strand cDNA sample.
By employing the second-strand cDNA as a template, antisense cRNA was synthesised
via in vitro transcription (IVT), which is a linear amplification step. IVT master mix
(containing T7 RNA polymerase) was added to cDNA sample and was incubated for
16 h at 40 °C, then overnight at 4 °C. At the end of the incubation, the mixture was
centrifuged briefly and kept on ice briefly before proceeding to the next step.
IVT Master Mix contained the following components and volumes per reaction:
IVT Buffer Mix 24 µl
IVT Enzyme Mix 6 µl
Total volume 30 µl
A total of 10 reactions was prepared at room temperature, and the mixture was mixed
well with gentle finger-flicking. After a brief centrifugation, 30 µl of IVT Master Mix
was dispensed into each 60 µl of cDNA sample.
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The newly synthesised antisense cRNA was purified using nucleic acid binding beads
to remove enzymes, phosphates, and unincorporated nucleotides in order to improve sta-
bility of cRNA. cRNA Binding Mix was added into cRNA sample, and mixed well with
gentle pipetting.
cRNA Binding Mix contained the following components and volumes per reaction:
Nucleic Acid Binding Beads 10 µl
Nucleic Acid Binding Buffer Concentrate 50 µl
Total volume 60 µl
A total of 10 reactions was prepared at room temperature. Nucleic Acid Binding Beads
were vortexed vigorously to ensure that the magnetic beads were fully dispersed. Nu-
cleic Acid Binding Buffer Concentrate was pre-warmed to 45 °C to solubilise the content
before used. The mixture was mixed well and 60 µl of cRNA Binding Mix was added
to each 90 µl of cRNA sample. The mixture was pipetted up and down three times and
transferred to individual well of a U-bottom plate, following which 60 µl of 100% iso-
propanol was added and mixed well by pipetting up and down three times.
The U-bottom plate was gently shaken for 2 min at 750 RPM to encourage binding
of cRNA to the nucleic acid binding beads, after which it was moved to a magnetic stand
and let stand for 5 min to capture the magnetic beads. The supernatant was then carefully
aspirated and discarded without disrupting the magnetic beads and the plate was removed
from the magnetic stand. A volume of 100 µl Nucleic Acid Wash Solution (containing
ethanol) was then added to individual well containing cRNA bound-magnetic beads and
mixed well with gentle pipetting. The U-bottom plate was gently shaken for 1 min at
1,200 RPM and the magnetic beads were captured on a magnetic stand and supernatant
carefully discarded as in previous step. The washing step was repeated once again with
100 µl of Nucleic Acid Wash Solution, after which the U-bottom plate was shaken vi-
gorously for 1 min at 1,350 RPM to evaporate residual ethanol from the magnetic beads.
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In order to elute cRNA from the magnetic beads, 40 µl of pre-heated Elution solu-
tion (55 °C) was added to each cRNA sample and let stand for 2 min without shaking.
The plate was then shaken vigorously for 3 min at 1,350 RPM to disperse the magnetic
beads, after which it was moved to a magnetic stand and let stand for 5 min to capture
the magnetic beads. Finally, the supernatant, now containing purified antisense cRNA,
was transferred to fresh nuclease free microtubes.
The yield of purified cRNA was determined using a Nanodrop® ND-1000 and the cRNA
size distribution was determined using an Agilent 2100 Bioanalyser. The cRNA yield
was within the expected range, and as shown in Figure 5.6, the cRNA sizes had an ex-
pected range of 50-4,000 nucleotides.
Second-cycle sense cDNA was then generated from the purified antisense cRNA. While
on ice, a volume containing 15 µg cRNA sample was measured out into a microtube,
and nuclease-free water was added to a final volume of 22 µl. A volume of 2 µl random
primers was added, after which the mixture was mixed well with gentle finger-flicking.
After a brief centrifugation, the mixture was incubated for 5 min at 70 °C, 5 min at
25 °C, then for 2 min at 4 °C. At the end of the incubation, the mixture was centrifuged
briefly and Second-cycle Master Mix (containing dNTP/dUTP mix) was added to each
cRNA sample. The mixture was mixed well with gentle finger-flicking. After a brief
centrifugation, the mixture was incubated for 10 min at 25 °C, 90 min at 42 °C, 10 min
at 70 °C, then for at least 2 min at 4 °C. At the end of the incubation, the mixture was
centrifuged briefly and kept on ice immediately.
The Second-cycle Master Mix contained the following components per reaction:
Second-cycle Buffer Mix 8 µl
Second-cycle Enzyme Mix 8 µl
Total volume 16 µl
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Figure 5.6: Size distribution of antisense cRNA. All samples from AGN193109 experi-
ment (A) and DEAB experiment (B) had an expected range of size distribution from 50
to 4,000 nucleotides, with most cRNA sizes in the range of 200 to 2,000 nucleotides.
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A total of 10 reactions was prepared on ice, and the mixture was mixed well with gentle
finger-flicking. After a brief centrifugation, 16 µl of Second-cycle Master Mix was dis-
pensed into each 24 µl of cDNA sample.
In order to eliminate cRNA from the second-cycle sense cDNA sample, 2 µl of RNase
H was added to each 40 µl of second-cycle cDNA sample on ice and mixed well with
gentle finger-flicking. After a brief centrifugation, the mixture was incubated for 45 min
at 37 °C, 5 min at 95 °C, then for at least 2 min at 4 °C. Purification of sense cDNA was
then performed immediately.
Purification of sense cDNA followed similar steps of antisense cRNA purification as
described before. A volume of 18 µl nuclease-free water was first pipetted into each
cDNA sample to achieve a final volume of 60 µl. cDNA Binding Mix was then added
to each cDNA sample and mixed well with gentle pipetting.
The cDNA Binding Mix contained the following components and volumes per reaction:
Nucleic Acid Binding Beads 10 µl
Nucleic Acid Binding Buffer Concentrate 50 µl
Total volume 60 µl
A total of 10 reactions was prepared at room temperature. Nucleic Acid Binding Beads
were vortexed vigorously to ensure the magnetic beads were fully dispersed and Nucleic
Acid Binding Buffer Concentrate was pre-warmed to 45 °C to solubilise the content be-
fore used. The mixture was mixed well and 60 µl of cDNA Binding Mix was added
to each 60 µl of cDNA sample. The mixture was pipetted up and down three times
then transferred to individual well of a U-bottom plate, following which 120 µl of 100%
ethanol was added and mixed well by pipetting up and down three times. Subsequent
steps of second-cycle cDNA purification was similar to that described for cRNA purifi-
cation.
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Elution of cDNA from the magnetic beads was the same as for elution of cRNA ex-
cept that only 30 µl of pre-heated Elution solution (55 °C) was added to each sample.
The yield of purified cDNA was determined using a Nanodrop® ND-1000 and the cDNA
size distribution was determined using an Agilent 2100 Bioanalyser. The cDNA yield
was within the expected range, and as shown in Figure 5.7, the median size of cDNA
samples was around the expected 400 nucleotides.
Figure 5.7: Size distribution of sense cDNA. All samples from AGN193109 experiment
(A) and DEAB experiment (B) had an expected median size of 400 nucleotides.
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Sense cDNA fragmentation, terminal labelling and hybridisation cocktail preparation
Fragmentation and terminal labelling of sense cDNA was performed using an Affymetrix®
GeneChip® WT terminal Labelling Kit, while hybridisation cocktail was prepared using
an Affymetrix® GeneChip® Hybridisation, Wash and Stain Kit following the manufac-
turer’s protocol5.
Fragmentation of sense cDNA was achieved by using uracil DNA glycosylase (UDG), an
enzyme that cleaves the DNA at sites where uracil was incorporated during the second-
cycle cDNA synthesis. The apurinic/apyrimidinic endonuclease 1 (APE 1) enzyme then
cleaves the phosphodiester backbone where the base is missing, leaving a 3’-hydroxyl
and a 5’-deoxyribose phosphate terminus.
A volume containing 5.5 µg cDNA was first measured out into a microtube, and nuclease-
free water was added to a final volume of 31.2 µl. Fragmentation Master Mix was then
added to each cDNA sample and mixed well with gentle finger-flicking. After a brief
centrifugation, the mixture was incubated for 60 min at 37 °C, 2 min at 93 °C, then for
at least 2 min at 4 °C.
The Fragmentation Master Mix contained the following components and volumes per
reaction:
RNase free water 10 µl
10x cDNA Fragmentation Buffer 4.8 µl
UDG, 10 U/µl 1 µl
APE 1, 1,000 U/µl 1 µl
Total volume 16.8 µl
A total of 10 reactions was prepared and the mixture was mixed well with gentle finger-
flicking. After a brief centrifugation, 16.8 µl of Fragmentation Master Mix was dis-
pensed into each 31.2 µl of cDNA sample.
5Affymetrix® GeneChip® WT Terminal Labelling and Hybridisation User Manual, P/N 702808 Rev. 4
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The fragmented cDNA was labelled using deoxynucleotidyl transferase (TdT) and DNA
Labelling Reagent containing Biotin Allonamide Triphosphate. A volume of 45 µl frag-
mented cDNA was pipetted into a nuclease-free microtube, to which Terminal Labelling
Master Mix was added and mixed well with gentle finger-flicking. After a brief centrifu-
gation, the mixture was incubated for 60 min at 37 °C, 10 min at 70 °C, then for at least
2 min at 4 °C.
The Terminal Labelling Master Mix contained the following components and volumes
per reaction:
5x TdT buffer 12 µl
TdT 2 µl
5 mM DNA Labelling Reagent 1 µl
Total volume 15 µl
A total of 10 reactions was prepared and the mixture was mixed thoroughly with gentle
finger-flicking. After a brief centrifugation, 15 µl of Terminal Labelling Master Mix was
dispensed into each 45 µl of fragmented cDNA sample.
In order to prepare the hybridisation cocktail, Hybridisation Master Mix was added to
60 µl of fragmented and labelled cDNA and mixed well with gentle finger-flicking. After
a brief centrifugation, the mixture was incubated for 5 min at 99 °C, cooled to 45 °C for
5 min, then centrifuged at 21,500 g for 1 min.
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Hybridisation Master Mix contained the following components and volumes per reac-
tion:
3 nM Control Oligonucleotide B2 3.7 µl
20x Eukaryotic Hybridisation Controls 11 µl
2x Hybridisation Mix 110 µl
DMSO 15.4 µl
Nuclease-free water 19.9 µl
Total volume 160 µl
The 20x Eukaryotic Hybridisation Controls were pre-heated to 65 °C for 5 min prior to
use. A total of 10 reactions was prepared and the mixture was mixed thoroughly with
gentle vortexing. After a brief centrifugation, 160 µl of Hybridisation Master Mix was
dispensed into each 60 µl of fragmented and labelled cDNA sample.
Control Oligonecleotide B2 was used to provide alignment signals for the microarray
software. Eukaryotic Hybridisation Controls contained bioB, bioC, and bioD from bio-
tin synthesis of E.coli, and cre from P1 bacteriophage, at a staggered concentration (final
concentrations would be 1.5 pM, 5 pM, 25 pM, and 100 pM for bioB, bioC, bioD, and
cre, respectively). Given that the Eukaryotic Hybridisation Controls were spiked into
hybridisation cocktail independent of RNA sample preparation, they serve as controls
for sample hybridisation efficiency.
All reagents such as master mixes were prepared in nuclease-free microtubes. A MJ
Research PTC-225 Peltier Thermal Cycler was used for incubation; a Jencon-PLS mini
centrifuge and an Eppendorf MiniSpin centrifuge machines were used for centrifuga-
tion; a Heidolph Titramax 100 shaker was used for plate shaking.
The basic principles and workflow of sample processing for microarray experiment is
illustrated in Figure 5.8.
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Figure 5.8: Please refer to the following page for figure legend.
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Figure 5.8: Workflow of sample processing for microarray experiments. First-strand
cDNA was first synthesised from total RNA using random primers containing T7 pro-
moter sequence (1). Second-strand cDNA was then synthesised by DNA polymerase
and RNA molecules were degraded by RNase H (2). By using the second-strand cDNA
as a template, antisense cRNA was synthesised using T7 RNA polymerase (3). After
a purification step (4), second cycle sense cDNA was synthesised with random primers
and dNTP/dUTP mix (5). RNA molecules were then degraded by RNase H (6), after
which the sense cDNA was purified (7). The purified sense cDNA was then fragmented
with UDG and APE1 (8), after which the fragmented cDNA was labelled with biotin
(9). Finally, the fragmented and labelled cDNA sample was hybridised to the array (10).
UDG: uracil DNA glycosylase; APE1: apurinic/apyrimidinic endonuclease 1; TdT: de-
oxynucleotidyl transferase.
Target hybridisation to microarray chip
Array was equilibrated to room temperature and labelled with sample name. A clean
pipette tip was inserted into one of the septum at the back of the cartridge to allow venting
of air from the hybridisation chamber. A volume of while 80 µl hybridisation cocktail
was withdrawn, avoiding the pellet at the bottom of the tube, and injected into the array
through the remaining septum (Figure 5.9). The septa were then sealed using Tough-
Tags® (Thistle Scientific Ltd., Glasgow, UK) and the array was incubated at 45 °C in
an Affymetrix® GeneChip® Hybridisation Oven 640, rotated at 60 rpm, for 17 hours
± 1 hour.
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Figure 5.9: Loading of hybridisation cocktail into array cartridge. A. A clean pipette
tip was pierced into one of the rubber septa at the back of the cartridge to serve as air
vent (1); 80 µl of hybridisation cocktail was loaded into the hybridisation chamber of
the cartridge via the remaining rubber septum (2). B. Side view of the array cartridge
shows the pipette that serves as air vent (1), the pipette through which hybridisation
cocktail was loaded (2), and the hybridisation cocktail in the hybridisation chamber, in
contact with the array glass mounted with probes. The volume of hybridisation cocktail
(80 µl) was slightly less than the capacity of the hybridisation chamber (100 µl), so that
during rotation the free-floating air bubble would allow a uniform contact between the
hybridisation cocktail and all portions of the array.
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Array washing and staining
Washing and staining of the arrays were performed using an Affymetrix® GeneChip®
Fluidics Station 450 machine. An experimental file was first created using an Affymetrix®
GeneChip® Command Console (AGCC) Portal software. Washing and staining were ex-
ecuted through the AGCC Fluidics Control software following the company’s protocol6.
The prepared and pre-tested washing and staining solutions used were as follows:
• Wash Bufer A (non-Stringent wash buffer), containing 6x SSPE (0.9 M NaCl,
0.06 M NaH2PO4, 0.006 M EDTA) and 0.01% Tween® 20.
• Wash Buffer B (stringent wash buffer), containing 100 mM
2-(N-Morpholino)ethanesulfonic acid hydrate (MES), 0.1 M Na+, and 0.01%
Tween® 20.
• Stain Cocktail 1, containing 10 µg/ml Streptavidin Phycoerythrin (SAPE) and
2 mg/ml BSA in stain buffer (100 mM MES, 1 M Na+, and 0.05% Tween® 20).
• Stain Cocktail 2, containing 3 µg/ml biotinylated anti-streptavidin, 0.1 mg/mL
goat IgG, and 2 mg/ml BSA in stain buffer.
• Array Holding Buffer, containing 100 mM MES, 1M Na+, and 0.01% Tween®
20.
Wash Buffer A, Wash Buffer B, and ultrapure water were filled into the appropriate reser-
voirs on the Fluidics Station. After priming the Fluidics Station, microtubes containing
600 µl of Stain Cocktail 1, 600 µl of Stain Cocktail 2, and 800 µl of Array Holding
Buffer were placed into sample holders 1, 2, and 3, respectively.
After hybridisation was completed, a clean pipette tip was inserted into one of the septa
at the back of the cartridge, and the hybridisation cocktail was extracted with another
pipette through the remaining septum. Without removing the vent tip, 100 µl of Wash
6Affymetrix® GeneChip® Expression Wash, Stain and Scan User Manual for Cartridge Arrays, P/N
702731 Rev. 3
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Buffer A was injected into the cartridge through another septum, and the cartridge was
inserted into the washblock probe array holder on the Fluidics Station. Washing and
staining of the arrays were then run using the FS450 0007 protocol7 as stipulated in Ta-
ble 5.1.
Table 5.1: FS450 0007 protocol for washing and staining
Procedure Steps and conditions
Post Hyb Wash 1 10 cycles of 2 mixes/cycle with Wash Buffer A at 30 °C
Post Hyb Wash 2 6 cycles of 15 mixes/cycle with Wash Buffer B at 50 °C
Stain Stain the probe array for 5 min in Stain Cocktail 1 at 35 °C
Post Stain Wash 10 cycles of 4 mixes/cycle with Wash Buffer A at 30 °C
2nd Stain Stain the probe array for 5 min in Stain Cocktail 2 at 35 °C
3rd Stain Stain the probe array for 5 minutes in Stain Cocktail 1 at 35 °C
Final Wash 15 cycles of 4 mixes/cycle with Wash Buffer A at 35 °C
Holding Buffer Fill the probe array with Array Holding Buffer
After washing and staining were completed, the arrays were removed from the Fluidics
Station and examined for presence of large bubbles. If bubble was trapped within the
array, the Array Holding Buffer was extracted manually with a pipette and 100 µl of
fresh Array Holding Buffer was injected manually into the array. The stained arrays
were then kept in the dark at room temperature and scanned immediately. The basic
principles of target hybridisation to array probes and the subsequent staining with SAPE
and biotinylated anti-streptavidin are summarised in Figure 5.10.
7Affymetrix® GeneChip® WT Terminal Labelling and Hybridisation User Manual, P/N 702808 Rev. 4
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Figure 5.10: Array hybridisation and signal amplification. Step 1: Biotinylated cDNA
targets hybridised to probes of complementary sequences by forming hydrogen bonds.
A stronger bond would form between targets and probes with high number of comple-
mentary base pairs; a weak bond between targets and probes with low or no comple-
mentary base pairs would be washed off. Step 2: Amplification of signal was achieved
by streptavidin-biotin interaction, the strongest known non-covalent bond in chemistry
(Kd = 1015 M) [107], as well as immunogenic interaction. The biotin molecules (green
sphere) on the cDNA targets were bound by streptavidin (blue cross) that is conjugated
to phycoerythrin (red star) (SAPE). Step 3: Streptavidin was either detected by anti-
streptavidin IgG (A), or was bound by the biotin molecule conjugated to anti-streptavidin
IgG (B). Step 4: SAPE was again used in this step. The biotin molecule conjugated to
anti-streptavidin IgG (A), and the anti-streptavidin IgG itself (B) would be bound by
streptavidin of the SAPE. Higher fluorescence signal corresponded to more copies of
cDNA targets.
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Scanning of microarray chips
Microarray cartridges were scanned using an Affymetrix® GeneChip® Scanner 3000
7G, executed via an AGCC Scan Control software, which performed auto-focus prior to
scanning. The scanner was turned on for at least 10 min prior to scanning. The array car-
tridges were handled with gloved hands and were inserted into the scanner after gently
wiping the surface with gloved fingers to get rid of dust that may interfere with scanning.
Software used for Data Summarising, Normalisation, and Analysis
An AGCC Expression ConsoleTM software was used for data summarising and the de-
fault Robust Multichip Average (RMA) method was used for data normalisation [128].
A Qlucore® Omics Explorer (QOE) software was used to generate lists of genes regula-
ted by the treatments.
Quality check on arrays
When the scan was completed, the image data for each array was reviewed for aberrant
signal using an AGCC Viewer software. As shown in Figure 5.11, positive and negative
signals were as expected, and aberrant signs, e.g., blotches of overt brightness or dim-
ness, were not observed in all the arrays.
Prior to normalisation, the general intensity of the arrays varied greatly ,i.e., some ar-
rays had a brighter signal in general compared to others (Figure 5.11), precluding a
direct comparison. By employing RMA normalisation algorithm, a more uniform gene-
ral intensity across all arrays was achieved (Figure 5.12).
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Figure 5.11: Please refer to the following page for figure legend.
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Figure 5.11: General appearance of array signal. All arrays from AGN193109 experi-
ment (Ai) and from DEAB experiment (B) had normal hybridisation signal. The success
of hybridisation was further confirmed by referring to several specific patterns given rise
by hybridisation of control oligonucleotide B2 to their probes on the arrays, including
the checker board pattern at the four corners and an alternating signal lining the border
of each array (Aii), the absence of signal in the expected region containing sense probes
(Aiii), and the square featuring a gradient of positive signal, flanked by checker board
pattern at four corners (Aiv). Similar specific patterns were also confirmed on arrays
from the DEAB experiment (B).
5.2. Material and methods 196
Figure 5.12: Normalisation of array intensity. Before normalisation, general intensity
of arrays from AGN193109 experiment (Ai) and from DEAB experiment (Bi) varied
greatly. By using a Robust Multichip Average (RMA) normalisation algorithm, a more
uniform general intensity was achieved for arrays from AGN193109 experiment (Aii)
and from DEAB experiment (Bii).
5.2. Material and methods 197
Additional quality check on array metrics was performed following manufacturer’s re-
commendation8. Specifically, hybridisation quality was confirmed from the bacterial
spikes showing an expected signal values of Cre>bioD>bioC>bioB in all samples.
Poly-A RNA Controls in all samples showed signal values of thr>dap>phe>lys, which
were different from the expected dap>thr>phe>lys (Figure 5.13). The situation could
happen occasionally with Gene ST arrays as the Poly-A RNA Controls were originally
designed for 3’-biased arrays, and it does not indicate failed labelling (personal commu-
nication with Dr. L Dupont, Affymetrix technical support supervisor). More importantly,
similar pattern of the poly-A RNA controls was observed in all the samples.
Two additional metrics, i.e., (i) “pos vs neg auc” and (ii) “all probe set rle mean”, were
also examined to further confirm sample quality. “pos vs neg auc” metric is a measure
of area under the curve for the receiver operating characteristic plot comparing signal
values of positive controls to negative controls; a typical range of pos vs neg auc”is
between 0.8-0.9, with a value of 1.0 being perfect. “all probe set rle mean” metric is the
mean of signal differences for each probe set compared to the median signal value of the
probe set in the study; a typical range is between 0.1-0.23 and a big value indicates outlier
array. As shown in Table 5.2, pos vs neg auc for all arrays had a value of ≥0.9, and
all probeset rle mean for all arrays were ≤0.17, indicating absence of obvious outliers.
Pearson’s correlation plot was generated to assess correlation between the biological
replicates. As shown in Figure 5.14, samples within the same batch of experiment cor-
related better with each other, compared to samples treated with the same reagents in
different batches of experiment. This suggested the presence of “batch effect”, whereby
culturing or treating different batches of cells on separate occasions are having a larger
effect on transcript expression compared to that given rise by the actual treatment.
8Affymetrix® QC Metrics for Exon and Gene Design Expression Arrays-A summary based on the
Affymetrix® Quality Assessment of Exon and Gene Arrays White Paper, edition 2008, P/N 702670 Rev. 1
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Figure 5.13: Bacterial spikes and Poly-A RNA Controls. Signal of bacterial spikes in ar-
rays from AGN193109 experiment(Ai) and DEAB experiment(Bi) showed the expected
values of Cre>bioD>bioC>bioB. Poly-A RNA Controls in arrays from AGN193109
experiment(Aii) and DEAB experiment(Bii) showed signal values of thr>dap>phe>lys.
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Table 5.2: Sample quality: pos vs neg auc metric and all probe set rle mean metric.
AGN193109 experiment
Samples pos vs neg auc all probe set rle mean
1 VEH 0.924494 0.148752
2 AGN193109 0.917751 0.104283
3 AGN193109 + tRA 0.924471 0.154551
4 VEH 0.912801 0.150857
5 AGN193109 0.914848 0.117575
6 AGN193109 + tRA 0.914030 0.102842
7 VEH 0.924404 0.161783
8 AGN193109 0.918907 0.150542
9 AGN193109 + tRA 0.919005 0.146593
DEAB experiment
Samples pos vs neg auc all probe set rle mean
VEH 7 0.925370 0.097598
VEH 4 0.927529 0.097436
VEH 1 0.920282 0.112337
DEAB + tRA 9 0.926551 0.091955
DEAB + tRA 6 0.924961 0.079631
DEAB + tRA 3 0.921759 0.139806
DEAB 8 0.924260 0.099301
DEAB 5 0.922637 0.094552
DEAB 2 0.920006 0.104863
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Figure 5.14: Pearson’s correlation plot for array comparisons. A. In AGN193109 expe-
riment, a better correlation was found among samples of the same batch (samples 1-3,
4-6, and 7-9 in dotted box labelled “i”, “ii”, and “iii”, respectively), compared to sam-
ples treated with the same reagent on separate occasions, i.e., samples 1, 4, and 7 (in
brown bracket labelled “a”), samples 2, 5, and 8 (in green bracket labelled “b”), and
samples 3, 6, and 9 (in yellow bracket labelled “c”). B. Similarly, in DEAB experiment,
a better correlation was found among samples of the same batch, i.e., samples 7-9 (in
brown bracket labelled “i”), samples 4-6 (in green bracket labelled “ii”), and samples
1-3 (in yellow bracket labelled “iii”), whereas biological replicates of three independent
experiments had a slightly poorer correlation (samples 1, 4, and 7 in dotted box labelled
“a”, samples 2, 5, and 8 in dotted box labelled “b”, and samples 3, 6, and 9 in samples
labelled “c”).
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5.2.4 Validation of candidate target genes shortlisted from microarray
experiments with RT-qPCR
The same total RNA samples used for microarray experiment were used to validate re-
gulation of target genes shortlisted from microarray experiments with RT-qPCR as de-
scribed in Section 5.2.2. The Taqman® Gene Expression Assays used for validation of
target genes are listed below:
1. Clca4: Mm00519742 m1 (amplicon length: 68)
2. Cpm: Mm01250796 m1 (amplicon length: 63)
3. Csn3: Mm02581554 m1 (amplicon length: 99)
4. Dhrs3: Mm00488080 m1 (amplicon length: 84)
5. Dusp1: Mm00457274 g1 (amplicon length: 65)
6. Ebf1: Mm00432948 m1 (amplicon length: 59)
7. Foxj1: Mm00807215 m1 (amplicon length: 98)
8. Galns: Mm00489576 m1 (amplicon length: 80)
9. Hrsp12: Mm00476177 m1 (amplicon length: 73)
10. Itga2: Mm00434371 m1 (amplicon length: 63)
11. Klhdc7a: Mm00557861 s1 (amplicon length: 117)
12. Lcn2: Mm01324470 m1 (amplicon length: 84)
13. Muc20: Mm00524818 m1 (amplicon length: 65)
14. Npr3: Mm00435329 m1 (amplicon length: 63)
15. Ppbp: Mm00470163 m1 (amplicon length: 62)
16. Slc37a1: Mm00461949 m1 (amplicon length: 78)
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17. Sorcs2: Mm00473050 m1 (amplicon length: 64)
18. Sprr1a: Mm01962902 s1 (amplicon length: 94)
19. Tgm2: Mm00436987 m1 (amplicon length: 72)
20. Tinag: Mm00496471 m1 (amplicon length: 78)
21. Tinagl1: Mm00469812 m1 (amplicon length: 57)
22. Tns1: Mm00452886 m1 (amplicon length: 91)
23. Upk3b: Mm00558406 m1 (amplicon length: 89)
24. 9930023K05Rik: Mm00554061 m1 (amplicon length: 110)
25. 2310007B03Rik: Mm00549644 m1 (amplicon length: 73)
5.2.5 Gene ontology analysis and transcriptomic database comparison
Gene ontology analysis was performed using two independent bioinformatic tools, i.e.,
Database for Annotation, Visualization and Integrated Discovery (DAVID)
(http://david.abcc.ncifcrf.gov/) [126] and GeneGO MetaCoreTM (http://www.genego.
com/metacore.php) for the validated genes shortlisted from microarray studies as well
as for Bmp7 and Foxa1 genes found to be significantly regulated by AGN193109 and
DEAB in the pilot study. Since mIMCD-3 is an SV-40 transformed cell line, its gene
expression profile might differ slightly from that of primary cells. Thus, expression of
the validated genes was compared to the transcriptomic databases derived from native
ureteric bud cells and matured inner medullary collecting duct (IMCD) cells available





As shown in Figure 5.15Ai and Aii, Bmp7 and Foxa1 mRNA expression was suppressed
by AGN193109; the suppression was at least partially abolished when exogenous tRA
was added simultaneously. On the other hand, mRNA expression of Wnt7b and Pax2
were not suppressed by AGN193109 (Figure 5.15Aiii and Aiv); in the simultaneous
presence of 0.2 µM tRA, mRNA expression of Wnt7b gene was higher than the vehicle
control group (Figure 5.15Aiv), which might indicate an RAR-independent regulation of
Wnt7b gene by tRA. Rarb expression in mIMCD-3 cells was relatively low with a high
CT value, which was rather close to the non-template control, as shown in Appendix B.1.
The low expression of Rarb would have precluded a fair comparison between treatments
and hence was not pursued further. Thus, among the five genes examined, Bmp7 and
Foxa1 were found to be regulated by RARs.
In order to further confirm if Bmp7 and Foxa1 were also regulated by endogenous RA,
their expression was examined following DEAB treatment. It was found that both Bmp7
and Foxa1 mRNA expression was also suppressed by DEAB; the suppression was at
least partially abolished in the simultaneous presence of 0.01 µM tRA (Figure 5.15B).
Taken together, Bmp7 and Foxa1 were identified as target genes of endogenous RA/RAR
in mIMCD-3 cells in the pilot study.
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Figure 5.15: Regulation of Bmp7, Foxa1, Pax2, and Wnt7b genes by AGN193109
and DEAB with and without all-trans retinoic acid (tRA). mRNA expression of Bmp7
(Ai) and Foxa1 (Aii) was suppressed by AGN193109; the suppression was at least par-
tially abolished in the presence of 0.2 µM tRA. Aiii. Pax2 mRNA expression was not
regulated by the treatments. Aiv. Wnt7b mRNA expression was not suppressed by
AGN193109 treatment but an induction beyond basal level was noted in the presence of
0.2 µM tRA. Bi. Bmp7 mRNA was suppressed by DEAB, and the suppression was re-
versed to a level higher than basal level in the presence of 0.01 µM tRA. Bii. Expression
of Foxa1 mRNA was suppressed by DEAB, and the suppression was partially abolished
in the presence of 0.01 µM tRA. Each dot represents mean values of three technical





A common criteria used in microarray experiment to select genes most significantly re-
gulated by a given treatment is the q value, also known as false discovery rate threshold,
of less than 0.05. When q<0.05 was used as a cut-off, neither Foxa1 nor Bmp7 made the
shortlist although a statistically significant change was found in the pilot study, which
was likely due to the low n number (n=3). Thus, instead of using q<0.05 as a cut-off,
Foxa1 gene was selected as the cut-off threshold to generate a list of genes that were
significantly regulated to an extent at least as great as that of Foxa1.
A multi-group comparison was performed using QOE software to detect differences
between vehicle, AGN193109-only, and AGN193109+tRA groups in the first set of ex-
periment, and between vehicle, DEAB-only, and DEAB+tRA groups in the second set
of experiment. The total entries were first filtered by variance to eliminate the non-
regulated genes using the in-built “Filter by variance” slider to the smallest possible q
value for Foxa1 gene. The resulting q value was then used as a cut-off to shortlist can-
didate target genes. In the AGN193109 experiment, a variance of 0.098 was selected,
which gave a q value of 0.623972 for Foxa1 gene; q value was thus set to 0.65 to se-
lect candidate target genes. In the DEAB experiment, a variance of 0.053 was selected,
which gave a q value of 0.272681 for Foxa1 gene; q value was thus set to 0.30 to se-
lect candidate target genes. Original raw data of microarray experiment was deposited
in NCBI’s GEO and are accessible through GEO Series accession number GSE33955
(http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE33955).
A list of 403 and 439 unique genes was generated from AGN193109 experiment and
DEAB experiment, respectively. As shown in Figure 5.16A, there were 133 overlap-
ping genes, of which 125 genes fulfilled all the three criteria described in Section 5.1,
i.e., (i) regulated by AGN193109 and the regulation was abolished or diminished in the
presence of exogenous tRA, (ii) regulated by DEAB and the regulation was abolished
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or diminished in the presence of exogenous tRA, (iii) the direction of regulation by
AGN193109 and by DEAB was the same. Thus, the 125 genes were regarded as candi-
date targets of endogenous RA/RAR, and designated as group 1 genes. In addition to the
group 1 genes, there were 213 genes that fulfilled only criteria (i), designated as group 2
genes, which were candidate genes regulated only by RARs but not by endogenous RA;
266 genes fulfilled only criteria (ii), designated group 3 genes, which were candidate
genes regulated only by endogenous RA but independent of RARs.
Of note, group 1 genes appeared to be the minority when all shortlisted genes were over-
lapped directly (Figure 5.16A). However, when the genes were ranked by fold-changes
and only the top 20 and top 10 most regulated genes were overlapped, the intersected
genes became the majority (Figure 5.16B and Figure 5.16C).
The top 20 most down- and up-regulated genes within group 1 are listed in Table 5.3 and
Table 5.4, respectively; top 10 most down- and up-regulated genes within group 2 are
listed in Table 5.5; top 10 most down- and up-regulated genes within group 3 are listed in
Table 5.6. The complete lists of intersected genes, genes regulated only by AGN193109,
and genes regulated only by DEAB are in Supplementary Table 1, Supplementary Table
2, and Supplementary Table 3, respectively, in the DVD attached.
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Group 1 (125 candidate target genes of endogenous RA/RARs):  
Maximum fold-change by AGN193109 was 9.49-fold;  
maximum fold-change by DEAB was 6.15-fold. 
Group 2 (213 candidate target 
genes of RARs):  
Maximum fold-change by 
AGN193109 was 2.36-fold. 
Group 3 (266 candidate target 
genes of endogenous RA): 
Maximum fold-change by DEAB 
was 1.83-fold. 
B              Top 20 most  
              regulated genes  
AGN193109 DEAB 
    16 4 4 
A    Candidate target genes shortlisted from microarray studies 
C          Top 10 most  
         regulated genes  
AGN193109 DEAB 









Figure 5.16: Candidate target genes shortlisted from microarray experiments. A. A total
of 403 and 439 unique genes were shortlisted from AGN193109 experiment and DEAB
experiment, respectively. There were 133 intersected genes, of which 125 genes, desig-
nated as group 1 genes, were regulated by AGN193109 and DEAB at similar directions,
and their regulation was abolished or diminished in the simultaneous presence of exo-
genous tRA; 270 genes were regulated only by AGN193109, of which regulation of
213 genes, designated as group 2 genes, was abolished or diminished in the simulta-
neous presence of exogenous tRA; 306 genes were regulated only by DEAB, of which
regulation of 266 genes, designated as group 3 genes, was abolished or diminished in
the simultaneous presence of exogenous tRA. The fold-changes of group 1 genes were
higher than those of group 2 and group 3 genes. When ranked based on fold-changes,


















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 5.5: Top 10 most up- and down-regulated genes within group 2: candidate target
genes of retinoic acid receptors. Shown here are mean fold-changes of gene expression
compared to vehicle control from three experimental groups. Genes were sorted by fold-
changes of AGN193109 group compared to vehicle group.
Gene Symbol AGN193109 AGN193109+tRA Entrez Gene
(I) Top 10 most down-regulated genes
1. G930009F23Rik -1.83 -1.30 100038726
2. Psca -1.82 -1.19 72373
3. Sgpp2 -1.81 -1.36 433323
4. Ly6g -1.76 -1.36 546644
5. Lbp -1.71 -1.41 16803
6. Gpr124 -1.71 -1.22 78560
7. Gm12185 ///
Tgtp1 /// Tgtp2
-1.66 -1.51 620913 /// 21822
/// 100039796
8. Mknk2 -1.63 -1.49 17347
9. Alkbh7 -1.51 -1.40 66400
10. Synpo -1.51 -1.35 104027
(II) Top 10 most up-regulated genes
1. Areg +2.36 +1.28 11839
2. 1810011O10Rik +2.07 +1.58 69068
3. Etv1 +1.76 +1.19 14009
4. Akr1c19 +1.73 -1.36 432720
5. Spry4 +1.62 +1.33 24066
6. Nr4a1 +1.60 +1.27 15370
7. Etv1 /// Gm5454 +1.54 +1.23 14009 /// 432800
8. Pvr +1.52 +1.16 52118
9. Ankrd22 +1.50 +1.01 52024
10. Dusp6 +1.46 +1.26 67603
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Table 5.6: Top 10 most regulated up- and down-genes within group 3: candidate target
genes of endogenous retinoic acid. Shown here are mean fold-changes of gene expres-
sion compared to vehicle control from three experimental groups. Genes were sorted by
fold-changes of DEAB group compared to vehicle group.
Gene Symbol DEAB DEAB+tRA Entrez Gene
(I) Top 10 most down-regulated genes
1. Slc16a12 -1.83 +1.17 240638
2. Gabrp -1.65 +1.61 216643
3. Gm8393 -1.64 -1.57 666972
4. Cp -1.54 +1.22 12870
5. 1700011H14Rik -1.49 -1.08 67082
6. Dcdc2a -1.46 +1.24 195208
7. Gstm6 -1.46 +1.30 14867
8. Ifi205 -1.45 -1.06 226695
9. Cpne8 -1.43 +1.11 66871
10. Cxcl10 -1.43 +1.02 15945
(II) Top 10 most up-regulated genes
1. Fgfbp1 +1.48 -1.32 14181
2. Gper +1.45 -1.22 76854
3. Ahnak2 +1.36 -1.23 100041194
4. Serpinb5 +1.32 -1.60 20724
5. Mir687 +1.29 +1.05 751541
6. Ramp3 +1.28 -1.17 56089
7. Ctsw +1.28 -1.39 13041
8. Emp1 +1.25 -1.04 13730
9. Klra5 +1.25 -1.06 16636
10. Pdk4 +1.24 -1.26 27273
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Group 1 genes: candidate targets of endogenous RA/RAR
The number and fold-changes of all group 1 genes are summarised in Figure 5.17. The
total number of genes suppressed by both AGN193109 and DEAB were about 3-fold
more than those induced by both AGN193109 and DEAB. Of note, there were 19 and 12
genes suppressed by AGN193109 and DEAB by 2-fold or more, respectively, but none
were induced by 2-fold or more. It was also noted that AGN193109 had a greater impact
on regulation of these genes compared to DEAB.
Number of candidate target genes of endogenous RA/RARs:  
suppressed genes vs induced genes and their fold-changes 
2x 1.5x 
Suppressed genes Induced genes 
AGN193109 
& DEAB 
1.25x 1.5x 1.25x 2x 
AGN193109 DEAB 
2x 1.5x-<2x 
Suppressed genes Induced genes 
AGN193109 
& DEAB 
<1.5x 1.5x-<2x 2x 
AGN193109 DEAB 
Candidate target genes of endogenous RA/RARs:  
number of suppressed genes vs induced genes and their fold-changes 
<1.5x 
Figure 5.17: Number of candidate target genes of endogenous retinoic acid and retinoic
acid receptors and their fold-changes. A total of 94 and 31 genes were down- and up-
regulated, respectively, by both AGN193109 and DEAB; regulation of these genes were
at least partially abolished in the presence of tRA. Of the 94 down-regulated genes, 38
were down-regulated by AGN193109 by less than 1.5-fold, 37 by more than 1.5-fold
but less than 2-fold, and 19 by 2-fold and more; 68 were down-regulated by DEAB by
less than 1.5-fold, 14 by more than 1.5-fold but less than 2-fold, and 12 by 2-fold and
more. Of the 31 up-regulated genes, 24 were up-regulated by AGN193109 by less than
1.5-fold, 7 by more than 1.5-fold but less than 2-fold, and none by 2-fold and more; none
of the genes were up-regulated by DEAB by 1.5-fold and more.
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5.3.3 Validation of candidate target genes of endogenous RA/RAR
Fold-changes of the no. 20 gene on the top 20 most down-regulated genes (Table 5.3),
i.e., Hrsp12 (-1.98-fold by AGN193109 and -1.65-fold by DEAB), are higher than those
of the no. 1 gene on the top 20 most up-regulated genes (Table 5.4), i.e., Anxa8 (+1.73-
fold by AGN193109 and +1.43-fold by DEAB). Thus, validation of gene expression was
focused on the top 20 most down-regulated genes. Five other genes of interest within
the down-regulated gene list, which were regulated by at least 1.45-fold by AGN193109,
i.e., Tgm2 (-1.97-fold), Tinag (-1.73-fold), Foxj1 (-1.68-fold), Tinagl1 (-1.53-fold), and
Dusp1 (-1.45-fold), were also examined.
Results of validation are summarised in Table 5.7 and graphs of fold-changes for in-
dividual gene are shown in Appendix B.2. Among the 25 genes examined, Csn3 gene
was not amplified. Of the remaining 24 genes, all were significantly down-regulated by
AGN193109; suppression of all genes, except Muc20, was at least partially abolished
in the simultaneous presence of exogenous tRA. In cells treated with DEAB, all genes
were significantly down-regulated, which the regulation was abolished in the simultane-
ous presence of tRA; suppression of Dusp1 was not statistically significant. Thus, while
Csn3, Muc20, and Dusp1 genes required further examination, the remaining 22 genes
along with Bmp7 and Foxa1 examined in the pilot study were confirmed as target genes
of endogenous RA/RAR. Hence, subsequent analysis was focused on these 24 validated







































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































It was noted that in the presence of DEAB, some of the genes were significantly in-
duced by tRA beyond basal level such as Sprr1a and Drhs3, whereas others such as
Hrsp12 and 2310007B03Rik were only marginally induced beyond basal level. In or-
der to determine whether these difference was associated with presence of RARE, a
search was performed on the DR5 RARE database of mouse whole genome, based on the
(A/G)G(G/T)T(C/G)A motif, published by Lalevee et al. [159]. Based on this database,
presence of DR5 RARE in the 24 validated target genes of endogenous RA/RAR is sum-
marised in Table 5.8, at (i) whole gene level and (ii) within 10 kb from transcription start
site or from gene end.
While all the 24 genes were validated as target genes of endogenous RA/RAR, not all
genes contain DR5 RARE. Among the 17 genes that were significantly down-regulated
by DEAB and induced beyond basal level in the simultaneous presence of tRA, 11 con-
tain at least one DR5 RARE at the whole gene level, of which 10 have one DR5 RARE
within 10 kb from transcription start site or from gene end. Among the 7 genes that
were significantly down-regulated by DEAB but was not induced beyond basal level,
five contain at least one DR5 RARE at the whole gene level, of which three have one
DR5 RARE within 10 kb from transcription start site or from gene end.
Thus, the presence of DR5 RARE was not the sole indicator of whether the target genes
would be induced beyond basal level. In addition, a direct correlation between the pre-
sence of DR5 RARE and the magnitude of regulation was lacking. For example, whereas
Foxa1 gene contains two DR5 RARE, one of which are within 10 kb from transcription
start site/gene ends, it was not significantly induced beyond basal level. On the other
hand, Clca4 were significantly induced by more than 2-fold although DR5 RARE was
not found in this gene.
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Table 5.8: Presence of direct-repeat 5 (DR5) retinoic acid response element (RARE) in
validated genes. Genes were sorted by fold-changes, from high to low, of DEAB+tRA
compared to vehicle. ˆ: Geometric means of fold-change compared to vehicle control
and 95% confidence interval in parenthesis; §: ±10 kb from transcription start site or
from gene end; *: p<0.05 vs vehicle, **: p<0.01 vs vehicle, and ***: p<0.001 vs
vehicle.
Gene Symbol DEAB+tRAˆ DR5 RARE DR5 RARE
(whole gene) (±10 kb)§
(I) Down-regulated genes significantly induced beyond basal level by tRA
1. Sprr1a 4.07 (2.80-5.93) *** 1 1
2. Dhrs3 2.81 (1.53-5.15) ** 6 1
3. Clca4 2.58 (1.87-3.55) ** 0 0
4. Ppbp 2.55 (1.96-3.32) *** 1 1
5. Npr3 2.08 (1.45-2.99) *** 3 1
6. 9930023K05Rik 2.05 (1.34-3.14) ** 1 1
7. Ebf1 1.54 (1.21-1.94) ** 9 1
8. Lcn2 1.52 (1.15-1.99) * 0 0
9. Tns1 1.52 (0.87-2.00) * 0 0
10. Cpm 1.46 (1.17-1.83) ** 0 0
11. Itga2 1.43 (1.14-1.81) * 2 1
12. Tinag 1.31 (1.13-1.52) ** 1 0
13. Slc37a1 1.29 (1.14-1.48) ** 0 0
14. Tinagl1 1.26 (1.12-1.43) ** 1 1
15. Bmp7 1.23 (1.08-1.41) * 4 1
16. Foxj1 1.21 (1.04-1.40) * 0 0
17. Upk3b 1.15 (1.06-1.25) ** 1 1
(II) Down-regulated genes not significantly induced beyond basal level by tRA
1. Sorcs2 1.33 (0.98-1.80) 11 0
2. Klhdc7a 1.27 (0.91-1.76) 1 0
3. Galns 1.25 (0.94-1.66 1 1
4. Tgm2 1.19 (0.96-1.50) 1 1
5. Hrsp12 1.18 (0.97-1.44) 0 0
6. 2310007B03Rik 1.12 (0.88-1.42) 0 0
7. Foxa1 0.95 (0.66-1.35) 2 1
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Gene ontology analysis and transcriptomic database comparison
Except for a few genes with unknown functions, namely, 9930023K05Rik, Klhdc7a,
Sorcs2, and 2310007B03Rik, the validated genes are associated with a broad spectrum
of biological processes and molecular functions. The complete list of gene ontologies
(last accessed on February 2012) is shown in Supplementary Table 4, saved in the DVD
attached.
A search through GEO databases for the expression of the validated genes was performed
in order to confirm their presence in native kidney ureteric bud/collecting duct cells. Two
GEO series were deemed highly relevant to mIMCD-3 cells: (i) E11.5 mouse ureteric
buds and E15.5 mouse medullary collecting duct cells (GEO accession: GSE6290), con-
tributed by GUDMAP (http://www.gudmap.org/) and (ii) inner medullary collecting duct
cells derived from 6- and 10-week-old rat kidney (GEO accession: GSE7891), con-
tributed by Uawithya et al. [305]. Transcriptomic profiling of inner medullary collecting
duct cells derived from adult mouse kidney was not available on GEO for comparison.
There were three biological replicates in each of the database, and a gene is considered
present if at least two out of three of the replicates had a “present” call, in at least one
probe set. A summary of gene ontologies and GEO database comparison is shown in
Table 5.9.
In addition to the RIKEN genes, i.e., 9930023K05Rik and 2310007B03Rik, which are
specific only to mouse, four other validated genes, i.e., Itga2, Klhdc7a, Upk3b, and
Galns, are also absent from the rat inner medullary collecting duct cell transcriptomic
profile. This is due to the fact that the probes on the rat array (Affymetrix® Rat Genome
230 2.0 array) were designed based on the public databases, Unigene and Baylor Col-
lege of Medicine Human Genome, built in 2002, whereas these genes were only added to
the databases after 2003 (personal communication with Affymetrix Application Support
Specialist, Ms. K Danielski). Therefore, the expression of these genes in native inner
medullary collecting duct cells are undetermined at present.
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Table 5.9: Summary of gene ontologies and GEO database comparison. E11.5 UB: em-
bryonic day 11.5 ureteric bud cells from mice (three samples), E15.5 mCD: embryonic
day 15.5 medullary collecting duct cells from mice (three samples), rat IMCD: inner
medullary collecting duct cells from rat (one sample from 6-week-old and two samples
from 10-week-old). +: present, -: absent, ud: undetermined; ˆ: present in 6-week-old
sample but absent from 10-week-old sample. Gene ontologies A: retinol metabolism,
B: cell-cell, -substrate interaction, C: ureteric bud branching, D: immune/inflammation,
E: oxidative stress, F: repair/regeneration, G: ion/solute/water transport and metabolism,
H: gene transcription/translation; pink: GeneGO Metacore, yellow: DAVID, green: both
GeneGO Metacore and DAVID, blue: additional literature reviews.
E11.5 UB E15.5 mCD rat IMCD A B C D E F G H
1. Dhrs3 + + +
2. Sprr1a + + +
3. Ppbp + + -
4. 9930023K05Rik - - ud
5. Cpm + + +
6. Tns1 + + +
7. Lcn2 - - +
8. Itga2 - - ud
9. Npr3 - + -
10. Klhdc7a - + ud
11. Sorcs2 - + +
12. Clca4 - - +
13. 2310007B03Rik - - ud
14. Upk3b - + ud
15. Galns + + ud
16. Slc37a1 + - +
17. Ebf1 - + +
18. Hrsp12 + + +
19. Tgm2 + + +
20. Tinag + + -
21. Foxj1 - - -
22. Tinagl1 + + +
23. Bmp7 + + +
24. Foxa1 - + +/-^
Genes
Native samples Gene ontologies
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5.4 Discussions
5.4.1 Canonical signalling of retinoids and its candidate target genes
By using two inhibitors that block endogenous RA/RAR signalling at different stages,
and by adding exogenous tRA simultaneously to the inhibitors to confirm their speci-
ficity of regulation, candidate target genes of endogenous RA/RAR were identified (group
1 genes, Supplementary Table 1). Among the validated genes, some were reported, in
original publication or review paper, to be regulated by RA, i.e., Dhrs3 (up-regulated)
[40, 78], Sprr1a (down-regulated) [90, 299], Cpm (down-regulated) [153], Itga2 (up-
regulated) [87], Ebf1 (up-regulated) [44], Lcn2 (up-regulated) [225], Tgm2 (up-regulated)
[12], Bmp7 (up-regulated) [243], and Foxa1 (up-regulated) [12]. Of these known target
genes, Ebf1 was induced during or after cell differentiation when RA was added, hence
may or may not be a direct target gene of RA. The remaining genes within the group 1
list, i.e., Ppbp, 9930023K05Rik, Tns1, Klhdc7a, Sorcs2, 2310007B03Rik, Galns, Npr3,
Clca4, Upk3b, Slc37a1, Hrsp12, Tinag, Foxj1, and Tinagl1 were not reported to be re-
gulated by RA yet. Thus, these genes represent novel target genes of RA/RAR identified
in this project.
In addition to the group 1 genes, two additional groups of genes were unveiled, i.e.,
genes that were regulated only by RARs (group 2 genes, Supplementary Table 2) and
genes that were regulated only by endogenous RA (group 3 genes, Supplementary Ta-
ble 3) (Figure 5.18). The group 2 genes were likely regulated by unliganded RARs or
by RARs activated by ligands other than endogenous RA hence perturbation of RAR-
mediated signalling by AGN193109 led to a change in gene expression; in the simulta-
neous presence of exogenous tRA, occupation of RARs by AGN193109 were relieved
hence the effect of AGN193109 were abolished or diminished. Group 3 genes were
likely regulated by endogenous RA but not via RAR-mediated pathways.
Taken together, the constitutively active RAR-dependent endogenous RA activity ob-
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Figure 5.18: Regulation of gene expression by endogenous retinoic acid (RA) and
retinoic acid receptors (RARs). While the primary aim was to identify target genes of en-
dogenous RA/RAR as shown in Figure 5.1, three main groups of candidate target genes
were identified from microarray studies. Group 1 genes were candidate target genes of
endogenous RA/RAR, which their expression was regulated by both AGN193109 and
DEAB at similar directions, and the regulation was abolished or diminished in the si-
multaneous presence of exogenous tRA (blue box); group 2 genes were candidate target
genes of RARs, which their expression was not dependent on endogenous RA (yellow
box); group 3 genes were candidate target genes of endogenous RA, which their expres-
sion was not dependent on RARs (purple box).
transcription of group 1 genes. At the same time, the retinoid system in mIMCD-3 cells
is also regulating transcription of group 2 and group 3 genes via non-canonical signalling
mechanisms. More importantly, although the number of genes within group 1 were not
as many as those within groups 2 and 3, it was clear that the most regulated genes, in
terms of their fold-changes, largely fall into the group 1 genes, i.e., regulated by both
endogenous RA and RARs (Figure 5.16). This suggests that the canonical signalling
activity is more dominant in regulating gene expression. In addition, the most regula-
ted genes were being down-regulated rather than up-regulated (Figure 5.17), suggesting
that endogenous RA/RAR signalling plays a primary role as “inducer” to support gene
expression rather than as “suppressor” to inhibit gene expression in mIMCD-3 cells.
5.4.2 Validation of microarray results
Among the 25 genes selected for RT-qPCR examination, all except Csn3, Muc20, and
Dusp1, were validated as target genes of endogenous RA/RAR (Table 5.7). Csn3 gene
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was not amplified, perhaps due to the discrepancy between 3’-biased method using oligo-
d(T) primers for reverse transcription for qPCR as opposed to the whole-gene cDNA
synthesis using random primers in microarray experiment. Muc20 was suppressed by
AGN193109 but the suppression was not relieved in the simultaneous presence of exo-
genous tRA perhaps due to the relatively low tRA dose used (0.2 µM), which might
not be sufficient to compete with AGN193109 for RARs. Dusp1 was significantly sup-
pressed only by AGN193109 but not by DEAB, which might either be due to suboptimal
DEAB dose or an insufficient treatment time to deplete the cells of endogenous RA.
The detailed molecular mechanisms involved in regulation of the validated genes by
endogenous RA/RAR in not known. Although the presence of DR5 RARE in some of
the validated genes might be a potential mechanism, their actual participation remains to
be further established. The presence of other yet identified RARE such as the DR1 and
DR2 RARE, as well as the possibility of endogenous RA/RAR in modulating stability
of gene transcripts might also contributes towards gene expression.
5.4.3 Top three most down-regulated genes: Dhrs3, Sprr1a, and Ppbp
Dhrs3 in retinoid metabolism
Dhrs3 gene encodes short-chain dehydrogenase/reductase 3 protein, which was first re-
ported in the photoreceptor cells and plays a role in the visual cycle [117]. Dhrs3a, the
Dhrs3 ortholog in zebrafish, was reported to constitute a negative feedback mechanism in
response to endogenous and exogenous tRA by reducing tRal to tRol in order to restrict
tRA biosynthesis [78]. In mIMCD-3 cells, AGN193109 and DEAB treatments resulted
in a profound suppression of Dhrs3 mRNA, suggesting that Dhrs3 gene is highly depen-
dent on endogenous RA/RAR. If the negative feedback mechanism of Dhrs3a reported
in zebrafish [78] was also true in mIMCD-3 cells, then the marked suppression of Dhrs3
mRNA following perturbation of endogenous RA/RAR signalling might be a mean to
increase the availability of tRal and hence tRA biosynthesis, in order to restore tRA level.
Recently, Dhrs3 mouse null mutants have been developed (www.mmrrc.org/catalog/
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sds.php?mmrrc id=32267). It was found that while heterozygotic knockout mutants are
viable and fertile, homozygotic knockout leads to pre- and post-natal lethality but the
cause of lethality was not described. A detailed investigation on the retinoid profile
and the kidney phenotype in Dhrs3 null mutants, e.g., whether there is a higher level of
endogenous tRA and presence of RA toxicity, should further complement the existing
knowledge on retinoid metabolism in the kidney.
Sprr1a in collecting duct cell preservation and regeneration
Sprr1a gene encodes small proline-rich protein 1a, also known as cornifin-A. It is well-
known to be expressed in squamous tissues and was associated with tissue keratini-
sation [299]. However, recent publications had reported its expression and its novel
functions in non-keratinising tissues. Specifically, in adult mouse neurons, Sprr1a was
found to be dramatically induced in dorsal root ganglions during the regeneration stage
after axotomy, and its expression promoted axonal outgrowth in both embryonic and
adult neurons culture in vitro [29, 287]; in rodent’s myocardium, Sprr1a was massively
induced in response to biomechanical- and ischemia-induced stress, and its overexpres-
sion was found to protect cardiomyocytes from ischemia-induced injury both in vitro
and in vivo [252]; in bleomycin-induced lung fibrosis, carbon monoxide was reported
to suppress α-smooth muscle actin expression in lung fibroblast, a marker of emerging
myofibroblast responsible for excessive generation of extra-cellular matrix, and Sprr1a
was proposed to be the key mediator in modulating this effect [340].
In all aforementioned studies, expression of Sprr1a gene was found to be minimum,
if any, in healthy or sham-control samples, but was consistently and dramatically up-
regulated during the regenerative or repair phases of injuries [29,252,287,340]. The low
basal expression of this gene in non-squamous tissues might have lead to its potential
roles in repair and regeneration being overlooked in the past. Thus, it is tempting to
speculate that Sprr1a might serve as an endogenous defence molecule to protect kidney
collecting ducts from damage and to facilitate repair processes during acquired injury.
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A higher level of Sprr1a transcript was detected following vitamin A deficiency, which
was correlated to squamous metaplasia [299]. On the contrary, disruption of endoge-
nous RA signalling in mIMCD-3 cells had lead to a marked decrease in Sprr1a expres-
sion in this study. It is not known whether this discrepancy is due to a cell type-specific
activity of RA. Given that embryonic stem cells of Sprr1a knockout are now commer-
cially available (http://www.knockoutmouse.org/martsearch/project/102753), physiolo-
gical and pathological functions of Sprr1a should be better elucidated soon.
Ppbp in kidney development and immune/inflammatory response
Ppbp encodes platelet basic protein that is subjected to a series of N-terminal truncation
yielding connective tissue-activating peptide, β -thromboglobulin, and finally neutrophil-
activating peptide 2 that is also known as Cxcl7 [34]. Among these peptides, Cxcl7 is
the most potent, acting on a number of target cells, such as neutrophils, mast cells, ba-
sophils, and lymphocytes to mediate immune and inflammatory responses, as well as on
fibroblasts to stimulate matrix component synthesis and glucose transport [34].
Novel actions of Cxcl7 in mediating kidney development, mediated through its putative
receptor, Cxcr2, was recently reported. By performing genomic profiling on metanephric
mesenchyme explant stimulated with Cxcl7, Levashova et al. reported an up-regulation
of genes associated with angiogenesis and survival, as well as endothelial and mesangial
cell marker, with functional evidence of increased tissue invasion; inhibition of Cxcr2
receptor in metanephric mesenchyme explant with chemical reagent led to a reduction in
nephron formation, as well as in ureteric bud branching that was deemed a secondary ef-
fect following a diminution of metanephric mesenchyme-derived factors [172]. If Cxcl7
is indeed the final product of Ppbp gene in collecting duct cells and in ureteric bud cells,
it might represent a novel molecule regulated by endogenous RA in modulation of kid-
ney development.
5.4. Discussions 225
Emerging publications are pointing towards essential roles of Cxcr2 receptor as an in-
nate defence molecule against bacterial infection in the course of acute pyelonephritis.
In experimental urinary tract infection, genetic deletion of Cxcr2 in mice resulted in a
delay in neutrophil recruitment, neutrophil retention, prolonged kidney inflammation,
epithelial proliferation, and kidney fibrosis [292, 293]. However, whether or not the
roles of Cxcr2 reported in the aforementioned studies were mediated by Cxcl7 remains
to be further established. In addition, since Ppbp transcript was only detected in the
developing ureteric bud cells and medullary collecting duct cells but not in adult rat
IMCD cells (Table 5.9), it might be playing a more dominant role during embryonic kid-
ney development. Heterozygotic deletion of Ppbp gene is now commercially available
(http://www.velocigene.com/komp/detail/10026), which should facilitate research into
the roles of this gene.
5.4.4 Potential roles of canonical signalling of endogenous RA/RAR
Gene ontology analysis suggested a broad spectrum of biological processes and mole-
cular functions associated with the genes examined. Certain genes such as Ebf1 and
Hrsp12 have rather general functions, e.g., modulating gene transcription and transla-
tion. Whereas, functions of several genes such as 9930023K05Rik and 2310007B03Rik
are not yet established. Given that the gene ontologies were derived from experimental
results involving multiple biological systems, potential functions of these genes in the
collecting duct and in the kidney were made by inference, as summarised in Table 5.9.
Accordingly, a list of hypotheses on the potential roles of the validated genes are gene-
rated and discussed below.
Regulation of kidney development: Ppbp, Tinag, and Bmp7
Besides Ppbp, there are evidence from ex vivo and in vivo studies that suggest the in-
volvement of Tinag and Bmp7, which encode tubulointerstitial nephritis antigen and
bone morphogenetic protein 7, respectively, in kidney development. Of note, both
Tinag and Bmp7 transcripts were detected in native ureteric bud cells and in embryo-
5.4. Discussions 226
nic medullary collecting duct cells (Table 5.9).
Tubulointerstitial nephritis antigen is an extra-cellular matrix (ECM) protein, which was
found in the basement membrane of developing glomeruli and renal tubules [140]. Inhi-
bition of Tinag gene translation in E13 metanephro explants using gene silencing tech-
nique did not affect glomerulogenesis but defective tubulogenesis of the nephron and
diminished ureteric bud branching was observed, which was speculated to be a result of
impaired communication between Tinag and the surrounding ECM protein [140]. The
importance of Bmp7 in kidney development was highlighted by kidney development im-
pairment in Bmp7-/- mice particularly at a later stage, i.e., after E14.5 [65, 132], which
might be a result of defective control in ureteric bud cell proliferation [251].
While the relationship between Tinag and RA had not been reported, Bmp7 transcrip-
tional activity was reported to be induced by RA [243]. In addition, a global down-
regulation of Bmp7 mRNA was found in autopods of RARb-/- / RARg-/- mice [68].
However, Bmp7 mRNA expression was no different in the developing kidney of E14
RARα / RARβ2 knockout mice and wild-type mice [204], suggesting metanephric
Bmp7 expression to be independent of RARα and RARβ2 receptors, at least up to stage
E14. Given that kidney development impairment was evident before E14 in RARa-/- /
RARb2-/- mice due to a deficiency in Ret, potential role of RA in regulating Bmp7 du-
ring later stages of kidney development and its implications remain to be determined.
The crucial involvement of RA in kidney development and the potential involvement
of Ppbp, Tinag, and Bmp7 in nephrogenesis suggest them to be novel targets of RA du-
ring kidney development [102, 255, 311]. Nonetheless, given that kidney development
is a highly dynamic process involving complex crosstalk between the ureteric bud cells
and mesenchymal cells, the actual involvement of these genes at various developmental
stages and their regulation by RA should be carefully addressed.
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Maintenance of cell integrity and polarity: Tns1, Itga2, Tgm2, and Tinagl1
Tns1, Itga2, Tgm2, and Tinagl1 are involved in cell-cell and cell-substrate adhesion.
Given that cell adhesion represents a central mechanism for maintenance of cell integrity
and polarity [115], these genes might be required to ensure survival and to preserve func-
tions of the collecting ducts.
Tns1 encodes Tensin 1 protein that is localised to focal adhesions, the macromolecular
assemblies via which cells bind to ECM. Genetic ablation of Tns1 lead to progressive
kidney degeneration, characterised by the presence of multiple cysts, irregular epithelial
cells, focal interstitial inflammatory infiltrates, and a near complete absence of cortex
and medulla in severe cases, all of which were speculated to be resulting from weaken-
ing of focal adhesions [179].
Itga2 encodes integrin α2 protein that forms heterodimer with integrin β1, and serves
as receptor for laminin and collagen [152]. Itga2-/- mice suffered moderate proteinuria,
as well as an enhanced glomerular and tubulointerstitial matrix deposition, which was
speculated to be due to a failure in cell-matrix interaction [103].
Tgm2 encodes transglutaminase II, which is an enzyme that binds and cross-links a num-
ber of ECM protein, thereby stabilising the ECM protein and facilitating cell-adhesion
to preserve tissue structure [81]. However, Tgm2 knockout mice was phenotypically
normal [53, 222], although impaired would healing associated with altered cytoskeletal
dynamics in fibroblasts isolated from Tgm2-/- mice was reported [81].
Tinagl1 encodes tubulointerstitial nephritis antigen-like 1 protein, also known as adreno-
cortical zonation factor 1, Tin-ag-RP, and lipocalin 7 [175]. Tinagl1 was speculated to
serve as a basement membrane protein that facilitates interaction between ECM and
cells, as well as to serve as a ligand of integrins to promote cell adhesion [175]. In-
terestingly, not only the Tinagl1 mRNA was found in IMCD cells, its protein was also
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detected with immunostaining in human medullary collecting duct cells [318].
Although cell adhesion is a crucial element in branching morphogenesis [115], Tns1-/-,
Itga2-/-, Tgm2-/- mice did not suffer kidney development impairment, which argue against
these genes playing an obligatory role in nephrogenesis. Thus, it is more likely that these
genes are acting predominantly at post-natal stages and during adulthood to maintain cell
integrity and polarity. Tinagl1-null mutants are not available, hence its functions in kid-
ney development remains unknown.
Loss of cellular integrity and polarity in collecting duct cells of post-natal VAD ani-
mals had not been widely reported. However, in mouse offspring restricted to vitamin
A supply, thickening of glomerular and tubular basement membrane in the renal cortex
was noted [192], which might be due to perturbation of cell-substrate and cell-cell inter-
action mediated by the aforementioned genes.
Regulation of cellular response towards stress and modulation of tissue repair:
Sprr1a, Cpm, Lcn2, and Bmp7
Collecting duct cells, particularly those residing in the inner medulla, are encounter-
ing immense stress from the hypertonic/hyperosmotic and hypoxic medullary environ-
ment [227], with higher chance of bacterial invasion due to their proximity to the lower
urinary tract. Besides Sprr1a, genes such as Cpm, Lcn2, and Bmp7 might also be play-
ing a role in the adaptation towards such stress factors and in facilitating repair in the
advent of stress-induced cell injury.
Cpm encodes carboxypeptidase M, a plasma membrane bound-enzyme that acts on a
wide range of substrates [55]. Although the actual physiological role of Cpm remains
poorly understood, it was proposed to play a role in inflammation and defence owing
to its potential function in modulating activities of anaphylatoxins, as well as kinins to
enhance kinin B1 receptor signalling [55, 337].
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Lcn2 encodes lipocalin 2, or better known as neutrophil gelatinase-associated lipocalin,
NGAL, which might have dual actions in the kidney [278]. A protective role of Lcn2
against oxidative stress had been reported, by inducing hemeoxygenase-1 (HO-1), a
scavenger molecule that clears up harmful oxidant molecule [9], as well as through other
HO-1-independent mechanisms [268]. Another well-established role of Lcn2 is its bac-
teriostatic effect by limiting bacterial invasion through sequestering iron ion crucial for
bacterial growth [83]. However, much remains to be learnt with respect to specific roles
of Lcn2 in the kidney tubular cells, as a recent report has shown that Lcn2 aggravates
renal damage in the advent of chronic kidney injury [309].
Other than playing a role in kidney development, Bmp7 was proposed as a crucial en-
dogenous defence molecule against kidney diseases [72]. Specifically, Bmp7 treatment
was found to modulate expression of genes encoding cytokines, chemokines, and hemo-
dynamics in human proximal tubular cells [110], as well as to prevent and reverse kidney
fibrosis [334].
The potential involvement of these genes in regulating inflammation, immune response,
oxidative stress, and tissue regeneration, fits well with the anti-inflammatory, immune-
modulatory, regenerative, and anti-apoptotic roles of RA in kidney. Therefore, it would
be of great interest to examine if the aforementioned effects of RA are at least in part
mediated by these genes.
Regulation of renal water homeostasis, chloride transport mechanisms, and
stone formation: Npr3, Foxa1, Tgm2, Clca4, and Galns
Being a member of the natriuretic peptide system, Npr3 is a gene encoding the natri-
uretic peptide receptor C, which interacts with natriuretic peptides [290]. Natriuretic
peptide receptor C was believed to act as a “clearance receptor” to eliminate natriuretic
peptides from circulation, thereby counter-balancing the effect of natriuretic peptides on
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their regulation of blood pressure and body fluid homeostasis mediated by the other two
receptors from the same family [196]. Mice with Npr3 gene deletion had significantly
higher urine output coupled with an increased in water intake, which were attributed to
a higher level of natriuretic peptides in the glomerular ultra-filtrates leading to a diuretic
effect [196].
Genetic deletion of Foxa1, a member of the winged helix family of transcription fac-
tors, lead to mild nephrogenic diabetes insipidus without water restriction or water load,
characterised by a dehydrated appearance, a reduction in urine osmolality, hydronephro-
sis, and a lack of response towards vasopressin in concentrating urine [19]. Interestingly,
expression of genes encoding several major ion/water transporters and channels in the
kidney were not diminished following Foxa1 gene ablation [19], leading to the proposal
of Foxa1 as a novel transcription factor that directly regulates renal water homeosta-
sis [79].
A less well-established gene in mediating water homeostasis is Tgm2, which encodes
transglutaminase II that was found highly enriched in rat IMCD cells compared to other
non-IMCD medullary cells [123, 305]. Given the ability of transglutaminase in me-
diating endocytosis in vitro [174], it was speculated that transglutaminase II might be
involved in vasopressin-induced aquaporin 2 trafficking hence facilitating water reab-
sorption although functional evidence is lacking at this point [123].
Clca4, which encodes chloride channel calcium activated 4, is a chloride secretory chan-
nel that is activated by a rise in intracellular Ca+ level [180]. While the role of Clca4
in collecting ducts remains to be characterised, transcript of another member within the
same family, Clca1, was detected in another mouse inner medullary collecting duct cell
line, which was proposed to mediate Ca+-dependent Cl- conductance [28].
Galns encodes N-acetylgalactosamine-6-sulfate sulfatase, which is involved in degrada-
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tion of keratan sulfate and chondroitin sulfate, two members of the glycosaminoglycans
(GAG). GAG such as chondroitin sulfate might play a role in inhibiting stone formation
but might also paradoxically promote stone formation, depending on the prevailing con-
ditions such as urine osmolality and presence of other molecules [147]. While mice with
Galns gene deletion exhibited higher urinary GAG and an increase in glomerular lysomal
storage, stone formation and individual components of GAG were not described [304].
Given the highly complex pathophysiology of stone formation that involves multiple
events including cell-crystal interaction and inflammation, whether loss of Galns gene
contributes towards modulation of this pathophysiological process requires further in-
vestigation.
Although polyuria is rather commonly found in farm animals with vitamin A deficiency,
such report in murine models of vitamin A deficiency is lacking. It might be that other
factors in rodents are able to compensate for the diminution of RA/RAR signalling in the
face of vitamin A deficiency. Perhaps the importance of RA in regulating these genes
and its relevance to water balance could be better addressed by subjecting animals to
fluid restriction and water load. On the other hand, given the roles of GAG in modu-
lating stone formation, increased incidence of urolithiasis in animals with Vitamin A
deficiency might be associated with regulation of galns by endogenous RA/RAR. VAD
rats were found to have lower urinary GAG [111] but since activities of GAG in mo-
dulation of stone formation is highly complex [147], the potential connection between
vitamin A deficiency and urolithiasis requires further investigation.
5.4.5 Concluding remarks
A list of endogenous RA/RAR target genes were identified from microarray studies.
This supports that the basal constitutive RAR-dependent activity in mIMCD-3 cells is
indeed playing a functional role. In fact, the most highly regulated genes were those that
their expression was maintained or induced by both endogenous RA and RARs, under-
scoring the importance of RA canonical signalling as an “inducer” of gene transcription.
Among the validated genes, some have not been reported to be regulated by RA before
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and hence represent novel target genes of RA/RAR. More importantly, the validated
genes are involved in some essential functions of collecting duct principal cells, inner
medullary collecting duct cells, and ureteric bud cells, as discussed before. Further stu-
dies on genes that their functions are less well-established, e.g., Sorcs2 and Klhdc7a,
would uncover other roles of endogenous RA/RAR in the collecting ducts.
Other than target genes of endogenous RA/RAR, the microarray experiments had also
unveiled a list of genes potentially regulated by non-canonical signalling of retinoids,
i.e., regulated only by RARs and only by endogenous RA. While regulation of these
genes remain to be validated, the results had indeed highlighted the complexity or retinoid
system in gene expression regulation.
It is worth noting that several well-established target genes of RA, for example Rarb
and Cyp26a1 that have more than one functional DR5 RAREs, were not shortlisted in
the microarray experiments. This could be explained by the cell type-dependent activity
of RA but the treatment length might also have an impact. For instance, these genes
might have been regulated at earlier time points but their expression was restored to the
basal level at the 24 h time point. Additional examinations at earlier time points,e.g., 4




General Discussion and Future Work
6.1 General discussion
It is well-established that endogenous RA and retinoid nuclear receptors are indispens-
able for kidney development. On the other hand, little is known about the role of endo-
genous RA and retinoid nuclear receptors in the kidney after birth. In order to address
this issue, this project started off by examining reporter activity of RA in the kidney of
RARE-hsp68-lacZ transgenic mice. Using both X-gal assay and immunostaining tech-
nique with carefully optimised and validated antibodies, the reporter signal was found to
be predominantly present in ureteric bud-derived collecting ducts in the post-natal and
adult mouse kidney.
In the developing kidney of RARE-hsp68-lacZ transgenic mice, reporter signal was de-
tected in the ureteric bud trunk and tip, which was shown to be mediated by RARs and by
tRA [267]. Thus, it is very likely that the reporter signal observed in the kidney collecting
ducts in this project was, at least in part, mediated by endogenous RA and RARs. This
deduction also fits well with other reports on the presence of RA [137,139,277,286,328],
retinoid nuclear receptors (www.nursa.org/10.1621/datasets.02001), and enzymes in-
volved in RA biosynthesis [4, 7, 57, 58, 118, 177, 232, 335] in the kidney after birth. The
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presence of reporter signal in collecting ducts suggests that the endogenous retinoid sys-
tem, which is an essential component for kidney development, continues to be functional
and is constitutively active in the healthy murine kidney. In an attempt to further exam-
ine the mediators of reporter transgene activation, immunostaining for RARβ , RARβ2,
Raldh1, and Raldh3 were performed. However, the results were ambiguous and incon-
clusive as the sensitivity and specificity of these antibodies were questionable.
While reporter signal was detected in the collecting duct, it remains an observation
that requires “loss-of-function” and “gain-of-function” interventions to further confirm
it being genuinely mediated by RA and RARs. In order to address this issue, a well-
established collecting duct cell line, mImCD-3 cells, were transfected with a RARE
reporter plasmid to examine the presence of reporter activity. Exogenous tRA treat-
ment on transfected cells cultured in medium supplemented with normal FBS or with
charcoal-stripped FBS resulted in poor induction, if any, of the reporter activity. How-
ever, AGN193109 and DEAB treatments resulted in a reduction of reporter activity to
about 50% of that of the control group. More importantly, reduction of the reporter ac-
tivity was abolished in the simultaneous presence of tRA, confirming the specificity of
regulation by these chemical reagents in inhibiting retinoid canonical signalling.
The results from reporter assay conducted in mIMCD-3 cells lead to three conclusions.
Firstly, a constitutively active RAR-dependent activity was detected. Secondly, the
RAR-dependent activity was likely given rise by a cell-autonomous synthesis of endo-
genous RA. Last but not least, the basal RAR-dependent endogenous RA activity might
be so high that renders further induction by exogenous tRA impossible. These conclu-
sions support that the reporter signal observed in the collecting duct of RARE-hsp68-lacZ
mice, at least in principal cells and inner medullary collecting duct cells, was indeed due
to the presence of a constitutively active RAR-dependent endogenous RA activity.
The presence of constitutively active endogenous RA/RAR signalling in the healthy
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murine kidney suggests that the retinoid system might be involved in mediating cer-
tain signalling events to ensure proper functioning of the kidney. In order to address
this issue, microarray experiment was performed to identify potential target genes of
endogenous RA/RAR. By employing AGN193109 and DEAB that inhibit retinoic acid
signalling at different stages and by adding exogenous tRA simultaneously to examine
the reversibility/prevention of the regulation exerted by the chemical inhibitors, a list of
specific target genes of endogenous RA/RAR was shortlisted. Among the most highly-
regulated target genes of endogenous RA/RAR identified and validated, Dhrs3, Sprr1a,
Cpm, Itga2, Ebf1, Lcn2, Tgm2, Bmp7, and Foxa1 were reported by others to be regula-
ted by RA [12, 40, 44, 78, 87, 90, 153, 225, 243, 299]. Whereas, Ppbp, 9930023K05Rik,
Tns1, Klhdc7a, Sorcs2, 2310007B03Rik, Galns, Npr3, Clca4, Upk3b, Slc37a1, Hrsp12,
Tinag, Foxj1, and Tinagl1 had not been reported to be regulated by RA and hence repre-
sent novel target genes of endogenous RA/RAR.
In summary, this project has confirmed the presence of a constitutively active RAR-
dependent activity, likely given rise by cell-autonomous synthesis of endogenous RA, in
the collecting duct of healthy murine kidney. By performing microarray experiments,
genes most dependent on endogenous RA/RAR were shortlisted and validated. Inter-
estingly, the validated genes are involved in biological processes such as kidney deve-
lopment and defence against inflammation and fibrogenesis, which fit well with some of
the reported functions of RA and RARs [329]. While renal anomalies such as increased
incidence of urolithiasis, renal infection, inflammation, and fibrogenesis, had been asso-
ciated with vitamin A deficiency in the past, a clear cause-and-effect relationship remains
elusive. This project has shed some light on the potential molecular mechanisms, which
might provide explanation towards some of these phenomena.
6.2 Future work
Before moving on to the next step, it is both prudent and desirable for the findings
summarised in this project be further validated and consolidated. Firstly, the reporter
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transgene activity of RARE-hsp68-lacZ transgenic mice should be further confirmed by
characterising the transgene expression, in terms of its sensitivity and specificity towards
reporting RAR-dependent activity of RA, at post-natal and adult stages, as discussed in
Chapter 3. It would also be of great interest to examine the RA activity using another
line of RA reporter mouse, when one becomes available.
One of the issues remain unresolved is the molecular mediators of the reporter signal
observed in the RARE-hsp68-lacZ reporter mouse model and in the mIMCD-3 cells
transfected with RARE-reporter plasmid. In supporting the 3R’s principle of Replace-
ment, Refinement, and Reduction, a few pilot studies can be performed on mIMCD-3
cells before in vivo experiments are carried out. For example, mIMCD-3 cells can be
treated with isotype-selective antagonists or inhibitors, or transfected with siRNA tar-
geting specific retinoid nuclear receptors or enzymes, to get some ideas into potential
molecular mediators that gave rise to the reporter activity. Should the activity of RA in
intercalated cells be further explored, then a cell model of intercalated cells would first
be established in the similar manner as for mIMCD-3 cells, as described in Chapter 4,
prior to target gene identification.
Identification and validation of target genes of endogenous RA/RAR in mIMCD-3 cells
represent only the first step towards understanding the physiological roles of endoge-
nous RA/RAR in kidney after birth. In the next step, it is imperative to perform further
studies focusing on two major aspects. Firstly, the physiological functions of the iden-
tified target genes in the collecting duct and in the kidney should be better established
as most of them had not been extensively studied in the renal system. Targeted knock-
out of the validated target genes from the collecting duct, especially the top three most
highly-regulated genes, i.e. Drhs3, Sprr1a, Ppbp, at different developmental stages and
after birth, should provide valuable information on their specific roles. Detailed mole-
cular mechanisms could be performed on mIMCD-3 cells whenever needed. Secondly,
regulation of the identified target genes should be further validated at the protein and
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functional level in mIMCD-3 cells. Following that, in vivo experiment can be planned,
for example by subjecting RARE-hsp68-lacZ mice to diet with varied amount of vitamin
A to examine the gene expression and to correlate that with the reporter signal as well as
with functional defects, if present.
The project could also be further extended to study the role of endogenous retinoid
system in renal pathology. For instance, alterations of endogenous RA/RAR activity
could be determined after inducing renal diseases in RA reporter mice. Further to that,
chemical reagents that diminish or enhance endogenous RA/RAR activity could be ad-
ministered to the reporter mice, and reporter signal and disease progression could then
be monitored. These studies should provide valuable insights on the involvement and
alteration of endogenous retinoid system in the advent of renal disease, and the effects
of endogenous retinoid system mobilisation on disease progression.
Although the non-canonical signalling of retinoids is not the primary focus of this project,
microarray experiments had unveiled a list of genes that their expression was only de-
pendent on RA as well as those dependent only on RARs. Although regulation of these
genes has not been validated and their fold-changes are not as dramatic as genes regu-
lated by both RA and RARs, it has highlighted the complexity of retinoid signalling.
It would be interesting to further explore in the future, whether the retinoid system is
modulating gene expression and the functions of collecting duct cells via both canonical
and non-canonical signalling in a coordinated manner.
While retinoids were discovered nearly 100 years ago, much remains to be learnt about
their activities and roles in the kidney. It is hoped that this project would serve as a
groundwork for further studies, to better understand the roles of endogenous retinoid





Figure A.1: pmaxGFP plasmid. pmaxGFP plasmid encodes the green fluorescent pro-
tein (GFP) from Copepod Pontellina plumata, which expression was driven by the cy-
tomegalovirus promoter (pCMV). Plasmid map is adapted from Amaxa Biosystems.
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A.2 Plasmid maps
A.2.1 pGL3-RARE-luciferase plasmid
Figure A.2: pGL3-RARE-luciferase plasmid. pGL3-RARE-luciferase contains three
copies of RARE that is inserted into the SacI site of the pGL3 luciferase promoter vector
(A). In the presence of retinoic acid and endogenous retinoic acid receptors, the plasmid
will be activated leading to expression of the luc+ gene driven by simian virus 40 (SV
40) promoter, producing firefly luciferase (B). Plasmid map of pGL3-RARE-luciferase
and pGL3 is adapted from Addgene Inc. and Promega UK Ltd., respectively.
A.2.2 pCI-β -galactosidase plasmid
Figure A.3: pCI-β -galactosidase plasmid. pCI-β -galactosidase contains the lacZ gene
construct that is inserted into pCI-vector. Driven by the human cytomegalovirus
immediate-early (CMV I.E) enhancer/promoter, β -galactosidase, a gene product of lacZ
gene is constitutively expressed upon transfecting into the cells. The plasmid map of
pCI-vector is adapted from Promega UK Ltd.
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A.3 Algorithm for image analysis
%% Analysis tool: Image processing toolbox version 7.2 Matlab 7.12.0 
%% Analyse GFP Image 
 
I = imread('gfp.png'); 
 
% Convert to grayscale 
gfp = rgb2gray(I); 
% Mask the label 
gfp(1965:2150,270:655) = 0;  
% Resize the images to make them comparable 
gfp = imresize(gfp,[500 600]); 
% Adjust the contrast 
gfp_histeq = adapthisteq(gfp); 
% Blob detection 
BW = im2bw(gfp_histeq, 0.15); 
% Detect boundary 
[B,~,N] = bwboundaries(BW); 
figure; imshow(BW); hold on; 
for k=1:length(B), 
    boundary = B{k}; 
    plot(boundary(:,2),boundary(:,1),'r','LineWidth',2); 
end 
% Compute area of GFP 
areaA = bwarea(BW); 
 
%% Analyse Phase Contrast Image 
I2 = imread('phase_contrast.png'); 
figure; imshow(I2); 
% Convert to grayscale 
phc = rgb2gray(I2); 
% Resize the images to make them comparable 
phc = imresize(phc,[500 600]); 
% Adjust contrast 
phc_histeq = adapthisteq(phc); 
% Blob detection 
BW2 = ones(size(phc_histeq)); 
BW2(phc_histeq > 50 & phc_histeq < 170) = 0;  
% Mask the label 
BW2(425:460,55:140) = 0;  
figure; imshow(BW2); 
% Compute area of phase contrast 
areaB = bwarea(BW2); 
 
%% Compute area ratio 
area_ratio = areaA/areaB; 
 
%% For visualisation: Overlay gfp boundary on phase contrast 
phc_final = zeros(500,600,3); 
phc_final(:,:,1) = 0.5.*BW2 + 0.5*BW; 
phc_final(:,:,2) = 0.5.*BW2 + 0.5*BW; 
phc_final(:,:,3) = 0.5.*BW2 + 0.5*BW; 
figure; imshow(phc_final); hold on; 
for k=1:length(B), 
    boundary = B{k}; 
    plot(boundary(:,2),... 









Preliminary experiment and validation
of microarray results
B.1 Preliminary experiments with RT-qPCR
Figure B.1: Amplification plot of Rarb and Gapdh. As opposed to Gapdh gene that
is abundantly expressed, expression of Rarb gene was very low, evident by huge gap
between technical triplicates from a single sample, which were rather close to the non-
template control (NTC) of Gapdh gene.
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B.2 Validation of microarray results with RT-qPCR
Figure B.2: Regulation of Clca4, Cpm, Dhrs3, and Dusp1 genes by AGN193109 and
DEAB with and without all-trans retinoic acid (tRA).
B.2. Validation of microarray results with RT-qPCR 243
Figure B.3: Regulation of Ebf1, Foxj1, Galns, and Hrsp12 genes by AGN193109 and
DEAB with and without all-trans retinoic acid (tRA).
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Figure B.4: Regulation of Itga2, Klhdc7a, Lcn2, and Muc20 genes by AGN193109 and
DEAB with and without all-trans retinoic acid (tRA).
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Figure B.5: Regulation of Npr3, Ppbp, Slc37a1, and Sorcs2 genes by AGN193109 and
DEAB with and without all-trans retinoic acid (tRA).
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Figure B.6: Regulation of Sprr1a, Tgm2, Tinag, and Tinagl1 genes by AGN193109 and
DEAB with and without all-trans retinoic acid (tRA).
B.2. Validation of microarray results with RT-qPCR 247
Figure B.7: Regulation of Tns1, Upk3b, 2310007B03Rik, and 9930023K05Rik genes
by AGN193109 and DEAB with and without all-trans retinoic acid (tRA).
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